Safe, effective, and patient-specific glycaemic control in neonatal intensive care. by Dickson, Jennifer Launa
Safe, Effective, and 
Patient-Specific Glycaemic Control  
in Neonatal Intensive Care 
 
 
 
Jennifer Dickson 
 
 
 
 
A thesis presented for the degree of 
Doctor of Philosophy 
in 
Mechanical Engineering 
at the 
University of Canterbury, 
Christchurch, New Zealand 
February 2015 
  
iii 
 
Acknowledgements 
 
It is my great pleasure to thank a number of people for helping to make this thesis possible. 
First of all, thank you to my supervisor, Prof. Chase, for the many opportunities and new 
horizons to explore. Thank you for your patience and guidance: both in terms of the details, 
and also the big picture. Thank you for the study and clinical opportunities, I have thoroughly 
enjoyed my phD experience. 
Thank you Dr Lynn, Adie, for your trust. Thank you for your enthusiasm and support of the 
project, and all your hard work in the clinical implementation.  
Thank you Prof. Benyo and Dr. Desaive for the enthusiasm and pride with which you 
welcomed us into your country and the opportunities you made available.  
To Liam: thank you for always making me question and defend my assumptions. Thank you 
for the challenges, the laughs, the fun, and for making the Budapest experience that much 
more fun. Thanks Chris for all the stats consultations. Thank you to the rest of the bio-eng 
crew for the friendships, laughs, good times (and food!) that so enrich the phD experience.  
Thanks Sarah, Ruhi, and Murni, for encouraging and supporting me, feeding me, laughing 
at/with me, and for making flatting such a rich experience. Thanks to my Campus Church 
family and friends (Katie, Jess, Narelle, Victoria) and the many people who have played such 
a large part in my life over the last few years. Thank you for the love, support, and 
encouragement to keep running the race set before me.  
My deepest love and thanks to my family: Mum and Dad who are always there and so 
continuously model a life of integrity and faith. Thanks Mum for the packages and notes, and 
Dad for the long phone conversations and your eternal optimism about my part in designing 
your new cowshed. To my big-little bothers, Matt and John, the solid rocks on which I can 
lean. And to my little bro Sam, who almost grew up without me noticing, thanks for your 
cheeky grin and some awesome beach holidays.  
Finally, thanks be to God: Father, Son, Spirit; in whom is our very life and breath and being, 
and through whom we have salvation in the Lord Jesus Christ. Gloria in excelsis Deo. 
iv 
   
  
v 
 
Contents 
 
List of Figures ........................................................................................................................ xiii 
List of Tables ......................................................................................................................... xvii 
Nomenclature .......................................................................................................................... xix 
Abstract ................................................................................................................................... xxi 
Chapter 1 - Prematurity and Neonatal Glycaemia ..................................................................... 1 
1.1 Prematurity ....................................................................................................................... 2 
1.1.1 Definition ............................................................................................................................... 2 
1.1.2 Epidemiology ......................................................................................................................... 2 
1.1.3 Outcomes of Prematurity ....................................................................................................... 4 
1.2 Neonatal Hyperglycaemia ................................................................................................ 5 
1.2.1 Definitions and Thresholds .................................................................................................... 5 
1.2.2 Prevalence of Hyperglycaemia .............................................................................................. 7 
1.3 Background Physiology: Glucose-Insulin Metabolism. .................................................. 7 
1.3.1 Glucose Production and Clearance ........................................................................................ 9 
1.3.2 Insulin Secretion and Clearance ........................................................................................... 10 
1.3.3 Glucagon's Regulatory Effect .............................................................................................. 11 
1.3.4 Glycaemic Levels and Hormones ........................................................................................ 12 
1.4 Neonatal Glycaemia ....................................................................................................... 12 
1.4.1 Foetal Glycaemic Development ........................................................................................... 12 
1.4.2 Causes of Neonatal Hyperglycaemia ................................................................................... 13 
1.4.3 The Effect of Hyperglycaemia on Outcomes in Critical Care ............................................. 16 
1.4.4 Hypoglycaemia .................................................................................................................... 18 
1.5 Summary ........................................................................................................................ 19 
Chapter 2: The Problem of Variability: Glycaemic Control in Neonatal Intensive Care ........ 21 
2.1 Insulin Therapy and Outcomes in Intensive Care .......................................................... 22 
vi 
   
2.1.1 Adult and Paediatric Intensive Care ..................................................................................... 22 
2.1.2 Neonatal Intensive Care ....................................................................................................... 23 
2.2 Glycaemic Control in Neonatal Intensive Care ............................................................. 25 
2.2.1 Current Clinical Practice ...................................................................................................... 25 
2.2.2 Insulin Therapy vs. Glucose Restriction .............................................................................. 26 
2.3 Studies on Insulin Therapy and Glycaemic Control in Neonatal Intensive Care .......... 27 
2.4 The Problem of Patient Variability ................................................................................ 29 
2.5 Capturing Patient Variability Using Model Based Methods ......................................... 31 
2.5.1 Glycaemic Control Challenges in Neonatal Intensive Care ................................................. 31 
2.5.2 Sources of Metabolic Variability ......................................................................................... 32 
2.6 Summary ........................................................................................................................ 35 
2.7 Preface............................................................................................................................ 36 
Chapter 3: Model structure ...................................................................................................... 37 
3.1 Metabolic Models in Critical Care ................................................................................. 38 
3.2 Neonatal Glycaemic Modelling ..................................................................................... 39 
3.3 The Intensive Care Insulin-Nutrition-Glucose (ICING) Model .................................... 41 
3.4 Insulin Sensitivity and Model Based Control ................................................................ 43 
3.5 Summary ........................................................................................................................ 45 
Chapter 4: Modelling Insulin Secretion ................................................................................... 47 
4.1 Introduction .................................................................................................................... 47 
4.2 Methods.......................................................................................................................... 48 
4.2.1 Clinical Cohort ..................................................................................................................... 48 
4.2.2 C-peptide Model .................................................................................................................. 49 
4.2.3 C-peptide Kinetic Parameters in Preterm Neonates ............................................................. 50 
4.2.4 Trend Analysis ..................................................................................................................... 51 
4.2.5 Statistical Analysis ............................................................................................................... 52 
4.3 Results ............................................................................................................................ 52 
4.3.1 Insulin Secretion and Clinical Characteristics ..................................................................... 52 
vii 
 
4.3.2 The Effect of Nutrition and Insulin on Insulin secretion ..................................................... 55 
4.3.3 Insulin Secretion and Blood Glucose Concentration ........................................................... 56 
4.4 Discussion ...................................................................................................................... 58 
4.4.1 Insulin Secretion and Sex ..................................................................................................... 58 
4.4.2 Insulin Secretion and Exogenous Insulin ............................................................................. 59 
4.4.3 Comparison to Literature ..................................................................................................... 60 
4.4.4 Glucose-Insulin Physiology ................................................................................................. 61 
4.4.5 Limitations ........................................................................................................................... 61 
4.5 Summary ........................................................................................................................ 62 
4.6 Acknowledgements ........................................................................................................ 62 
Chapter 5: Modelling Insulin Clearance and Degradation ...................................................... 63 
5.1 Introduction .................................................................................................................... 63 
5.2 Methods.......................................................................................................................... 64 
5.2.1 Modelling Insulin Dynamics ................................................................................................ 64 
5.2.2 Clinical Data ........................................................................................................................ 65 
5.2.3 Determining Insulin Clearances ........................................................................................... 65 
5.2.4 Determination of Fluid Distribution Volumes ..................................................................... 67 
5.3 Results ............................................................................................................................ 68 
5.3.1 Fluid Volumes ...................................................................................................................... 68 
5.3.2 Insulin Clearance Parameters ............................................................................................... 70 
5.3.3 Summary of Insulin Model .................................................................................................. 71 
5.4 Discussion ...................................................................................................................... 72 
5.5 Summary ........................................................................................................................ 73 
5.6 Acknowledgements ........................................................................................................ 74 
Chapter 6: Modelling Endogenous Glucose Production .......................................................... 75 
6.1 Introduction .................................................................................................................... 75 
6.2 Methods.......................................................................................................................... 76 
6.2.1 Literature Review ................................................................................................................. 77 
viii 
   
6.2.2 Model Fit to Clinical Data ................................................................................................... 77 
6.2.3 Control Based Analysis ........................................................................................................ 81 
6.3 Results ............................................................................................................................ 82 
6.3.1 EGP and Patient Metrics ...................................................................................................... 82 
6.3.2 EGP and Glucagon ............................................................................................................... 83 
6.3.3 EGP and Blood Glucose ...................................................................................................... 85 
6.3.4 Control Analysis of EGP ...................................................................................................... 88 
6.4 Discussion ...................................................................................................................... 89 
6.4.1 Study Results ....................................................................................................................... 89 
6.4.2 Comparison to Literature ..................................................................................................... 90 
6.4.3 Study Limitations ................................................................................................................. 91 
6.5 Summary ........................................................................................................................ 92 
6.6 Acknowledgements ........................................................................................................ 92 
Chapter 7: Modelling Non Insulin-Mediated Central Nervous Glucose Uptake ..................... 93 
7.1 Introduction .................................................................................................................... 93 
7.2 Methods.......................................................................................................................... 94 
7.2.1 Central Nervous System Uptake .......................................................................................... 94 
7.2.2 Other Non-Insulin Mediated Glucose Uptake ...................................................................... 94 
7.2.3 Brain Mass Estimation ......................................................................................................... 94 
7.2.4 Patient Data .......................................................................................................................... 96 
7.2.5 Analyses ............................................................................................................................... 97 
7.3 Results ............................................................................................................................ 98 
7.3.1 Brain Mass Model Comparison ........................................................................................... 98 
7.3.2 Effect on Model-Based Insulin Sensitivity .......................................................................... 99 
7.3.3 Effect on Control ................................................................................................................ 101 
7.4 Discussion .................................................................................................................... 104 
7.5 Summary ...................................................................................................................... 105 
7.6 Acknowledgements ...................................................................................................... 105 
ix 
 
Chapter 8: Modelling Intestinal Glucose Absorption ............................................................ 107 
8.1 Introduction .................................................................................................................. 107 
8.2 Methods........................................................................................................................ 108 
8.2.1 Adaptation of the NICING Glucose-Insulin Model for Older Neonates ........................... 108 
8.2.2 The Gut Model ................................................................................................................... 109 
8.2.3 Parameter Identification ..................................................................................................... 110 
8.2.4 Feed Methods ..................................................................................................................... 110 
8.2.5 Clinical Data Cohorts ......................................................................................................... 111 
8.2.6 CGM Recalibration ............................................................................................................ 111 
8.2.7 Reported Absorption Rates for Comparison ...................................................................... 112 
8.3 Results .......................................................................................................................... 114 
8.3.1 Intestinal Glucose Absorption Constants from CGM Data ................................................ 114 
8.3.2 Comparison to Reported Absorptions ................................................................................ 119 
8.4 Discussion .................................................................................................................... 120 
8.4.1 CGM Derived Results ........................................................................................................ 120 
8.4.2 Contributions of Gastric Emptying and Feed Composition ............................................... 121 
8.4.3 Study Limitations ............................................................................................................... 122 
8. 5. Summary .................................................................................................................... 123 
8. 6. Acknowledgements .................................................................................................... 123 
Chapter 9: Model Summary ................................................................................................... 125 
9.1 Neonatal Intensive Care Insulin-Glucose-Nutrition (NICING) model ........................ 126 
9.1.1 Insulin ................................................................................................................................ 126 
9.1.2 Glucose .............................................................................................................................. 127 
9.1.3 Gut Model .......................................................................................................................... 128 
9.2 Model Solution and Fitting .......................................................................................... 129 
9.3 Summary ...................................................................................................................... 129 
Chapter 10: Protocol Development and Optimisation ........................................................... 131 
10.1 Introduction ................................................................................................................ 131 
x 
   
10.2 Methods...................................................................................................................... 132 
10.2.1 Stochastic Targeted Protocol Designs .............................................................................. 132 
10.2.2 Virtual Trial Methods....................................................................................................... 135 
10.2.3 Virtual Patient Data .......................................................................................................... 135 
10.2.4 Analyses and Performance Metrics .................................................................................. 137 
10.3 Results ........................................................................................................................ 137 
10.3.1 Comparison of Protocols .................................................................................................. 137 
10.3.2 Sensitivity Analysis on Protocol 1 ................................................................................... 140 
10.3.3 Selected Protocol.............................................................................................................. 140 
10.4 Discussion .................................................................................................................. 141 
10.5 Summary .................................................................................................................... 143 
Chapter 11: Clinical results .................................................................................................... 145 
11.1 Introduction ................................................................................................................ 145 
11.2 Methods...................................................................................................................... 145 
11.2.1 Model Dynamics and Stochastic Forecasting .................................................................. 145 
11.2.2 Protocol Definition ........................................................................................................... 146 
11.2.3 Clinical Cohorts ............................................................................................................... 146 
11.2.4 Clinical Implementation ................................................................................................... 148 
11.2.5 Analysis ............................................................................................................................ 151 
11.3 Results ........................................................................................................................ 151 
11.3.1 Clinical Results ................................................................................................................ 151 
11.3.2 Comparison to Simulation ............................................................................................... 153 
11.3.3 Per-patient Results ........................................................................................................... 153 
11.4 Discussion .................................................................................................................. 157 
11.4.1 Protocol Performance ....................................................................................................... 157 
11.4.2 Comparison to Simulation ............................................................................................... 158 
11.4.3 Comparison to Literature Results .................................................................................... 158 
11.4.4 Strengths and Limitations ................................................................................................ 159 
xi 
 
11.5 Summary .................................................................................................................... 161 
Chapter 12: Cohort Based Insulin Sensitivity Analysis ......................................................... 163 
12.1 Introduction ................................................................................................................ 163 
12.2 Methods...................................................................................................................... 164 
12.2.1 Glycaemic and Stochastic Models ................................................................................... 164 
12.2.2 Clinical data cohorts......................................................................................................... 165 
12.2.3 Calculation of Stochastic Model Accuracy ...................................................................... 166 
12.2.4 Stochastic Forecasting in Prematurity and Gender Sub-Cohorts ..................................... 167 
12.2.5 Statistical analysis ............................................................................................................ 167 
12.3 Results ........................................................................................................................ 167 
12.3.1 Insulin Sensitivity Across Different Cohorts ................................................................... 167 
12.3.2 Per-patient Stochastic Model Performance ...................................................................... 170 
12.3.3 Stochastic forecasting and SGA/AGA cohorts ................................................................ 172 
12.3.4 Gestational Age and Weight Sub-Cohorts ....................................................................... 173 
12.3.5 Insulin Sensitivity and Sex ............................................................................................... 176 
12.4 Discussion .................................................................................................................. 177 
12.4.1 Clinical Cohorts in Stochastic Models ............................................................................. 177 
12.4.2 Insulin Sensitivity and Patient Bedside Metrics ............................................................... 179 
12.5 Summary .................................................................................................................... 179 
Chapter 13: Conclusions ........................................................................................................ 181 
13.1 Major Chapter Outcomes ........................................................................................... 181 
13.2 General Conclusions .................................................................................................. 185 
Chapter 14: Current and Future Work ................................................................................... 187 
14.1 Use in Different NICU Centres .................................................................................. 187 
14.2 Quantification of the Effect of Glycaemic Control on Clinical Outcomes ................ 188 
14.3 Expansion of Approach into Paediatric Intensive Care ............................................. 188 
14.4 Quantification of External Contributions to Insulin Sensitivity ................................ 189 
14.5 Quantification of Physiological Influences on Insulin Sensitivity ............................ 189 
xii 
   
14.6 Investigation of SGA and Sex Based Cohorts ........................................................... 190 
14.7 Validation of Gut Models .......................................................................................... 190 
14.8 CGM use in Premature Infants .................................................................................. 190 
References .............................................................................................................................. 195 
 
  
xiii 
 
List of Figures 
 
Figure 1.1:  Preterm births in the USA by year and type. .......................................................... 3 
Figure 1.2: Population based model for prediction of survival rates in preterm infants. .......... 4 
Figure 1.3: Definition of hyperglycaemia, criteria for starting insulin, and blood glucose level 
(mM is mmol/L) range targeted for babies on insulin in neonatal units in Australasia............. 6 
Figure 1.4: Laboratory estimates of the whole blood glucose from a prospective study of 
babies born <32 weeks in England. ........................................................................................... 7 
Figure 1.5: The glucose insulin regulation system. ................................................................... 9 
Figure 1.6: Pathophysiology of stress hyperglycaemia in critical illness. ............................... 16 
Figure 2.1: Meta-analysis of risk ratios for mortality in trials comparing intensive insulin 
therapy (IIT) to conventional glycaemic control. .................................................................... 24 
Figure 2.2: Comparison of different glycaemic control approaches and their ability to capture 
patient variability. .................................................................................................................... 30 
Figure 2.3: Model based insulin sensitivity (SI) is independent of blood glucose (BG) 
concentration. ........................................................................................................................... 31 
Figure 3.1: NICU model of glucose-insulin metabolism. ........................................................ 40 
Figure 3.2: Pictorial description of the ICING model. ............................................................ 42 
Figure 3.3: Comparison of two models for glucose appearance from enteral feeds................ 43 
Figure 3.4: Stochastic forecasting of insulin sensitivity (SI) and blood glucose (BG) 
outcomes. ................................................................................................................................. 44 
Figure 4.1: Blood glucose, plasma insulin and C-peptide concentrations and insulin secretion 
at the time of randomisation to the HINT trial and 7-14 days later. ........................................ 53 
Figure 4.2: Endogenous insulin secretion and blood glucose with respect to protein (a & b) 
and total dextrose intake (c & d) on the day the sample was taken. ........................................ 55 
Figure 4.3: Endogenous insulin secretion with a) BG and plasma insulin concentration, and b) 
plasma insulin. ......................................................................................................................... 56 
Figure  5.1: Decrease of extracellular volume (ECV) with postnatal age. .............................. 69 
xiv 
   
Figure 5.2: Plasma and blood volume changes over time. ...................................................... 69 
Figure 5.3: Model based liver clearance parameters derived from plasma C-peptide and 
insulin concentrations. ............................................................................................................. 71 
Figure 6.1: Methodological approach to analysis, modelling, analysis, and evaluation of 
models of EGP in very premature infants. ............................................................................... 76 
Figure 6.2: Relationships between endogenous glucose production (EGP) with birth weight 
(BW) and gestational age (GA). .............................................................................................. 83 
Figure 6.3: Relationships between endogenous glucose production (EGP) with blood glucose 
(BG), plasma insulin, and glucose infusion rate (GI). ............................................................. 84 
Figure 6.4: Endogenous glucose production (EGP) and plasma glucagon concentration. ...... 84 
Figure 6.5: Plasma glucagon and: a) blood glucose (BG) and b) plasma insulin concentration.
.................................................................................................................................................. 85 
Figure 6.6: Endogenous glucose production (EGP) as a function of blood glucose (BG) over 
the literature cohort of 177 data points. ................................................................................... 86 
Figure 6.7: Sub-cohorts of studies which show: a) increasing endogenous glucose production 
(EGP) with blood glucose (BG), and b) suppression of EGP with BG. .................................. 86 
Figure 6.8: Comparison of literature based model of endogenous glucose production (EGP) 
with blood glucose (BG) and the minimum EGP required for adequate fit to clinical data 
(EGPmin). .................................................................................................................................. 87 
Figure 7.1: Comparison of BM and HC model estimations for brain mass, highlighting SGA 
infants. ...................................................................................................................................... 99 
Figure 7.2: Comparison of BM and HC model estimations for brain mass at different birth 
weight percentiles .................................................................................................................. 100 
Figure 7.3: Matched insulin interventions by birth weight cohort for a) cases A vs. B, and b) 
cases A vs. D .......................................................................................................................... 103 
Figure 8.1: Increasing CNS uptake with increasing conceptual gestational age (CGA), where 
CGA = GA + PNA/7. ............................................................................................................. 108 
Figure 8.2: Extracellular fluid volume (ECV) with gestational and postnatal age. ............... 109 
Figure 8.3: Linear glucose concentration across the small intestine. .................................... 113 
xv 
 
Figure 8.4: Per patient gut glucose absorption constants (d2) across the SUGAR-BABIES and 
Budapest cohorts .................................................................................................................... 114 
Figure 8.5: Fitting error over a representative selection of CGM trace sections from SUGAR-
BABIES data .......................................................................................................................... 116 
Figure 8.6: Fitting error across the d2 range for different feed administration periods. ........ 117 
Figure 8.7: A typical error surface showing sensitivity and trade off of gastric emptying (d1 ) 
and gut absorption (d2) parameters for a two compartment gut model. ................................. 118 
Figure 8.8: A typical error surface showing sensitivity and trade off gut absorption (d2) and 
insulin sensitivity (SI) parameters for a two compartment gut model. .................................. 118 
Figure 10.1: Stochastic forecasting of insulin sensitivity (SI) and blood glucose (BG) 
outcomes. ............................................................................................................................... 132 
Figure 10.2: Stochastic targeting and treatment selection for Protocols 1-4. ........................ 134 
Figure 10.3: Virtual patient development and in silico simulation method. .......................... 136 
Figure 10.4: Cumulative distributions of BG outcomes for Protocols 1 – 4. Distributions are 
presented for simulations marked 
† 
in Table 10.2. ................................................................. 138 
Figure 11.1: Dosing protocols use the forecast ranges of likely BG outcomes to select an 
appropriate insulin dose. ........................................................................................................ 147 
Figure 11.2: Clinical implementation of STAR glycaemic control. ...................................... 148 
Figure 11.3: STAR-GRYPHON graphical user interface for treatment calculation. ............ 150 
Figure 11.4: Blood glucose (BG) distributions for each patient cohort. ................................ 153 
Figure 11.5: STAR-GRYPHON clinical results for a) Patient 1, and b) Patient 2. Plots show 
blood glucose (BG), model-based insulin sensitivity (SI), and clinical insulin and nutrition 
treatments. .............................................................................................................................. 156 
Figure 12.1: Hourly insulin sensitivity variation data with probability bounds and example 
curve showing probability bounds. ........................................................................................ 164 
Figure 12.2: Stochastic model for 4 hourly predictions in insulin sensitivity (SI). ............... 165 
Figure 12.3: SI distribution and variability for Retrospective, STAR-NICU, and STAR-
GRYPHON clinical data cohorts. The legend applies to both plots. ..................................... 169 
xvi 
   
Figure 12.4: Per-patient performance across the entire patient cohort (N=95) of stochastic 
models generated from the entire patient cohort (N=95). ...................................................... 170 
Figure 12.5: Per-patient performance across the retrospective patient cohort (N=25) of 
stochastic models generated from the retrospective patient cohort (N=25). ......................... 171 
Figure 12.6: Per-patient performance across the STAR-GRYPHON patient cohort (N=16) of 
stochastic models generated from the STAR-NICU and retrospective patient cohorts (N=79)
................................................................................................................................................ 172 
Figure 12.7: Cumulative distributions of insulin sensitivity (SI) and variation in insulin 
sensitivity on the basis of weight for gestational age. ........................................................... 173 
Figure 12.8: Insulin sensitivity (SI) and insulin sensitivity variability with tertiles in a) 
gestational age (GA), and b) weight. ..................................................................................... 174 
Figure 12.9: Insulin Sensitivity with a) patient weight and b) gestational age. ..................... 175 
Figure 12.10: Insulin sensitivity (SI) and glycaemic variability between male and female 
infants. .................................................................................................................................... 176 
Figure 13.1: Humans are horribly variable. ........................................................................... 186 
  
xvii 
 
List of Tables 
 
Table 1.1 Common classifications of prematurity ..................................................................... 2 
Table 1.2: Worldwide rates of preterm birth. ............................................................................ 2 
Table 1.3: Survival outcomes in extremely preterm infants from several studies ..................... 5 
Table 1.4: Prevalence of hyperglycaemia over several studies ................................................. 8 
Table 1.5: Prominent glucose transporters in the human body ................................................ 11 
Table 4.1: Characteristics of babies randomised to the HINT trial whose plasma samples were 
analysed for plasma C-Peptide concentrations. ....................................................................... 49 
Table 4.2: Kinetic C-peptide parameter ranges in adults. ........................................................ 51 
Table 4.3: Insulin secretion and plasma glucose, insulin, IGF-1, C-peptide and cortisol 
concentrations. ......................................................................................................................... 52 
Table 4.4: Clinical characteristics, nutritional data and plasma insulin and c-peptide 
concentrations in boys and girls. .............................................................................................. 54 
Table 5.1: C-peptide model parameter values from Equations 4.4-4.7 ................................... 66 
Table 5.2: Clearance Parameters based on HINT C-peptide analysis and physiological ranges 
in adult subjects........................................................................................................................ 70 
Table 6.1 Overview of literature studies in endogenous glucose production in premature 
infants ....................................................................................................................................... 78 
Table 6.2:  Summary of patient metrics between the literature data and the clinical data 
cohorts ...................................................................................................................................... 80 
Table 6.3: Glucose model parameters used in the EGP analysis ............................................. 81 
Table 6.4: Values of constant EGP used to investigate effect on control ................................ 82 
Table 6.5: Comparison of model fit and control performance across different endogenous 
glucose production (EGP) models. .......................................................................................... 88 
Table 7.1: Mean statistics on body and brain mass. ................................................................ 95 
Table 7.2: Parameters in HC model. ........................................................................................ 96 
Table 7.3: Median [IQR] cohort demographics ....................................................................... 97 
xviii 
   
Table 7.4: Glucose model parameters used in the EGP analysis ............................................. 97 
Table 7.5: Combinations of assumed model and controller-perceived model used in virtual 
trials.......................................................................................................................................... 98 
Table 7.6: Deviations in SI profiles under different models .................................................. 100 
Table 7.7: Control interventions and outcomes from virtual trials for the entire cohort. ...... 101 
Table 7.8: Control interventions and outcomes from virtual trials for the SGA cohort ........ 102 
Table 7.9: Comparison of insulin interventions in simulation ............................................... 102 
Table 8.1: SUGAR-BABIES and Budapest patient cohort characteristics. ........................... 112 
Table 8.2: Glucose absorption constants with gestational age (GA) ..................................... 115 
Table 8.3: Intestinal glucose absorption rate constants derived from literature. ................... 119 
Table 9.1: Insulin kinetic parameters ..................................................................................... 127 
Table 9.2: Glucose kinetic parameters ................................................................................... 128 
Table 9.3: Glucose kinetic parameters ................................................................................... 128 
Table 10.1: Clinical characteristics of virtual patient cohort ................................................. 136 
Table 10.2: Virtual trial results for Protocols 1-4 .................................................................. 139 
Table 10.3: Virtual trial results for the optimisation of Protocol 1. ....................................... 141 
Table 11.1: Clinical results and glycaemic statistics by cohort. ............................................ 152 
Table 11.2:Virtual trial vs. Clinical results for the STAR-GRYPHON protocol. ................. 154 
Table 11.3: Individual results and protocol compliance across the STAR-GRYPHON cohort.
................................................................................................................................................ 155 
Table 12.1: Summary characteristics and glycaemic control statistics for retrospective, 
STAR-NICU, and STAR-GRYPHON clinical cohorts. ........................................................ 166 
Table 12.2: Whole cohort percentage of SI predictions within the 25
th
-75
th
 and 5
th
-95
th
 
percentile prediction ranges. .................................................................................................. 168 
Table 12.3: Patient numbers and SI hours for tertiles of gestational age (GA) and weight .. 174 
  
xix 
 
Nomenclature 
 
BG  Blood glucose 
BM model  Body mass model 
BW  Birth weight 
cdf  Cumulative distribution function 
CGM  Continuous glucose monitor 
CNS  Central nervous system 
CRIB2  Clinical risk index for babies 2 
DOR  Day of randomisation 
EBM  Expressed breast milk 
ECV  Extra-cellular volume 
EGP  Endogenous glucose production 
ELBW  Extremely low birth weight 
EN  Enteral nutrition 
GA  Gestational age 
GFR  Glomerular filtration rate 
GI  Glucose infusion 
GLUT  Glucose transporters 
HC model  Head circumference model 
HINT  Hyperglycaemia and Insulin in Neonates Trial 
ICING model  Intensive Care Insulin-Nutrition-Glucose model 
ICU  Intensive care unit 
IGF-1  Insulin-like growth factor 1 
IGUR  Inter-uterine growth retardation 
IIT  Intensive insulin therapy 
IQR  Inter quartile range 
ISIG  CGM measured current 
IV  Intra-venous 
IVH  intraventricular haemorrhage 
LBW  Low birth weight 
NEC  necrotising enterocolitis 
NICING model  Neonatal Intensive Care Insulin-Nutrition-Glucose model 
NICU  Neonatal intensive care unit 
NIRTURE  Neonatal Insulin Replacement Therapy in Europe 
NZ  New Zealand 
xx 
   
PICU  Paediatric intensive  care unit 
PN  Parenteral nutrition 
PNA  Post natal age 
PROM  Premature rupture of membranes 
ROP  Retinopathy of Prematurity 
SEM  Standard error measurement 
SGA  Small for gestational age 
SI  Insulin sensitivity 
STAR  Stochastic TARgeted 
STAR-GRYPHON protocol  
Stochastic TARgeted Glucose Regulation sYstem to Prevent Hyper- 
and hypO-glycaemia in Neonates protocol 
STAR-NICU protocol  Stochastic TARgeted NICU protocol 
SUGAR-BABIES trial  
Randomised control trial of dextrose gel to treat hypoglycaemia in 
neonates 
TGC  Tight glycaemic control 
TPN  Total parenteral nutrition 
USA  United States of America 
VLBW  Very low birth weight 
   
   
   
   
   
   
   
 
 
  
xxi 
 
Abstract 
 
In neonatal intensive care hyperglycaemia is a common complication of prematurity, and has 
been associated with worsened outcomes. While not as extensive as in adult and paediatric 
intensive care, there is still a great deal of debate and study surrounding the use of insulin 
therapy for glycaemic control in premature infants. It has been well established that insulin 
therapy allows greater glucose tolerance and weight gain. 
However, the effect of insulin therapy on other clinical outcomes is not as well defined. In 
particular, a much higher incidence of hypoglycaemia is seen in many studies of insulin 
therapy in this cohort, which confounds results. Thus, the primary weakness of most studies 
in this area is that they seek to establish the effect of tight glycaemic control on outcomes 
without first developing a safe and effective protocol or tool for insulin therapy.  
In neonatal intensive care there is no universal consensus on insulin therapy implementation, 
or well established threshold for hyperglycaemia and defined, outcome-based target range for 
control. When insulin therapy is used, many protocols are ad hoc, or utilise sliding scale 
based methods that fail to account for variability between patients, or changing patient 
condition over time. This situation is completely analogous to the adult intensive care 
situation. 
Physiological model-based protocols offer great potential for allowing patient-specific care. 
Model-based tight glycaemic control methods have been shown to provide safe and effective 
control in adult intensive care units, and have demonstrated improved outcomes in treated 
patients. To date, only one such protocol exists in neonatal intensive care. The aim of this 
thesis is to improve on this protocol through more comprehensive modelling of glucose-
insulin physiology, and optimisation of the clinical application of these methods.  
Over the course of this thesis the NICING (Neonatal Intensive Care Insulin-Nutrition-
Glucose) model is developed. This model is based on the best aspects of two previously 
clinically validated models in neonatal and adult intensive care, respectively. In particular, 
the resulting model is more physiologically descriptive than the previous neonatal glucose-
insulin model. 
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A model of insulin secretion was developed specific to very premature infants using very 
unique data set collected from a recent study of glycaemic control in neonatal intensive care. 
In particular, C-peptide was used to provide quantitative estimates for insulin secretion, 
where previous work in the literature has only indirectly assessed it through peak plasma 
insulin concentration, or plasma insulin AUC. Results showed that insulin secretion was best 
modelled as a function of blood glucose concentration, and that it differed significantly 
between male and female very premature infants, a unique discovery in its own right.  
Insulin clearance was examined, and different clearance pathways of insulin are modelled. 
These pathways include liver and kidney clearance, trans-capillary diffusion, and cellular 
degradation. In particular, kidney clearance is made more patient-specific, and interstitial 
fluid volume contraction following birth has also been incorporated into the model.  
Endogenous glucose production was examined through extensive analysis of tracer studies in 
the literature for the very premature infant cohort. While endogenous glucose production 
varied significantly between patients and between studies, production was found to be 
suppressed with increasing glucose infusion over all studies, and suppressed with increasing 
blood glucose concentration over most of the studies. However, the major conclusion of the 
analysis was that variability outweighs the ability to derive a patient-specific model of 
endogenous glucose production. As a result, a simple constant for endogenous glucose 
production proved most effective in modelling and control. 
Central nervous system uptake plays a significant role in non-insulin mediated glucose 
uptake. While relatively constant in adults, brain mass in premature infants is more variable 
than in adults, both between patients and over time. As a result central nervous system uptake 
is modelled as a constant proportional to brain mass, and two models for brain mass 
estimation were compared. Both head circumference and body mass based models resulted in 
similar model-based insulin sensitivity profiles, and thus similar control outcomes.  
One significant inclusion in the new NICING model was a two compartment gut model. The 
two compartments of the new model include glucose appearance in the stomach and gut. In 
premature infants gastric emptying is slower than in term infants, so can be modelled with a 
half life of around 40 minutes (d1=0.017 min
-1
), as opposed to around 20 minutes in term 
infants. CGM data showing the appearance of glucose from enteral feeds in term and 
premature infants was used to estimate the rate constant for glucose absorption from the gut 
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to the bloodstream. This absorption rate constant varied between infants and over time, and 
the median absorption constant was found to be d2=0.014 min
-1
, which corresponds to an 
absorption half life of 50 minutes.  
The new NICING model was used alongside stochastic forecasting methods in simulation to 
develop and optimise a STAR (Stochastic TARgeted) glycaemic control protocol for neonatal 
intensive care. This protocol used forecast ranges of likely insulin sensitivity outcomes to 
generate likely outcomes in blood glucose. Insulin doses were chosen such that these blood 
glucose outcome ranges overlapped a clinically specified target range. The resulting protocol, 
denoted the STAR-GRYPHON (Glucose Regulation sYstem to Prevent Hyper- and hypO-
glycaemia in Premature Neonates) protocol, dosed insulin such that the 5
th
 percentile of blood 
glucose predictions was within a lower limit tolerance of 4.0-4.4 mmol/L. Additional limits 
on the amount by which insulin can increase were applied. These limits are blood glucose 
dependent, and allow higher changes between doses at blood glucose levels greater than 9.0 
mmol/L. They also limit the amount by which an insulin infusion can potentially increase to 
0.01 U/kg/hr at blood glucose concentrations less than 6.0 mmol/L, thus adding additional 
safety from hypoglycaemia. 
The STAR-GRYPHON protocol was implemented clinically. A total of 13 patients, spanning 
16 glycaemic episodes, were treated under this protocol, and showed 76.6% of blood glucose 
within the clinically targeted range of 4.0-8.0 mmol/L. This performance is similar to the 
performance predicted in simulation of 76.9%. There were no incidences of blood glucose 
less than 3.5 mmol/L, and the incidence of hyperglycaemia was almost half that predicted in 
simulation.  Overall performance is significantly better than retrospective and previous 
clinical results, and is better than any literature results to date, indicating that STAR-
GRYPHON is safe and effective in clinical use.  
Overall, a series of analyses have lead to a more physiologically descriptive model and 
optimised glycaemic control model and protocol for glycaemic control in very premature 
infants. Early results show significantly improved performance and safety over previous work 
and all the literature to date.  Future work will follow up on its use in other New Zealand 
neonatal intensive care units (NICUs), and also NICU‟s in Europe.  
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Chapter 1 - Prematurity and Neonatal Glycaemia 
 
 
 
 
 
The economics of healthcare are becoming increasingly difficult. Healthcare costs are 
increasing rapidly, driven in part by greater technological use and the increasing demand 
generated by higher critical illness/injury survival rates and aging populations (Bloomfield, 
2003, Dorman and Pauldine, 2007). Such economic trends are unsustainable, eroding the 
quality, access and equity of healthcare for all. In addition, the future of health is increasingly 
viewed as personalised, predictive, preventive and participatory (Hood and Friend, 2011), as 
well as needing to be more productive and economically affordable. In summary, better, more 
productive and less costly care is the necessary future of healthcare. 
Disproportionate to both cohort and patient size, the neonatal intensive care cohort is one of 
the most vulnerable, and the most expensive, hospital cohorts. The costs associated with 
neonatal care increase with increasing prematurity, and are highest  in premature infants born 
with a birth weight of less than 1000g birth weight (Kromhout et al., 1987). Despite higher 
mortality rates (Costeloe et al., 2012), costs associated with these infants are much higher due 
to increased incidence and severity of morbidities in surviving infants (Kromhout et al., 
1987).  
Hyperglycaemia, abnormally elevated blood glucose concentrations, is a common 
complication of prematurity, stress, and illness in neonatal intensive care. Hyperglycaemia 
has been associated with a range of common morbidities in neonatal intensive care. This 
chapter will first introduce prematurity and its incidence and outcomes. It will then describe 
the effect of prematurity on glucose and insulin metabolism, and its associated detrimental 
effects on outcomes. The purpose is to provide a case for research into the treatment of 
hyperglycaemia in this cohort, and a basis for the potential benefits of this therapy.  
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1.1 Prematurity 
1.1.1 Definition  
Premature infants are those born before the standard gestational period (in humans ~40 
weeks) is completed. These infants are commonly classified according to their birth weight 
(BW) and/or gestational age (GA), as summarised in Table 1.1. While prematurity is 
commonly defined as infants born less than 37 weeks GA, this cohort is further divided into 
very premature (GA<31 weeks) and extremely premature (GA<27-28 weeks) infants. 
Alternatively, premature neonates may be categorised as low birth weight (LBW: 
BW<2,500g), very low birth weight (VLBW: BW<1,500g), extremely low birth weight 
(ELBW: BW<1,000g), or micropremie (BW<800g). 
Table 1.1 Common classifications of prematurity 
Classification by gestational age (GA) Classification by birth weight (BW) 
Premature : GA<37 weeks 
Very premature: GA<31 weeks 
Extremely premature: GA≤27 weeks 
Low birth weight (LBW): BW<2,500g 
Very low birth weight (VLBW): BW<1,500g 
Extremely low birth weight (ELBW): 
BW<1,000g 
Micropremie: BW<800g 
 
1.1.2 Epidemiology 
Across Europe and most developed countries around 5-9% of all births are premature. This 
rate is higher in the USA with around 12-13% of all births being premature (Goldenberg et 
al., 2008, Tucker and McGuire, 2004). Table 1.2 provides a broad international set of rates of 
premature birth (Table 1.1). In New Zealand around 6.4% of all births are preterm (Beck et 
al., 2010). The incidence of premature birth before 32 weeks gestational age is around 1-2% 
(Tucker and McGuire, 2004).  
Table 1.2: Worldwide rates of preterm birth. Adapted from: Beck et al. (2010) 
Country Preterm birth rate % 
World Total 9.6 
Africa 11.9% 
Asia 9.1% 
Europe 6.2% 
North America 10.6% 
Australia/New Zealand 6.4% 
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There are 3 main reasons for premature birth: 1) Maternal or foetal indications; 2) 
spontaneous labour; and 3) premature rupture of membranes (PROM). Maternal or foetal 
medical indications account for 30-35% of all preterm births (Goldenberg et al., 2008), and 
include cases such as preeclampsia, inter-uterine growth retardation (IGUR), small size for 
gestational age (SGA), foetal distress, and placental abruption, to name a few (Ananth and 
Vintzileos, 2006). Spontaneous labour accounts for 40-45% of preterm births, while PROM 
accounts for 35-35% of preterm birth in the USA (Goldenberg et al., 2008). Figure 1.1 
provides a breakdown for the USA as an illustration. 
 In the USA, overall preterm birth rates are slowly rising (Figure 1.1). This rise is 
predominantly due to an increase in medically indicated preterm deliveries, although 
spontaneous preterm births have dropped slightly (Goldenberg et al., 2008). Other factors 
contributing to the increase in preterm births include increasing use of assisted reproduction 
techniques,  changes in clinical practice, and misclassification of foetal loss/stillbirth/foetal 
death (Tucker and McGuire, 2004).  
 
 
Figure 1.1:  Preterm births in the USA by year and type. Source: Goldenberg et al. 
(2008). 
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Risk factors and causes of premature birth are hard to pinpoint, but include 
infection/inflammation, utero-placental ischemia or haemorrhage, uterine over distension, 
stress,  or immunological mediated processes (Goldenberg et al., 2008). Prominent risk 
factors include: ethnicity, socio-economic factors, previous pregnancy history, multiple births 
(i.e. twins or triplets), and smoking (Goldenberg et al., 2008, Tucker and McGuire, 2004). In 
New Zealand, maternal smoking and multiple births have been identified as important risk 
factors (Wright et al., 1998). 
1.1.3 Outcomes of Prematurity 
It is estimated that 75-80% of all perinatal deaths occur in foetuses delivered prematurely, 
and that 40% of these deaths occur in infants born at less than 32 weeks gestation (Ananth 
and Vintzileos, 2006).  Survival increases with gestational age and birth weight, as shown in 
Figure 1.2 and Table 1.3, with a gestational age of 22-23 weeks typically considered the limit 
for viability outside the womb. Over 22-27 weeks gestational age, the rates of survival 
increase significantly, and around 85% of preterm neonates born at 27 weeks gestational age 
survive the neonatal period.  
 
 
Figure 1.2: Population based model for prediction of survival rates in preterm infants. 
Source : Manktelow et al. (2013). 
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Table 1.3: Survival outcomes in extremely preterm infants from several studies 
 Survival rate (%) 
 22 weeks 23 weeks 24 weeks 
25 
weeks 
26 
weeks 
27 weeks 
Kyser et al. (2012) 33 58 87 85 - - 
Draper et al. (1999) 2 6 16 54 72 84 
Manktelow et al. 
(2013) 
- 27 52 65 77 85 
Costeloe et al. 
(2012) 
3 26 51 3 81  
 
In surviving infants, preterm birth is implicated in long term morbidities, developmental 
disabilities, and thus high healthcare costs (Ananth and Vintzileos, 2006). Further, because of 
increased survival, it is estimated that infants born with birth weight less than 1000g 
represent most of the patient days in the NICU (Farrag et al., 1997). Hence, these ELBW 
(Table 1.1) infants are of particular concern. 
1.2 Neonatal Hyperglycaemia 
1.2.1 Definitions and Thresholds 
Hyperglycaemia is generally defined as abnormally elevated blood glucose (BG) 
concentration. There is no universally accepted quantitative description or threshold for 
clinical hyperglycaemia, or a best practice target range for glycaemic control. This lack of 
definitions was demonstrated in a recent survey of neonatal units in Australasia (Alsweiler et 
al., 2007), where there was significant variation in the range of basal BG levels targeted. 
Figure 1.3 summarises these results, and clearly shows a wide range of expectations.  
While clinical hyperglycaemia is commonly defined as BG>10 mmol/L (180 mg/dL), in the 
literature this threshold is often significantly lower at 6.9-8.3 mmol/L (125-150 mg/dL) 
(Cowett et al., 1979, Hall et al., 2004, Hays et al., 2006, Louik et al., 1985, Vaucher et al., 
1982). Current working definitions for hyperglycaemia (BG> 7-8 mmol/L) are based on 
statistical distributions of BG levels in term infants (Hey, 2005). However, these statistical 
definitions may describe what is “normally” found, but not necessarily what is clinically 
desirable in this cohort (Hey, 2005).  
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Figure 1.3: Definition of hyperglycaemia, criteria for starting insulin, and blood glucose 
level (mM is mmol/L) range targeted for babies on insulin in neonatal units in 
Australasia. Circles show definition of hyperglycaemia, open/closed squares show the 
threshold for starting insulin therapy (without/with additional glycosuria thresholds). 
Arrows define the target blood glucose range for a unit. Source Alsweiler et al. (2007). 
 
For example, Figure 1.4 shows the distribution of BG levels in preterm infants of gestational 
age 32 weeks or less. While the 50
th
 percentile is roughly “normal,” a high percentage of BG 
levels were hypoglycaemic (BG<2.5 mmol/L), and also hyperglycaemic (BG>7-8 mmol/L), 
by statistical definition. In addition, no studies have attempted to define hyperglycaemia in 
the ELBW  preterm infant (BW<1000g) (Pildes and Pyati, 1986). Thus there is a lack of clear 
definition of what are acceptable levels of BG in these cohorts. 
In his review, Hey suggests a pragmatic working definition of hyperglycaemia is 
BG>12mmol/L (Hey, 2005).  However, as shown in Figure 1.3, insulin treatment is often 
initiated at much lower BG levels. In the Christchurch Women‟s Hospital NICU, the clinical 
centre for this thesis, hyperglycaemia is clinically defined as BG>10.0 mmol/L, and insulin 
therapy is initiated with two consecutive BG>10.0 mmol/L. 
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Figure 1.4: Laboratory estimates of the whole blood glucose from a prospective study of 
babies born <32 weeks in England. Source: Hey (2005). 
 
1.2.2 Prevalence of Hyperglycaemia 
Hyperglycaemia is a common complication of prematurity, particularly with lower 
gestational age and/or lower birth weight infants (Lilien et al., 1979, Louik et al., 1985). 
Table 1.4 reflects this increasing prevalence in lower birth weight infants across a number of 
studies. Differences in the definition of hyperglycaemia and weight ranges between studies 
make overall incidence difficult to determine. However, it can be reasonably stated that 
around 30-50% of infants with birth weight less than 1.5 kg are likely to have a least one 
BG>8.3 mmol/L (150 mg/dL). Hyperglycaemia is more common in infants receiving more 
than 8 mg/kg/min of glucose infusion (Brans et al., 1974, Cowett et al., 1979, Pildes and 
Pyati, 1986), whereas the term infant is better able to tolerate much greater glucose delivery  
(Brans et al., 1974). 
1.3 Background Physiology: Glucose-Insulin Metabolism.  
Glucose is a six carbon sugar that is a key fuel source in the body. When food is ingested, 
complex carbohydrates and sugars are broken down into glucose, which is the fundamental 
building block of carbohydrate molecules. The glucose is then absorbed into the blood 
stream, and is either utilised for energy or stored as fat or glycogen for later utilisation.  
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Table 1.4: Prevalence of hyperglycaemia over several studies 
Study Cohort Incidence 
Dweck and 
Cassady 
(1974) 
Birth 
weight<1.1kg 
 85% had episode(s) of BG> 6.9 mmol/L (125 mg/dL) 
 72% had episode(s) of BG> 16.7 mmol/L (300 mg/dL) 
Cowett et 
al. (1979) 
AGA preterm 
infants with 
BW<1.5kg 
 0% of infants receiving ~8 mg/kg/had BG>8.3 
mmol/L (150 mg/dL) 
 50% of infants receiving ~11 mg/kg/min had 
maximum BG> 8.3 mmol/L (150 mg/dL), and 50% 
had maximum BG> 11.1 mmol/L (200 mg/dL) 
 100% of infants receiving ~14 mg/kg/min had 
maximum BG> 8.3 mmol/L (150 mg/dL), and 50% 
had maximum BG> 11.1 mmol/L (200 mg/dL) 
Louik et al. 
(1985) 
Preterm infants 
 BW<1kg: 29% had episode(s) of BG>8.3 mmol/L 
(150 mg/dL) 
 1kg<BW<1.5kg: 8.6% had episode(s) of BG>8.3 
mmol/L (150 mg/dL) 
Heimann 
et al. 
(2007) 
BW<1.5kg 
 49.6% had 1-3 BG measures > 8.3 mmol/L (150 
mg/dL) 
 19.9% had more than 4 BG measures > 8.3 mmol/L 
(150 mg/dL) 
Hays et al. 
(2006) 
BW<1kg 
 From days 2-7, 57% had BG> 8.3 (150 mg/dL), and 
32% had BG> 13.9 mmol/L (250 mg/dL) 
 Of ELBW infants, 42% had BG> 8.3 mmol/L (150 
mg/dL) consistently 
 Of all infants, 25% had consistent BG> 11.1 mmol/L 
(200mg/dL), and 16% had consistent BG> 13.9 
mmol/L (250 mg/dL) 
Hall et al. 
(2004) 
Infants with 
necrotising 
enterocolitis 
BW: 1.31 ± 
0.09kg SEM 
 69% of infants had episode(s) of BG> 8 mmol/L 
Zarif et al. 
(1976) 
BW<2kg 
 BG> 6.9 mmol/L (125 mg/dL) was observed in 32 of 
75 infants (43%) 
Brans et al. 
(1974) 
Term and 
premature 
(BW<1.5KG) 
 BG> 6.9 mmol/L (125 mg/dL) was observed in all 
premature infants (n=11). No hyperglycaemia was 
seen in term infants at all feed rates. 
 
In contrast to muscle cells, which have a local store of glycogen, central nervous and 
neuronal tissues require a constant supply of free glucose (Tirone and Brunicardi, 2001). The 
brain is the single largest consumer of glucose in the adult body, accounting for 
approximately 50% of the body's glucose use, while 25% is used by the liver, and the 
remainder by insulin-dependent tissues, such muscle and adipose tissue (Triplitt, 2012).  
Thus, the brain and other neuronal tissues are heavily reliant on a constant supply of glucose 
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delivered via the blood stream as their main fuel source. Accordingly, blood glucose 
concentrations are regulated to a tight normal range, and concentrations outside this range 
either deprive cells of fuel or have patho-physiological effects. Regulation of blood glucose 
involves the complex interaction of a number of blood species, including glucose, insulin, 
glucagon, and a number of hormones, shown schematically in Figure 1.5.   
1.3.1 Glucose Production and Clearance  
Within the body, glucose can be produced from fat breakdown, from proteins via 
gluconeogenesis, and from glycogen via glycogenolysis. Gluconeogenesis occurs primarily in 
the liver, although after prolonged fasting and sustained acidosis it can also occur in the 
kidneys (Tirone and Brunicardi, 2001). Gluconeogenesis is regulated by pancreatic 
hormones, intracellular substrate levels, free fatty acid levels, and counter regulatory 
hormones. In addition, it can also be regulated by the central nervous system, whereupon 
sympathetic and parasympathetic nerves stimulate glucose production in the liver in response 
to hypoglycaemia in the brain (Tirone and Brunicardi, 2001).  
 
 
Figure 1.5: The glucose insulin regulation system. Blue, red, and grey arrows represent 
glucose,  insulin, and glucagon respectively. Plus (+) and minus (-) signs are used to 
described the effect of glucose, insulin, and glucagon and metabolic process. Source: 
Schaller et al. (2013). 
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Gluconeogenesis is supplemented by glycogenolysis, which is the process that converts 
glycogen stores to glucose for use. In an adult, glycogen stores in the body can be used for 
approximately 8 hours before they run out (Tirone and Brunicardi, 2001). Following a 10 
hour fast, gluconeogenesis makes up approximately 30% of total hepatic glucose production, 
while the rest is produced via glycogenolysis (Tirone and Brunicardi, 2001).  
Counter-regulatory hormones, such as cortisol, growth hormones, thyroid hormones, and 
catecholamines like adrenalin, epinephrine, and norepinephrine, and angiotensin II, can 
stimulate hepatic glucose production. For example, epinephrine stimulates glycogenolysis, 
cortisol stimulates gluconeogenesis, and norepinephrine and angiotensin indirectly promote 
glycogenolysis via intracellular signalling (Tirone and Brunicardi, 2001). Thus, these 
hormones, often seen as part of any stress response, can also stimulate energy creation as part 
of the "fight or flight" reflex. 
Glucose uptake by cells is facilitated by glucose transporters (GLUTs). These transporters 
provide an aqueous pore through which glucose can pass through the hydrophobic cell 
membrane. Once glucose enters a cell it is used either as a fuel source or is stored. It cannot 
leave the cell after entering. There are 5 main types of GLUT transporter, varying by tissue 
location (Tirone and Brunicardi, 2001, Triplitt, 2012). These are summarised in Table 1.5. 
Importantly, the GLUT4 glucose transporter is the insulin dependent transporter that enables 
the muscle/adipose cell to take up glucose via insulin-mediated exchange.  
1.3.2 Insulin Secretion and Clearance 
Insulin is an important agent in the regulation of blood glucose. Insulin mediates the uptake 
of glucose in muscle and adipose tissues by increasing the number of activeGLUT 4 
transporters in the cell membrane (Tirone and Brunicardi, 2001). Insulin is produced by Beta 
cells in the Islets of Langerhans in the pancreas, and is secreted into the portal vein in 
response to elevated blood glucose levels, such as following glucose ingestion (Tirone and 
Brunicardi, 2001, Triplitt, 2012). There is a first pass hepatic extraction of this insulin of ~30-
80% (Ferrannini and Cobelli, 1987, Meier et al., 2005, Toffolo et al., 2006) before the 
remainder is transported around the body.  Elevated plasma insulin concentrations restrict 
lipolysis and proteolysis, reducing glucose precursor availability to the liver, and thus, in 
normal function, inhibiting hepatic glucose production (Tirone and Brunicardi, 2001).  
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Table 1.5: Prominent glucose transporters in the human body 
Glucose 
Transporter 
Tissues found 
in 
Insulin 
dependency 
Action 
GLUT1 All cells Independent 
Particularly responsible for glucose 
transport across blood-brain barrier 
GLUT2 
Primarily 
pancreas and 
liver 
Independent 
Not easily saturated, therefore allows 
Beta cells in Pancreas to be sensitive 
to changes in glucose concentrations 
GLUT3 
Neurons, 
intestine, 
testicles, 
kidneys 
Independent 
Allows uni-directional co-transport of 
sodium and glucose in small intestine 
and proximal tubules of kidney. Can 
transport glucose against glucose 
concentration gradient when it is along 
a sodium concentration gradient. 
GLUT4 
Muscle and 
Adipose tissue 
Dependent 
Insulin causes translocation of GLUT4 
from intracellular vesicles to the cell 
membrane 
GLUT5 
Jejununal brush 
border 
(intestines) 
Independent Transports Fructose 
 
The liver and the kidneys are the primary sites of insulin clearance in the body, accounting 
for the majority of peripheral insulin clearance. Liver clearance of insulin increases with 
nutrient uptake via the gut, due to hormone signalling. A glucose infusion delivered directly 
into the portal vein does not have this effect. Liver clearance of insulin is also a receptor-
binding process, so while at elevated plasma insulin concentrations overall insulin clearance 
may be higher, the total fractional extraction is often lower, (Duckworth et al., 1998).  
The kidneys clear approximately 50% of peripheral circulating insulin, and are also 
responsible for the clearance of around 50% of pro-insulin, an insulin precursor, and 70% of 
C-peptide, a molecule secreted in equal molar quantities with insulin due to the cleavage of 
pro-insulin into insulin and C-peptide. Insulin is cleared in the kidneys via glomerular 
filtration  and absorption from the peritubular capillaries (Rabkin et al., 1984). Cleared 
insulin is degraded, so very little insulin is eventually secreted into urine (Duckworth et al., 
1998).  
1.3.3 Glucagon's Regulatory Effect  
Glucagon is another regulatory hormone secreted by the Alpha cells in the Islets of 
Langerhans in the pancreas.  Elevated plasma insulin levels, and/or low blood glucose levels, 
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stimulate glucagon secretion by the pancreas and mobilise glucogenetic precursors. Elevated 
glucagon concentrations in the portal vein stimulate both gluconeogenesis and glycogenolysis 
in the liver. Glucagon‟s effect on gluconeogenesis is persistent, whereas its effect on 
glycogenolysis is more short lived (Tirone and Brunicardi, 2001). In turn, the increased 
hepatic glucose production raises blood glucose levels, which suppresses the secretion of 
glucagon (Tirone and Brunicardi, 2001). Glucagon is thus an important and powerful 
hormone that is used to raise blood glucose levels and ensure the brain and other organs 
receive enough glucose to meet their demands. 
1.3.4 Glycaemic Levels and Hormones 
Overall, blood glucose levels are tightly regulated by a range of hormone actions. Blood 
glucose levels are raised by gluconeogenesis and glycogenolysis, instigated by glucagon or 
counter-regulatory hormones, such as cortisol, growth hormones, thyroid hormones or 
catecholamines. Blood glucose levels are lowered primarily by insulin mediated uptake by 
the liver and periphery. In normal function, these hormones act in concert to maintain or 
restore normal glycaemic levels or glucose homeostasis. 
1.4 Neonatal Glycaemia  
1.4.1 Foetal Glycaemic Development 
While in the womb, foetal glucose homeostasis is dependent on placental glucose transfer, 
where the foetal glucose pool is in equilibrium with the mother‟s, and foetal endogenous 
glucose production is minimal or non-existent (van Goudoever et al., 1993). During a normal 
term birth the supply of glucose is interrupted, and the infant‟s body mounts an endocrine 
stress response. Catecholamines concentrations, such as adrenaline and epinephrine, cortisol, 
and glucagon, increase, and plasma insulin concentrations decrease. The low plasma insulin 
to glucagon ratio then stimulates both glycogenolysis and gluconeogenesis, and lipolysis and 
muscle protein breakdown provides substrates for these processes (van Goudoever et al., 
1993). Glucose uptake in all cells is primarily due to the presence of GLUT1 transporters in 
the foetus (Cowett and Farrag, 2004). After birth, GLUT1 decreases and the amounts of other 
GLUT transporters increase (Cowett and Farrag, 2004).   
However, in the case of the premature infant, the glucose regulation system is under-
developed. In the womb, the foetal pancreas appears to be the major source of insulin (Adam 
13 
 
et al., 1969b), and it been shown to secrete insulin in response to glucose or amino acids from 
the 20
th
 week of gestation (van Goudoever et al., 1993). Overall foetal plasma insulin levels 
are higher than in the adult case, but the action of this insulin is modulated by glucocorticoids 
and is inactive until sometime later in the second trimester of pregnancy (weeks 13-28) (van 
Goudoever et al., 1993). One study suggests that bi-phasic insulin secretion in response to 
nutrient release does not begin to mature until after birth (Otonkoski et al., 1988). Thus, 
premature infants have reduced capacity to secrete and utilise insulin to lower blood glucose, 
in comparison to their term counterparts.  
Glycogen synthesis starts in the second trimester, and increases slowly until the 36
th
 week of 
gestation. Glycogen is not stored until the 27
th
 week of gestation (van Goudoever et al., 
1993). Thus, if an infant is extremely premature (<27 weeks gestation) it lacks the glycogen 
stores of adults and older babies that are used to provide energy. These infants typically 
require exogenous intra-venous (IV) glucose infusion soon after birth to prevent 
hypoglycaemia. In addition, premature infants have also been shown to have inadequate 
glucagon secretion at low blood glucose levels, and thus have low hepatic glucose 
production, even if substrates are available (Hume et al., 2005). Hence, these infants have 
inadequate and dysfunctional regulation with respect to the ability to raise low blood glucose 
levels.  
Similarly, in the presence of an exogenous glucose infusion persistent endogenous glucose 
production was observed in new born infants, particularly in the premature infant group 
(Cowett et al., 1983). This result is in  to contrast with the normal adult case, where 
endogenous glucose production is suppressed with high exogenous glucose infusion (Wolfe 
et al., 1979).  Thus, equally, there is a dysfunctional regulation response to higher blood 
glucose levels and availability.  
1.4.2 Causes of Neonatal Hyperglycaemia 
Defective beta-cell processing of proinsulin 
Pro-insulin is a polypeptide chain that is a precursor to insulin and C-peptide, and is 10 times 
less active than insulin (van Goudoever et al., 1993). It has been shown that the pancreas of a 
premature neonate is sensitive to changes in blood glucose, and will secrete pro-insulin in 
response to elevated blood glucose levels and decrease secretion in response to an insulin-
infusion induced drop in blood glucose. However, insulin levels were not significantly 
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different than in euglycaemic (normal blood glucose) premature infants, suggesting defective 
processing of the proinsulin to insulin (Mitanchez-Mokhtari et al., 2004), which enables 
rising glucose. 
Relative insulin resistance 
Elevated plasma insulin and C-peptide concentrations of preterm infants in comparison to 
term infants has been used as evidence to suggest that premature infants are more resistant to 
insulin. In addition, similar plasma insulin concentrations in hyperglycaemic infants when 
compared to euglycaemic infants, and subsequent treatment with exogenous insulin to bring 
about euglycaemia, suggests that hyperglycaemic premature infants are more resistant than 
their euglycaemic counterparts (Mitanchez-Mokhtari et al., 2004). Thus, these infants are less 
able to use insulin to lower blood glucose levels than normal, term infants. 
No suppression of endogenous glucose production 
Several studies show that endogenous glucose production in the term infant persists, despite 
exogenous glucose infusions around basal rates (4-6 mg/kg/min) (Cowett et al., 1983, 
Sunehag et al., 1994b). Only one study has observed suppression of endogenous glucose 
production with intravenous glucose (Hertz et al., 1993). This lack of suppression contrasts 
the normal adult case in which endogenous glucose production is suppressed with high 
exogenous glucose infusion (Wolfe et al., 1979). Equally, glucose production has also been 
shown to persist in the presence of exogenous insulin infusion (Farrag et al., 1997), where the 
normal response would be suppression. Hence, unsuppressed endogenous glucose production 
enables rising blood glucose. 
Glucose Transporters (GLUTs)  
In new-borns and premature infants the concentrations of the GLUT1 transporter are 
relatively high, while other transporters, including GLUT2 are low (Mitanchez, 2007). The 
lower number of GLUT2 transporters (see Table 1.5) could mean that pancreatic beta cells 
are not as sensitive to changes in blood glucose as in adults, thus reducing the degree to 
which the liver can respond to increased glucose and insulin concentrations (Farrag and 
Cowett, 2000). In addition, diminished GLUT4 transporters would limit the amount of 
insulin-mediated glucose uptake by muscle and adipose tissue (Farrag and Cowett, 2000). All 
these effects reduce the ability to lower elevated blood glucose levels. 
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Infection 
Hyperglycaemia has also been identified as a predictor for septicaemia in this cohort 
(Fanaroff et al., 1998). In a trial of glycaemic control, increased sepsis was seen in the control 
group, and was identified as a contributor to glucose intolerance (Collins et al., 1991). In turn, 
infection is associated with increased neurologic morbidities (Van Kempen et al., 2005a). 
However, whether hyperglycaemia is a risk factor or a result of infection is debated, with 
both likely to be true in reality (Bistrian, 2001). Metabolically, infection reduces the ability of 
insulin to act. 
Stress 
Stress leads to counter-regulatory hormone secretion. In some studies stress was shown to be 
a significant factor responsible for hyperglycaemia in a study of VLBW premature infants 
(Table 1.1) (Lilien et al., 1979, Louik et al., 1985). In a study of term infants during surgery 
and anaesthesia, hyperglycaemia was a commonly observed complication (Anand et al., 
1987, Anand et al., 1988, Srinivasan et al., 1986).  
The pathophysiology of stress hyperglycaemia is summarised in Figure 1.6. Stress can cause 
increased levels of cortisol, glucagon and catecholamines in the blood, which increase 
endogenous glucose production (Tirone and Brunicardi, 2001). Increased levels of these 
molecules are associated with conditions such as surgery and anaesthesia (Anand et al., 
1987), respiratory distress, cardiac failure, sepsis, and necrotising enterocolitis (Farrag and 
Cowett, 2000). In adults, they are also associated with suppressed insulin production and 
action (McCowen et al., 2001).  All these outcomes enable hyperglycaemia. 
Drug therapy 
Hyperglycaemia may also be drug related. For example steroids, methylxanthines 
(theophylline), or dopamine (Farrag and Cowett, 2000) can raise endogenous glucose 
production, and/or antagonise the secretion and action of insulin to lower insulin. This effect 
has also been observed in critically ill adults (Pretty et al., 2012). Thus, hyperglycaemia may 
be iatrogenically induced by other necessary therapies. 
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Figure 1.6: Pathophysiology of stress hyperglycaemia in critical illness. Source: Reitano 
et al. (1978). 
 
Exogenous glucose infusion 
The incidence of hyperglycaemia has been shown to increase with higher glucose infusions 
(Cowett et al., 1979, Dweck and Cassady, 1974, Farrag and Cowett, 2000, Louik et al., 
1985). Cowett et al. (1979) found that infants receiving ~8mg/kg/min of glucose had blood 
glucose and plasma insulin levels similar to baseline steady state measures. However, in the 
groups receiving ~11-12 mg/kg/min and ~14 mg/kg/min there were incidences of 
hyperglycaemia (BG>8.3 mmol/L (150 mg/dL)) and glucosuria (trace or greater glucose in 
the urine) in half and all of the infants respectively. In comparison, term infants are better 
able to tolerate higher than normal glucose infusions (Brans et al., 1974). Hence, these 
infusions, coupled with other factors, may be another iatrogenic source of hyperglycaemia. 
1.4.3 The Effect of Hyperglycaemia on Outcomes in Critical Care 
In adult and paediatric intensive care there is a wealth of literature relating to the effect of 
hyperglycaemia on outcomes and the use of insulin to treat it. Hyperglycaemia in intensive 
care patients has been associated with increased mortality (Capes et al., 2000, Holm et al., 
2004, Krinsley, 2006, Sperry et al., 2007), organ failure (Chase et al., 2010b, Sperry et al., 
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2007, Van den Berghe et al., 2001), and risk of congestive heart failure or cardiogenic shock 
(Capes et al., 2000). In the paediatric ICU (PICU) hyperglycaemia is associated with 
increased mortality (Baumeister et al., 2001, Cser and Milner, 1975, Mitanchez, 2007), high 
wound infection rates (Van Kempen et al., 2003b), increased mechanical ventilation (Grasso 
et al., 1973), increased length of stay (Grasso et al., 1973) and total length of hospital stay in 
abdominal surgery patients (Wu et al., 2013). In trauma patients it has been associated with 
increased mortality (Wahl et al., 2008), length of hospital stay (Bochicchio et al., 2007, 
Bochicchio et al., 2005, Yendamuri et al., 2003), ventilator dependence (Bochicchio et al., 
2007, Bochicchio et al., 2005, Sung et al., 2005), and infection (Bochicchio et al., 2007, 
Bochicchio et al., 2005, Laird et al., 2004, Sung et al., 2005). It has also been suggested that 
the relationship between hyperglycaemia and mortality/morbidity may be stronger in trauma 
patients as opposed to those in surgical intensive care (Vogelzang et al., 2006). 
In addition, there is debate as to whether hyperglycaemia is a cause or result of infection, or 
both (Bistrian, 2001). In the adult and paediatric patient, elevated blood glucose levels have 
been associated with sepsis and septic shock (Branco et al., 2005). Elevated blood glucose 
levels have also been associated with increased infection related mortality (Yendamuri et al., 
2003). 
Although far from as extensive as the adult literature in this area, a number of studies in 
preterm neonates have been conducted to assess the effect of hyperglycaemia on clinical 
outcomes in this cohort. Overall, these studies indicate that hyperglycaemia is associated with 
increased morbidity and mortality. The definitions of hyperglycaemia differ across articles, 
but overall conclusions tend to be consistent. In particular: 
Mortality: Hyperglycaemia has been associated with increased mortality (Alaedeen 
et al., 2006, Hall et al., 2004, Hays et al., 2006). It has been shown that this 
association is particularly strong in the case of severe early (Kao et al., 2006) and 
persistent or repeated hyperglycaemia (Heimann et al., 2007, Kao et al., 2006). 
Hospital length of stay: Although one study saw no association of hyperglycaemia 
with hospital length of stay (Kao et al., 2006), the majority of the literature suggests 
that the two are linked (Alaedeen et al., 2006, Hall et al., 2004, Hays et al., 2006), 
particularly in the case of persistent or prolonged hyperglycaemia (Hays et al., 2006).  
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Ventilator dependence: It has been suggested that hyperglycaemia is associated with 
increased  duration of mechanical ventilation (Alaedeen et al., 2006), but another 
study has not seen this result (Kao et al., 2006). 
Intraventricular Haemorrhage: Increased incidence of severe intraventricular 
haemorrhage is associated with hyperglycaemia (Hays et al., 2006).  
Retinopathy of prematurity: Hyperglycaemia is associated with increased incidence 
of retinopathy of prematurity (ROP) (Blanco et al., 2006, Ertl et al., 2006, Garg et al., 
2003). 
1.4.4 Hypoglycaemia 
Hypoglycaemia, or low blood glucose levels, can also occur frequently in premature infants,  
even in  the absence of insulin therapy (Sexson, 1984). By definition, hypoglycaemia results 
in significantly restricted availability of metabolic fuel for cell function and growth, as well 
as to the brain. Thus, it is also associated with adverse neurological outcomes in neonates 
(Koh et al., 1988a, Lucas et al., 1988). 
 Definitions of hypoglycaemia and its clinical significance have varied historically, and 
between studies (Cornblath et al., 2000, Koh et al., 1988a, Koh et al., 1988b, Sexson, 1984). 
Across medical textbooks thresholds range from 1.7 – 2.5 mmol/L, while clinically it can 
vary from 1.0 – 4.0 mmol/L, with a modal average of 2.0 mmol/L in one review (Koh et al., 
1988b). Historically, clinically significant hypoglycaemia had to fulfil a threefold criterion: 
1) clinical manifestations; which are 2) coincident with low blood glucose measurements; and 
3) with clinical symptoms resolving within minutes when euglycaemia is re-established. 
However, this definition excludes infants with extremely low blood glucose levels that were 
asymptomatic (Cornblath et al., 2000). 
Symptomatic hypoglycaemia may manifest in the infant as tremors, sweating, sudden apathy 
or limpness, cyanosis and apnea, high-pitched cry, convulsions, coma, or cardiovascular 
collapse (Cornblath et al., 2000, Pildes and Pyati, 1986). It is generally regarded to be more 
serious than asymptomatic hypoglycaemia (Cornblath and Schwartz, 1976). Controversy 
remains as to the effect of asymptomatic hypoglycaemia on the brain (Cornblath et al., 1990, 
Koh et al., 1988b). Treatment of hypoglycaemia can include intravenous boluses of dextrose 
to induce euglycaemia. A recent study in New Zealand has investigated the use of dextrose 
gel applied to the gums to prevent transient hypoglycaemia in the first few days of life (Harris 
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et al., 2013), and long term follow up assessing cognitive and developmental impacts is 
currently in progress (Harris et al., 2014). 
1.5 Summary 
Worldwide, around 9.6% of all births are premature and 1-2% of all births are very 
premature. Increasing prematurity is associated with increased severity of illness, and thus 
increased risk of mortality and increased burden of care. Higher degrees of prematurity are 
also associated with increased incidence of hyperglycaemia, which can affect up to 70% of 
extremely premature infants in neonatal intensive care. In turn, it is well established that 
hyperglycaemia is associated with increased risk of mortality and morbidities, and, in 
particular, a higher risk of infection. Controversy remains as to whether hyperglycaemia is a 
marker for, or a cause of, illness and injury, with the likely case that both are true. 
Much research is being carried out in neonatal and wider intensive care settings to investigate 
the benefits of insulin therapy and glycaemic control. However, hypoglycaemia is also 
dangerous, can commonly occur with insulin therapy, and is associated with adverse 
neurologic outcomes. If the incidence of hyperglycaemia can be reduced, without increasing 
the incidence of hypoglycaemia, and it translates to a reduction in the incidence of 
morbidities, then not only is long term patient outlook improved, but the burden of the cost of 
care may also be reduced. 
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Chapter 2: The Problem of Variability: Glycaemic 
Control in Neonatal Intensive Care  
 
 
 
Hyperglycaemia is an extremely common complication of prematurity (Brans et al., 1974, 
Dweck and Cassady, 1974, Hall et al., 2004, Louik et al., 1985, Zarif et al., 1976) and has 
been associated with increased mortality and morbidity (Alaedeen et al., 2006, Garg et al., 
2003, Hall et al., 2004, Hays et al., 2006, Hey, 2005, Kao et al., 2006). Thus, it is not 
surprising that increasingly blood glucose (BG) control is becoming a concern in intensive 
care contexts in general. In particular, the body of literature around glycaemic control in 
premature infants is increasing.  
Insulin facilitates the transport of glucose into cells, and is widely used to treat 
hyperglycaemia in diabetic and in adult intensive care cohorts. Its use in critically ill adults 
for tight glycaemic control is endorsed by many organisations (Wiener et al., 2008), including 
the Surviving Sepsis Campaign (Dellinger et al., 2004), American Association of Clinical 
Endocrinologists (AACE, 2002), and the American Diabetes Association (Grasso et al., 
1990). In paediatric care, the use of insulin to treat hyperglycaemia has been supported by the 
American Academy of Paediatrics since 1985 (American Academy of Pediatrics Committee 
on Nutrition, 1985).  
Ideally, a glycaemic control protocol lowers BG to a euglycaemic range without driving BG 
concentrations dangerously low. To meet this goal, it must account for changes in patient 
condition over time, as glucose-insulin metabolism is affected by prematurity (Louik et al., 
1985), stress (Lilien et al., 1979, Louik et al., 1985), and drug therapy (Farrag and Cowett, 
2000), among many factors. This chapter evaluates current clinical practice and its 
limitations, as well as reviewing the effect of insulin therapy to treat hyperglycaemia on 
clinical outcomes. Model based methods are presented as a potentially more effective tool for 
managing patient variability, and thus for glycaemic control, than conventional therapy 
approaches.  
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2.1 Insulin Therapy and Outcomes in Intensive Care 
While the association of hyperglycaemia with increased mortality and morbidities is 
increasingly well established, the use of insulin therapy to treat this condition and its effect on 
outcomes is less clear. As there is a larger body of literature surrounding the use of insulin 
therapy in adult and paediatric care, its effect on outcomes in these cohorts will be briefly 
reviewed first, as the main risks and elements are defined. It is then followed by a review of 
insulin therapy in neonatal intensive care. 
2.1.1 Adult and Paediatric Intensive Care 
In a few early studies, insulin therapy to maintain euglycaemia was shown to either leave 
unchanged (Van den Berghe et al., 2006b) or reduce mortality rates in critically ill (Chase et 
al., 2008a, Krinsley, 2004, Van den Berghe et al., 2001), paediatric, and non-diabetic patients 
(Krinsley, 2006, Van den Berghe et al., 2006a). It was associated with lower incidence of 
multiple organ failure (Van den Berghe et al., 2001), protection of renal function (Schetz et 
al., 2008, Van den Berghe et al., 2006b, Van den Berghe et al., 2006a) and reduced renal 
failure (Krinsley, 2004, Van den Berghe et al., 2001), reduced critical illness polyneuropathy 
(Van den Berghe et al., 2001), lowered incidence of blood transfusions (Krinsley, 2004, Van 
den Berghe et al., 2001), and reduced length of mechanical ventilation (Van den Berghe et 
al., 2006b) and length of stay (Krinsley, 2004, Van den Berghe et al., 2006b). It thus reduced 
the overall cost associated with treating the patient (Krinsley and Jones, 2006, Van den 
Berghe et al., 2001).  
Other studies have shown benefits, such as protection of the thin endothelial cell layer lining 
the circulatory system (Ellger et al., 2006, Langouche et al., 2005), which in turn contributes 
to the prevention of organ failure (Langouche et al., 2005). Insulin therapy has been shown to 
suppress the inflammatory response (Das, 2003, Hansen et al., 2003) and thus be of use in 
reducing the incidence of infection in diabetic (Furnary et al., 1999, Pomposelli et al., 1998, 
Zerr et al., 1997), surgical (Van den Berghe et al., 2001), and intensive care (Van den Berghe 
et al., 2001) patients. It has also been shown to be of use in treating sepsis/septic shock (Das, 
2003, Oddo et al., 2004), and the Surviving Sepsis Campaign recommends the use of insulin 
in managing septic patients (Dellinger et al., 2004). In addition, intensive insulin therapy has 
been shown to reduce mortality in septic patients (Ellger et al., 2008, Hansen et al., 2003), 
reduce renal failure (Hansen et al., 2003), and to reduce the duration of antibiotics and hyper- 
or hypo- thermia (Hansen et al., 2003). It is suggested that the benefits of insulin use are 
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associated with the reduction in hyperglycaemia, and not associated with the administration 
of insulin itself (Orford, 2006).   
However, the reduction in mortality has not been seen in other studies (Brunkhorst et al., 
2008, Finfer et al., 2009, Hirasawa et al., 2009, Liu and Mauvais-Jarvis, 2010, Morimoto et 
al., 2001, Preiser et al., 2009), and much higher incidence of hypoglycaemia has cast doubt 
on the use of insulin in critical care cohorts (Brunkhorst et al., 2008, Orford, 2006, Van den 
Berghe et al., 2006a).  Two recent meta-analyses looking primarily at mortality (Figure 2.1) 
and hypoglycaemic outcomes have questioned the benefits of insulin therapy (Griesdale et 
al., 2009, Wiener et al., 2008), particularly in the light of a 5-6 fold increase in the risk of 
hypoglycaemic events (Griesdale et al., 2009, Wiener et al., 2008), which are associated with 
a higher mortality risk (Wiener et al., 2008).  
Significant heterogeneity between studies in terms of threshold, intervention protocols, and 
results was noted, and thus the possibility that some patients may benefit from insulin therapy 
was not excluded (Griesdale et al., 2009). A significant inability of many studies to 
consistently meet glycaemic targets was also noted (Penning et al., 2014, Wiener et al., 
2008), where consistent control to target has been associated with reduced mortality and 
organ failure (Chase et al., 2010b, Chase et al., 2008a) and increased odds of survival 
(Penning et al., 2015, Pielmeier et al., 2010b), regardless of how that control was obtained. In 
only one of the analyses were other outcomes (septicaemic risk and need for dialysis) 
considered, finding a reduction in septicaemia in ICU patients was associated with insulin 
therapy (Wiener et al., 2008).  
2.1.2 Neonatal Intensive Care 
The use of insulin therapy to treat hyperglycaemia and its effect on outcomes is not well 
defined in the premature NICU cohort. While short term weight gain and increased glucose 
tolerance have been well reported (Binder et al., 1989, Collins et al., 1991, Kanarek et al., 
1991, Meetze et al., 1998, Ostertag et al., 1986, Pollak et al., 1978, Thabet et al., 2003, 
Vaucher et al., 1982), as well as a reduction of the incidence of sepsis (Collins et al., 1991), 
few studies have examined long term outcomes in this cohort. One study has shown increased 
28 day mortality despite reduced hyperglycaemia, although this was not the case at the 
expected date of delivery (Beardsall et al., 2008). A recent study has questioned the 
advantage of increased weight gain with insulin therapy, proposing that it results in increased 
adipose tissue, and does not necessarily translate to an increase in linear growth and muscle 
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development (Alsweiler et al., 2012). In addition, many studies have seen a significant 
increase in hypoglycaemia (Alsweiler et al., 2012, Beardsall et al., 2008).  
Thus, further studies are required to evaluate the potential benefits of insulin therapy to treat 
hyperglycaemia in NICU cohorts. In particular, it must avoid increasing the incidence of 
hypoglycaemia, which may confound results, and led to the early stoppage of one major trial 
(Beardsall et al., 2007a). Study protocols must be effective and consistent enough to 
determine if quality of control can be linked to clinically beneficial outcomes.  
 
 
Figure 2.1: Meta-analysis of risk ratios for mortality in trials comparing intensive 
insulin therapy (IIT) to conventional glycaemic control. Source: Griesdale et al. (2009). 
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2.2 Glycaemic Control in Neonatal Intensive Care 
2.2.1 Current Clinical Practice 
There is also currently no global best practice method or target for glycaemic control in pre-
term infants. A recent survey of neonatal hyperglycaemia in Australasia found that all of the 
23 (of 27) surveyed units that responded use insulin (Alsweiler et al., 2007). Of these 23 
units, 8 only use it very occasionally, 22 had a guideline or protocol for insulin use, and 17 
would use glucose restriction as a first response to hyperglycaemia. Hyperglycaemia was 
generally defined as BG>10 mmol/L, there was large variation in both the glycaemic control 
range targeted, and the glycaemic threshold for starting insulin, as shown in Figure 1.3.  
In a survey of neonatal units in the Los Angeles County (Simeon and Gottesman, 1991), 80% 
(10 neonatal units) of those surveyed used insulin therapy to treat infants. Of these, only 2 
had protocols and procedures for insulin use. In addition, 70% gave insulin to control 
hyperglycaemia and/or to lower serum potassium. Regarding hyperglycaemic threshold to 
commence insulin therapy, 60% of units that gave insulin required BG > 9.7 – 13.9 mmol/L 
(175 - 250 mg/dL) and/or glycosuria (elevated glucose levels in urine) before starting insulin. 
Methods of administration also varied between and within units, with 80% responding that 
they would give insulin as an IV infusions, 20% giving it as an IV bolus, 10% giving it 
subcutaneously, and 20% giving it intramuscular. It should be noted that some of the 
responding units gave insulin in more than one way. Only 50% of the units flushed the 
apparatus with a primer solution of insulin before administering insulin to the patient 
(Simeon and Gottesman, 1991), which can significantly increase the insulin delivered. 
In particular, one important source of clinical error can result from insulin binding to IV 
tubing (Fuloria et al., 1998, Hewson et al., 2000). The percentage loss of insulin in this 
manner changes over time and is dependent on the flow rate, but can be as high as 90% in the 
first hour without priming, and 80% in the first hour if the tubing is primed first. At 8 hours, 
the percentage loss can be around 50% in un-primed tubing, whereas it is close to 0% when 
the tubing has been flushed with insulin prior to use (Fuloria et al., 1998). It is estimated that 
even with insulin priming of the IV tubing, consistent insulin delivery is not achieved until 6-
8 hours after delivery began (Fuloria et al., 1998, Hewson et al., 2000). Thus, insulin priming 
and binding can have an important effect on the quality of glycaemic control by increasing 
certainty in the amount of insulin used. 
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Many studies tend to report very few statistics with respect to the quality of glycaemic 
control. Rates of hypoglycaemia, when discussed, are often reported as the percentage of all 
BG measures taken, and are typically less than 1% BG<2.2  mmol/L or 2.6 mmol/L. In 
addition, target ranges and definitions of hyper- and hypo- glycaemia vary between the 
studies. Such controversies and contradictions in literature highlight the need for an effective 
tool for glycaemic control in order to effectively evaluate the effect of insulin therapy on 
clinical outcomes in the NICU.  
Lack of consensus in the definition of hyperglycaemia, target basal BG ranges, and 
thresholds for the initiation of insulin therapy reflect differing clinical guidelines around the 
practice of insulin therapy in neonatal intensive care units.  Fixed or ad hoc protocols are 
often utilised, which lack patient specificity or rely extensively on clinical judgment. As such, 
protocols often fail to effectively account for variability in patient metabolic intake and 
response over time and between patients, resulting in poor control and oscillations between 
hyper- and hypo- glycaemia. This issue is confounded by errors and inconsistencies in 
clinical practice with respect to the physical delivery of insulin.  
2.2.2 Insulin Therapy vs. Glucose Restriction 
Early approaches to neonatal hyperglycaemia used caloric restriction. Nutrition regimes in 
the NICU primarily aim to achieve weight gain comparable to foetal growth without causing 
additional metabolic stress (Ditzenberger et al., 1999). Thus, the benefits of insulin therapy to 
promote increased glucose tolerance and weight gain have been well reported (Binder et al., 
1989, Collins et al., 1991, Kanarek et al., 1991, Meetze et al., 1998, Ostertag et al., 1986, 
Pollak et al., 1978, Thabet et al., 2003, Vaucher et al., 1982).  
While permissive underfeeding could be beneficial  in the adult ICU (Arabi et al., 2011). It is 
not the case for neonatal intensive care, where limited storage of fuel substrates mean that 
glucose infusion is required to avoid hypoglycaemia (van Goudoever et al., 1993), as well as 
for the continued growth and development of the neonate outside of the womb (Clark et al., 
2003a, Hay, 2006). The use of insulin to treat hyperglycaemia, and thus improve glucose 
uptake and tolerance, results in increased carbohydrate intake, and increased weight gain.   
However, a recent study has questioned the advantage of this increased weight gain, 
proposing that it results in increased adipose tissue, and does not necessarily translate to an 
increase in linear growth and muscle development (Alsweiler et al., 2012). In addition, the 
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high incidence of hypoglycaemia observed in the tight glycaemic control group with received 
intensive insulin therapy led to a conclusion that the risks of insulin therapy outweigh any 
perceived  benefits (Alsweiler et al., 2012).   
2.3 Studies on Insulin Therapy and Glycaemic Control in Neonatal 
Intensive Care 
Several studies have looked at various aspects of the use of insulin therapy to treat 
hyperglycaemia (Alsweiler et al., 2012, Beardsall et al., 2008, Binder et al., 1989, Collins et 
al., 1991, Kanarek et al., 1991, Meetze et al., 1998, Ng et al., 2005, Ostertag et al., 1986, 
Pollak et al., 1978, Thabet et al., 2003, Vaucher et al., 1982). While most of these have 
focused or based their primary result around  insulin therapy versus standard treatment or 
glucose restriction for glucose tolerance and/or weight gain (Binder et al., 1989, Collins et al., 
1991, Kanarek et al., 1991, Meetze et al., 1998, Ostertag et al., 1986, Pollak et al., 1978, 
Thabet et al., 2003, Vaucher et al., 1982), the following studies more specifically examined 
glycaemic control performance and its effect on a wider array of outcomes.  
Ng et al, 2005 
Ng and colleagues (Ng et al., 2005) carried out a study comparing glycaemic control in 
hyperglycaemic ELBW and LBW  infants. Hyperglycaemia was defined as two BG>12 
mmol/L over the course of at least 4 hours. Insulin was titrated to maintain BG levels in a 
targeted 4-8 mmol/L glycaemic band. BG was measured hourly upon initiation of insulin 
therapy until BG was stable within the target band, it was measured 2-4 hourly thereafter. 
Treatment was stopped when the BG remained in the target band for more than 24 hours.  
ELBW infants required much longer periods of insulin infusion until treatment was stopped, 
and required more insulin to maintain euglycaemia.  Hypoglycaemic incidence (BG<2.6 
mmol/L) was 15% in the ELBW and 11% in the LBW groups, which are still a relatively 
high incidence, although better than other studies. 
NIRTURE – Beardsall et al, 2007 
The NIRTURE (Neonatal Insulin Replacement Therapy in Europe) trial was a multicentre 
randomised trial that compared VLBW infants receiving early insulin therapy with a control 
group who received standard care (Beardsall et al., 2007b, Beardsall et al., 2008). The early 
insulin group targeted BG to 4-8 mmol/L.  Infants received a fixed insulin infusion of 0.05 
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U/kg/hr, alongside a 20% dextrose infusion to maintain euglycaemia. Additional dextrose 
was given if BG dropped below 4.0 mmol/L, and insulin was discontinued if BG continued to 
drop. Persistent hyperglycaemia (BG>10.0 mmol/L) was treated with additional insulin or 
reduced dextrose. In the control group, hyperglycaemia was treated with insulin or glucose 
restriction if there were 2 BG>10 mmol/L. This study was stopped early because of increased 
incidence of parenchymal lesions in the early insulin group, and concerns regarding mortality 
outcomes in the study (Beardsall et al., 2007b). 
 Results show a high rate of hypoglycaemia (defined as BG<2.6 mmol/L for more than 60 
minutes when measured by continuous glucose monitor (CGM)), with 29% of infants 
receiving early insulin therapy experiencing one or more hypoglycaemic events compared 
with 17% in the control group. There was no statistically significant difference between the 
early insulin and control groups with respect to morbidity and mortality rates at the expected 
due date. However, 28 day mortality rates were higher in the early insulin group. They 
concluded that there is little clinical benefit to early insulin therapy (Beardsall et al., 2007b). 
However, again, safety from hypoglycaemia was not obtained. 
HINT – Alsweiler et al, 2014 
In a randomised control trial (Hyperglycaemia and Insulin in Neonates Trial (HINT)) of tight 
glycaemic control (TGC) and standard care, Alsweiler and colleagues  questioned whether 
the benefits of TGC are outweighed by the risks of hypoglycaemia(Alsweiler et al., 2012). 
Tight glycaemic control targeted the 4-6 mmol/L range, and the control group was only 
treated with insulin if the infant had BG>10mmol/L with glycosuria, and the infant was 
tolerating less than <100kcal/kg/day in nutritional input.  Their results show greater weight 
gain in infants treated with insulin, with similar nutritional intake between the two groups. 
However, this increased weight gain did not translate into an increase in linear growth, 
suggesting that weight gain was due to an increase in fat mass rather than muscle or bone 
growth.  
 A doubling of the number of incidences of hypoglycaemia, where 58% of infants had one or 
more BG < 2.6 mmol/L in the TGC group compared with 27% in the control group, was 
reported, despite the fact that around a third of the control group ended up being treated with 
insulin as well (Alsweiler et al., 2012). Overall, the authors suggest that the risks of insulin 
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infusion may exceed any perceived benefits and that further trials are required to determine 
the relative risks and benefits. 
2.4 The Problem of Patient Variability 
What current studies examining insulin therapy in neonatal intensive care have failed to do is 
first establish an effective tool or protocol for glycaemic control. Effective, safe control needs 
to be achieved before examining outcomes. None of the studies discussed so far detail their 
glycaemic control protocol. Instead, they often refer to generic „titration of insulin with BG 
level.‟ 
Titration of insulin with BG, or sliding scale based methods, are inherently flawed in their 
inability to consistently dose insulin between patients and over time. Strict sliding scale type 
protocols do not differentiate between patients or take into consideration differing patient 
condition, instead treating all patients the same all the time. In addition, they typically do not 
account for the nutritional intake, neglecting this important contributor to glycaemia. On the 
other hand, protocols that allow room for clinical judgement are biased by the attending 
clinician‟s past and present clinical experience and context. All these prior protocols left 
managing variability of patient response to ad hoc clinical inputs, or simply ignored them 
with a one size fits all approach. What is required are protocols that explicitly account for 
nutrition, variability, and patient-specific response. 
The advantage of model-based control is that estimations of current glucose-insulin 
metabolism can be made based on the measurable metabolic response to insulin. In the 
metabolic model presented in this thesis, the parameter insulin sensitivity (SI) describes 
patient specific whole-body SI, which is allowed to change over time as a patient-specific 
response to therapy evolves. Hence, the variability in response between patients and over 
time can be seen, calculated, and accounted for. 
In an analysis of the effect of patient variability on glycaemic control, Le Compte et al. 
(2013) contrasted model based control and its treatment of SI with some of the assumptions 
underlying conventional protocol approaches. In contrast to patient specific and time-varying 
SI, fixed sliding scale protocols implicitly assume SI is constant across an entire patient 
cohort, as this method treats all patients the same. Similar methods, which adapt sliding scale 
based protocols to patient metrics such as weight (e.g. Beardsall et al. (2007a)), effectively 
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assume SI is constant across a patient, and does not change with time. Figure 2.2, from Le 
Compte et al. (2013), compares model based adaptive control to conventional methods. It is 
clear that for a large percentage of the time, whole cohort and per-patient constant methods 
fail to describe a specific patient's metabolic state. Le Compte et al. concluded that effective 
glycaemic control required the ability to effectively address inter- and intra- patient 
variability (Le Compte et al., 2013), which matches results in the adult ICU domain (Chase et 
al., 2011b). 
It could be argued that sliding scale based protocols to some degree implicitly allow for some 
degree of change in SI over time indirectly through the titration of insulin to different BG 
levels. However, these methods are still deficient, because if this is the case they still assume 
the same SI within each BG range across an entire range of patients. This assumption is not 
accurate in the adult ICU or the NICU, as shown in  (Chase et al., 2011b), and requires SI to 
change with BG when it is in fact a measure of response to insulin and nutrition inputs, not 
BG level.  
 
Figure 2.2: Comparison of different glycaemic control approaches and their ability to 
capture patient variability. The whole-cohort constant insulin sensitivity (SI) is 
comparable to fixed sliding scale methods, the per-patient constant SI describes sliding 
scale protocols that are modified by patient characteristics such as weight, and the 
adaptive SI describes the model based approach. Source: Le Compte et al. (2013). 
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In particular, Figure 2.3 was derived as part of this work from per-patient time-varying 
insulin sensitivity profiles over a large cohort of very/extremely premature infants in neonatal 
intensive care. It clearly shows that BG alone is insufficient as a marker for metabolic state, 
and insulin sensitivity in particular, since it is a function of insulin input, nutrition, and other 
interactions in patient-specific response or metabolic reactions. Therefore, effective 
glycaemic control must be able to make some estimate of a patient's specific metabolic state. 
 
 
Figure 2.3: Model based insulin sensitivity (SI) is independent of blood glucose (BG) 
concentration. 
2.5 Capturing Patient Variability Using Model Based Methods 
2.5.1 Glycaemic Control Challenges in Neonatal Intensive Care 
In any clinical context, for a computer model to be useful it must not require more clinical 
measurements than are feasible and/or cost effective. In the case of the premature infant, this 
requirement is of even greater importance due to their inherent fragility and very low blood 
volume, which limits sampling. This restriction places larger burden on a model to manage 
any variability between samples as patient condition evolves continuously.  
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More specifically, the premature infant's inherent fragility imposes many constraints on what 
can be measured and observed in this cohort in both clinical and research contexts.  Such 
constraints (Farrag and Cowett, 2000) include:  
 Minimal or non-invasive procedures 
 Small and infrequent blood sampling due to limited blood volume 
 Extrapolation of sampled data beyond the immediate context 
 Study design to maximise information obtained 
 Difficulty in recruiting large numbers of patients, particularly in studies with more 
than one trial arm. 
Thus, metabolic models in neonatal intensive care must be identifiable, as well as safe and 
effective, using currently available clinical measurements and patient characteristics. 
Metabolic models must capture, as accurately as possible, the physiology relevant to the 
patient cohort and condition, but must also be flexible enough to be used over the range of 
patient specific conditions seen clinically.  
2.5.2 Sources of Metabolic Variability  
Glucose-insulin metabolism in infants changes over time, and between patients. In particular, 
it may be different from adult metabolism, justifying independent models for glycaemic 
control. These models can be based upon, or adapted from, adult models. However, they will 
have clear cohort specific differences, although the underlying fundamental metabolic 
pathways and dynamics are the same. 
In addition, to best capture variability over time and differences between patients, the model 
should take into account a number of possible sources of metabolic change. This change may 
arise from: endogenous glucose production, central nervous system uptake, endogenous 
insulin secretion, insulin clearance, and glucose absorption in the gut. All of these differences 
can result from evolving patient specific condition and stress response. 
In particular, differences in glucose-insulin metabolism between patients can potentially be 
captured through patient descriptors, such as weight, age, and condition. Changes in glucose-
metabolism over time may also be described as a function of patient condition, nutritional 
and medicinal input, and blood species. Thus, the more accurate and effective the model, the 
more model-based SI changes reflect actual changes in peripheral and whole body SI. If SI 
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changes can be tightened to predominantly reflect changes, then control can be tighter and 
safer. 
Endogenous insulin secretion 
From early in the gestational period, the foetal pancreas is a major source of insulin (Adam et 
al., 1969b). However, bi-phasic insulin secretion in response to nutrient release may not 
begin to mature until after birth (Otonkoski et al., 1988). For this reason, it is reasonable to 
assume that insulin secretion in premature infants is different from the adult case, and 
justifies its own model. However, like the adult case, there are no such models in the 
literature. 
Insulin secretion in preterm babies has only been indirectly analysed by observing plasma 
insulin concentrations. However, insulin is cleared by both the kidneys and the liver in a 
highly variable manner, as well as being cleared in peripheral tissues. These factors ensure 
that plasma insulin concentrations are an inaccurate measure of insulin secretion. Pancreatic 
insulin secretion has been estimated in adults using models of C-peptide kinetics (Eaton et al., 
1980, Polonsky et al., 1986, Van Cauter et al., 1992), as C-peptide is secreted in equimolar 
quantities with insulin, but is only cleared by the kidney. Therefore, the much simpler 
kinetics of C-peptide provide a more accurate method of estimating insulin secretion rates 
(Van Cauter et al., 1992), but have not been used in the past with neonates.  
Insulin clearance pathways 
Insulin is cleared via a number of pathways, including the liver, kidneys, and peripheral 
degradation. Glomerular filtration rate (GFR) is commonly used to assess renal function. 
GFR increases with gestational and postnatal age in premature infants (Coulthard, 1985), and 
rises during childhood through to puberty (Lebenthal and Lebenthal, 1999). It is likely that 
these changes in GFR translate to changes in the kidney clearance of insulin with age. In 
addition, several studies have also shown that plasma insulin levels are higher in preterm than 
term infants (Broussard, 1995, Pollak et al., 1978, Tyrala et al., 1994), reflecting a whole 
body difference in clearance dynamics. Thus, prematurity specific models of insulin 
clearance would enable more accurate modelling of insulin concentrations, and thus better 
assessment of SI for safer dosing. 
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Endogenous glucose  
Endogenous glucose production (EGP) plays a central role in glucose homeostasis in the 
body. Glucose production occurs mainly in the liver, and its main processes are 
gluconeogenesis and glycogenolysis. These processes are affected by prematurity. In 
particular EGP is observed to persist in premature infants (Cowett et al., 1983, Farrag et al., 
1997), which contrasts the normal adult case (Wolfe et al., 1979). EGP in very premature 
infants has been shown to be responsive to exogenous glucagon (Van Kempen et al., 2003b), 
but not exogenous administration of amino acids (Diderholm et al., 1999, Van Kempen et al., 
2003a) or plasma insulin (Sunehag et al., 1994b). It can also to vary with patient weight 
and/or gestational age (Keshen et al., 1997, Van Kempen et al., 2003b). There is thus scope 
and potential to build EGP  models to describe the unique physiology of the premature infant 
and capture sources of inter- and intra- patient variability. 
Insulin-independent central nervous system uptake 
In the adult, the brain accounts for approximately 50% of the bodies glucose uptake (Triplitt, 
2012), so it must be accounted for in any model-based approach. In a metabolic model of 
adult critical care insulin-glucose dynamics (Lin et al., 2011) central nervous system (CNS) 
uptake is modelled as population constant, which reflects the relatively constant brain mass 
across individuals and resulting constant glucose metabolism by the brain (Gruetter et al., 
1998).  However, in infants CNS increases with increasing gestational age (Koh et al., 
1988b), and infants have larger brain-body weight ratios than adults (Farrag et al., 1997, 
Hertz et al., 1993). So brain weight, and thus CNS uptake, may be better predicted by patient-
specific head circumference (Cornblath et al., 1990).  
Glucose absorption in the gut 
The small intestine is a major site of nutrient and water absorption. During the last trimester 
of pregnancy the foetal intestine lengthens (Aynsley-Green, 1983), and enzyme activity 
increases (Lebenthal and Lebenthal, 1999).  However, mature levels of digestive enzyme 
secretion are not reached until the end of foetal gestation (Rouwet et al., 2002), and lactase 
secretion is only ~30%  of mature secretion at 34 weeks (Lebenthal and Lebenthal, 1999). 
Gastrointestinal motility is also not mature until the 40th week gestational age (Berseth, 
1996). Further, exposure of the neonatal small intestine to enteral feeds results in changes in 
mucosal structure and function (Aynsley-Green, 1983). Thus gastro-intestinal permeability 
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changes with gestational and post natal age (Rouwet et al., 2002), with absorption capacity 
most limited in neonates born <28 weeks gestational age (Rouwet et al., 2002), and is thus a 
further source of variability.  
2.6 Summary 
Insulin therapy is widely used to treat hyperglycaemia in intensive care. While early studies 
in the adult ICU showed significant benefits and reduced mortality associated with the use of 
insulin therapy, some later studies have not been able to replicate these results, and 
controversy remains. In most cases, both in adults and neonates, insulin therapy is associated 
with significantly higher incidence of hypoglycaemia, which carries significant attendant 
risks.  
In neonatal intensive care, the literature surrounding the effect of insulin therapy on outcomes 
is relatively scarce, and reflects similar mixed results and controversy. However, what current 
studies fail to do is to first develop a tool for safe and effective glycaemic control, before 
trying to establish the effect on outcomes. Hence, there is a need for better dosing methods 
before being able to assess the impact of glycaemic control on clinical outcomes. 
There is no universal or widely accepted protocol for insulin dosing, nor threshold for starting 
intervention. In addition, clinical titration methods in all reported studies fail to adequately 
account for variability between patients and within patients over time. Model based 
approaches offer this capability.  
Potential sources of metabolic variability that such models need to capture include 
endogenous glucose production, central nervous system uptake of glucose, pancreatic insulin 
secretion, insulin clearances in the body, and gut absorption of glucose. This thesis aims to 
analyse and create the first models of these aspects of glucose-insulin metabolism in the 
preterm neonate to better capture inter- and intra- patient variability in response to insulin, 
and thus enable safer, more effective glycaemic control. 
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2.7 Preface 
The remaining thesis chapters cover this topic as follows: 
Chapter 3 presents common metabolic models of the glucose insulin system, and introduces 
the basic form of the model developed throughout this thesis. 
Chapters 4 and 5 examine insulin secretion and clearance in premature neonates using 
unique clinical data from a VLBW cohort. Gender and BG based models of insulin secretion 
are developed, and insulin clearance pathways are identified and modelled. 
Chapter 6 explores the contribution of endogenous glucose production to glycaemic control, 
and develops models based on literature data and glycaemic control outcomes in simulation. 
Chapter 7 examines non-insulin mediated pathways for glucose clearance, focusing in 
particular on the central nervous system uptake and estimation of this based on brain mass 
and head circumference. 
Chapter 8 uses continuous glucose monitor (CGM) data in premature and term infants to 
estimate glucose absorption in the gut. 
Chapter 9 summarises the model developed in Chapters 4 to 8. 
Chapter 10 uses clinical data and stochastic modelling to develop and optimise a model-
based protocol for glycaemic control in the NICU. 
Chapter 11 presents clinical results from the protocol developed in Chapter 10. 
Chapter 12 analyses SI and its variability based on clinical cohorts, birth weight, and 
gestational age.  
Chapter 13 and 14 summarise the conclusions drawn from this thesis, and examine potential 
avenues for future work. 
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Chapter 3: Model structure 
 
Physiological models of the glucose-insulin system have been developed with differing levels 
of complexity for a wide range of scientific and clinical applications. Some are utilised for 
the determination of model-based measures of physiology, such as insulin sensitivity, or to 
accurately capture or determine aspects of human metabolism and physiology. Such models 
tend to be more complex and comprehensive, requiring higher data density and/or 
measurements of multiple metabolic species. Other models are designed for specific clinical 
applications, such as glycaemic control in intensive care, or Type 1 Diabetes cohorts. Such 
models tend to be less complex, as metabolic measurements are minimised in clinical settings 
due to cost, availability, time constraints, clinical workload, or patient condition and comfort. 
Thus, model capabilities are determined not only by the degree to which they accurately 
reflect physiological processes, but also the context within which they are designed and 
implemented (Chase et al., 2011a). 
One very common form of physiological model is the compartment model. The compartment 
model is physiologically intuitive, as it consists of a series of 'compartments' where model 
species exist at some concentration. Changes in compartment concentrations are brought 
about by the appearance and disappearance of species from these compartments. In a 
physiological sense, species can appear via secretion or exogenous administration, and appear 
and/or disappear due to diffusion/transport between compartments or interactions between 
substances. Species can disappear via known clearance mechanisms, such as glomerular 
filtration in the kidney, or via degradation in their metabolic utilisation. In this way, 
compartment based models can be designed to capture key dynamics to a chosen level of 
resolution, suitable to their intended use. 
Choosing the degree of resolution of a model is important. Such models must capture key 
physiological dynamics to be physiologically valid and relevant within their application. 
However, they must also be mathematically identifiable (Docherty et al., 2011) and 
practically applicable given the available measurement within their chosen application (Chase 
et al., 2006). In clinical practice, a key constraint is the availability of clinical data in terms of 
both measurement type and frequency. Limited data availability limits parameter 
identification capabilities. The primary aims of a physiological model in critical care is to 
improve the quality of care without an unnecessary increase in clinical workload and cost of 
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care, a very difficult trade-off. This trade-off typically eliminates the ability to add 
measurements to enhance the model application. 
While several models have been developed for use in adult critical care or diabetes, 
physiological modelling of neonatal glucose-insulin metabolism is far less common. To date, 
only Le Compte (Le Compte, 2009) has developed a model for glycaemic control in 
premature infants. This chapter will briefly review several glycaemic control approaches in 
adult critical care as a basis for general control approaches, and will present the model of Le 
Compte (2009) as a starting point for further model development in this thesis. 
3.1 Metabolic Models in Critical Care 
Several approaches to modelling and/or managing glucose-insulin metabolism in adults have 
been developed (Bergman et al., 1979, Chee et al., 2003, Hovorka et al., 2004, Kovatchev et 
al., 2009, Lehmann and Deutsch, 1998, Pielmeier et al., 2010b, Sorenson, 1985, Van Herpe et 
al., 2006). Typical examples of approach to glycaemic control include Chee et al. (2003), 
Hovorka et al. (2004), and Bergman et al. (Bergman et al., 1985, Bergman et al., 1979). 
These models/methods are reviewed more extensively elsewhere (Chase et al., 2006, Le 
Compte, 2009, Lin, 2007), but differ in structure and implementation, each with different 
strengths and weaknesses. 
The approach developed by Chee et al. (2003) is based on traditional control theory. While 
the results show a significant tightening of glycaemic control, mean BG remained high (Chee 
et al., 2003). This control method is not based on a physiological modelling, and thus must be 
tuned to different cohorts, a process that is likely unintuitive.  
Hovorka et al. (2004) developed a sophisticated physiological model for glycaemic control in 
Type 1 Diabetes, and a modified version for glycaemic control in critical care (Plank et al., 
2006). This model is compartment based, with 9 population constants, and 6 patient specific 
constants. The relative complexity and physiological comprehensiveness of this model reflect 
its origins in physiological research (Hovorka et al., 2002). However, practical identifiability 
may be a problem in critical care settings with this model and minimal blood sampling due to 
workload or other clinical concerns. 
The minimal model of Bergman et al. (Bergman et al., 1985, Bergman et al., 1979) has been 
extensively utilised and modified over time. Many compartment models used for glycaemic 
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control or studies of metabolic physiology have some degree of origin in it (Chase et al., 
2006). It forms the basis for the ICING model (Evans et al., 2011, Lin et al., 2011) used for 
glycaemic control in adult intensive care, and the NICU model developed for use in neonatal 
intensive care (Le Compte, 2009, Le Compte et al., 2009, Le Compte et al., 2010a).  
Before adoption as a standard of care, model based control should be extensively tested for 
safety and effectiveness. Clinically, such testing requires extensive clinical time and 
resources, and may pose a risk to the patient. Alternatively, extensive testing can be carried 
out using virtual patients, but such testing is most effective when virtual patients based on 
clinical data and metabolic models are used (Chase et al., 2007, Chase et al., 2010a). It is 
equally important that such virtual patients be validated (Chase et al., 2010a). 
Overall, many such models exist, but few have been used clinically. Equally, virtual patients 
can be used to optimise design, but often lack validation in clinical or other use. Thus, models 
offer potential, but are often not as clinically feasible or relevant, as needed.  
3.2 Neonatal Glycaemic Modelling 
In the case of the very/extremely preterm neonate, to date, only Le Compte et al. have 
attempted to model the glucose-insulin regulatory system of this cohort (Le Compte, 2009, 
Le Compte et al., 2010a).  This NICU model is structurally based on the model by Lin (2007) 
and is shown pictorially in Figure 3.1. Its parameters are adapted to reflect premature infant 
physiology, and it contains additional terms for endogenous glucose production (EGP), 
central nervous system uptake of glucose (CNS), and insulin secretion (structure:    
   . 
These models utilise a time varying whole body insulin sensitivity (SI) parameter to describe 
changes in patient metabolic condition.  
The NICU model of Le Compte et al. (Le Compte, 2009, Le Compte et al., 2010a) has 3 main 
compartments in Figure 3.1 (G (t), I(t), and Q(t)), which are mathematically defined: 
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Figure 3.1: NICU model of glucose-insulin metabolism. Arrows show movement of 
glucose (red) and insulin (blue) into and out of central compartments. Insulin sensitivity 
mediates the uptake of glucose by the liver and other body cells.  
 
In the blood glucose compartment (G),    is non-insulin mediated clearance of glucose (e.g. 
by kidneys),    is the insulin sensitivity that drives insulin-mediated uptake of glucose,    
saturates the insulin-mediated uptake of glucose,      is the exogenous intravenous glucose 
appearance,     is glucose appearing via the enteral route,     is the basal endogenous 
glucose production,     is the non-insulin mediated central nervous system uptake.         
is the volume of distribution of glucose,      is the mass of the body, and            is the 
fraction of brain to body mass.  
In the plasma insulin compartment (I),        is the exogenous insulin input,    is basal 
insulin secretion, which is modified by an exponential representing the suppression of insulin 
secretion in the presence of exogenous insulin, as determined by   . The rate parameters   
and   determine the clearance of insulin from the system and the transport between the 
plasma (I) and interstitial compartments (Q) respectively.         is the distribution volume of 
insulin, and    saturates insulin clearance. 
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Absorption of glucose via the enteral route was modelled: 
                                   
           for              (3.4) 
where the effective half life of glucose transport from gut to plasma (   [min
-1
]) is defined 
according to whether feed rates are increasing (   ) or decreasing (   ): 
      
                          
                         
  (3.5) 
3.3 The Intensive Care Insulin-Nutrition-Glucose (ICING) Model 
Both the adult ICU model by Lin (Lin, 2007) and the NICU model by Le Compte (Le 
Compte, 2009) sought to balance model simplicity with physiological descriptiveness. A later 
iteration of the adult ICU model is the Intensive Care Insulin-Nutrition-Glucose (ICING) 
model (Lin et al., 2011), which was developed to include greater physiological 
descriptiveness, particularly around the clearance pathways of insulin, without sacrificing 
identifiability and clinical applicability.  
 The basic ICING model structure, shown pictorially in Figure 3.2, uses some of the main 
compartments and is defined: 
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(3.12) 
Structurally, Equation 3.6, which describes the rate of change of BG, is similar to Equation 
3.1. However, the simple insulin clearance dynamics (driven by   and  ) of Equation 3.7 are 
more physiologically comprehensive, including first part hepatic extraction of pancreatic 
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insulin secretion (   , insulin saturated clearance of insulin by the liver (  ), kidney 
clearance (  ), and diffusion of glucose between the plasma and peripheral compartments 
(  ). The volumes of distribution of insulin in plasma is   . Pancreatic insulin secretion (   ) 
has a base rate,   , which is suppressed by parameters    and   .  
 
 
 
 
Figure 3.2: Pictorial description of the ICING model.  Arrows show movement of 
glucose through gastro-intestinal compartments (orange) and into and outcome a 
central blood glucose compartment (red). Blue arrows show insulin movement between 
plasma and interstitial compartments, as well as secretion and clearance. 
 
43 
 
 
Figure 3.3: Comparison of two models for glucose appearance from enteral feeds. 
Figure derived from enteral feed data for a preterm infant, using adult d1 and d2 
parameters. 
 
Of note, is the change in the model for gastro-intestinal processing and absorption of insulin. 
One of the main issues with Equations 3.4 and 3.5 is that they do not necessarily conserve 
mass. The ICING model uses a simple 2 compartment gut model from Dalla Man et al. 
(2006) to describe the absolute amount of glucose ([mmol]) in the stomach (  ) and small 
intestine (  ). Glucose from an enteral feed (P) is transferred via gastric emptying from the 
stomach to the intestine (  ). Absorption from the intestine to the blood stream is driven by 
the rate constant   , with a maximal glucose transport rate of     . A comparison of the two 
models is shown in Figure 3.3, where the failure of the NICU gut model to conserve mass is 
clearly apparent.  
3.4 Insulin Sensitivity and Model Based Control 
The model-based glycaemic control framework used in this thesis is known as STAR 
(Stochastic TARgeted) because of its use of stochastic forecasting models. Stochastic models 
of likely future changes in SI are used to actively target likely BG outcomes to a clinically 
defined target range (Evans et al., 2011, Le Compte et al., 2009, Luque et al., 2009). In this 
model based framework, SI is patient-specific and time-varying, describing a patient‟s 
current metabolic state. This model parameter is identified on an hour-to-hour basis from 
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clinical data using integral-based fitting (Hann et al., 2005). In addition to being a marker of 
peripheral insulin sensitivity, SI also captures uncertainty around patient-specific endogenous 
insulin and glucose production (Chase et al., 2011b, Dickson et al., 2013).  
A detailed description of stochastic modelling and validation can be found in (Lin, 2007, Lin 
et al., 2008). In summary, kernel density estimate methods are applied to matched pairs of SI 
now and SI in a defined number of (k) hours time (e.g.             ), to generate a 
continuous probability distributions across the range of observed SI based on a cohort of 
identified SI values. Thus, for any identified     the stochastic model provides a probability 
density function describing likely values of      , on a cohort basis over the next k hours.  
These distributions of likely insulin sensitivity outcomes can then be used to generate BG 
outcome distributions for a given insulin and nutrition treatment, as shown in Figure 3.4. 
Insulin treatment can then be selected based on likely BG outcomes, using defined targets 
and thresholds. In particular, hypoglycaemic risk can be quantified (usually as the %BG< 4.0 
or 4.4 mmol/L) and directly managed (Evans et al., 2011, Fisk et al., 2012), which is unique 
to this approach. 
 
Figure 3.4: Stochastic forecasting of insulin sensitivity (SI) and blood glucose (BG) 
outcomes. First a patient’s current SI is determined. Distributions of future insulin 
sensitivity are generated from stochastic models, and these are used to generate 
distributions of BG outcomes for a given insulin/nutrition treatment (usually 
characterised by the 5th, 50th, and 95th percentiles).  
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Stochastic models are generated on a cohort-specific basis, and the median likely change in 
SI is no change. However, any single patient is not guaranteed to follow the whole-cohort 
defined behaviour. In practice, it usually means the stochastic model is conservative for many 
patients, with wider 5th - 95th percentile bands than may be seen on a patient specific basis. 
Inevitably, this conservatism has an impact on the tightness of control. However, it also 
allows unusually variable patients, who are most at risk of hypoglycaemia, to be treated in a 
safe manner. Thus, this approach to model creation, as well as its application, favours safety 
over performance. 
Generation of stochastic models requires sufficient data density (minimum of ~1300 patient 
hours) (Lin et al., 2006). Thus, sub-cohort defined stochastic models based on patient 
characteristics for specific groups are not always possible. Such sub-cohort models could 
offer greater precision and specificity to control. Stochastic models must also balance the 
desired tightening of percentiles, perhaps by sub-cohort definition, with the increased risk for 
patients who are not well defined by any sub-cohort. 
3.5 Summary 
Physiological models must be physiologically valid, mathematically identifiable, and 
clinically useful. This chapter presented the NICU model for glycaemic control in neonatal 
intensive care, and the ICING model for glycaemic control in adult intensive care. These 
models are used as a starting point from which a Neonatal Intensive Care Insulin-Nutrition-
Glucose (NICING model) will be developed. Adaptation of the ICING model with respect to 
neonatal physiology will revisit the modelling approach of Le Compte et al. (Le Compte, 
2009, Le Compte et al., 2010a), and attempt to more comprehensively model certain aspects 
of neonatal insulin-glucose metabolism, moving beyond simple population constants where 
possible, feasible, and relevant. This modelling will be based on meta-analyses of published 
literature data, as well as a data cohort of relatively rare and abundant clinical measurements 
made available from a large scale glycaemic control trial in very premature infants (Alsweiler 
et al., 2012).  
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Chapter 4: Modelling Insulin Secretion  
4.1 Introduction 
Adequate modelling of endogenous (pancreatic) insulin secretion plays an important part in 
model-based glycaemic control. During intervals when no exogenous insulin is being 
delivered, pancreatic insulin secretion is the only source of insulin, and thus has a large 
impact on identified, model-based SI. When exogenous insulin is being delivered, pancreatic 
insulin secretion makes up a small proportion of all insulin appearance, thus affecting this SI 
to a much smaller degree. Proper modelling of insulin secretion can reduce model identified 
SI variability, as patient-specific perturbations from modelled dynamics are reduced. As a 
result, identified, model-based SI would more accurately reflect peripheral SI, and overall 
glycaemic control could be improved. 
All prior studies into neonatal insulin secretion have relied on plasma insulin concentration 
alone as a qualitative surrogate indicator of increased insulin secretion (e.g. Andronikou and 
Hanning (1987), Cser and Milner (1975), Grasso et al. (1975), Grasso et al. (1990), Grasso et 
al. (1973), Grasso et al. (1968), Grasso et al. (1970), Reitano et al. (1978)). Importantly, in all 
these studies, there has been little or no discussion of clearance kinetics or other factors 
impacting the results when using this approach. However, insulin is highly unreliable in this 
role because of its multiple clearance pathways, as well as the variability in the clearance rate 
of these pathways between patients and over time.  
Pancreatic insulin secretion has typically been estimated in adults using models of C-peptide 
kinetics (Eaton et al., 1980, Polonsky et al., 1986, Van Cauter et al., 1992). C-peptide is 
secreted in equimolar quantities with insulin, but is only cleared by the kidney, a well known 
and measureable clearance pathway. C-peptide concentration is thus a more accurate 
predictor of insulin secretion compared with plasma insulin concentration due to its simpler, 
less variable, and more measureable clearance kinetics (Van Cauter et al., 1992). Thus, a very 
important aspect of the dataset in this chapter is the availability of C-peptide measurements, a 
protein that relatively few studies have reported for this population due to sampling 
difficulties and limits in neonates because of their very small blood volume.  
This aim of this study was to determine insulin secretion in premature neonates, calculated 
from plasma C-Peptide concentrations. It is based on clinical data from premature babies 
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enrolled in a randomised controlled trial of tight glycaemic control (Alsweiler et al., 2012). A 
particular goal is to determine predictors for insulin secretion in hyperglycaemic preterm 
babies, and create a model suitable for use in glycaemic control.  
4.2 Methods 
4.2.1 Clinical Cohort 
Plasma samples were collected from 88 preterm babies during a prospective, randomised trial 
of tight glycaemic control of preterm babies, the HINT trial, (Alsweiler et al., 2012) 
Australian Clinical Trials Registry 12606000270516, ethics approval from the New Zealand 
Northern X Ethics Committee. This trial compared tight glycaemic control (TGC) using 
insulin to maintain the BG 4-6 mmol/L
 
 in hyperglycaemic preterm babies, with standard care 
(control group), at the National Women‟s Health NICU in Auckland, New Zealand 
(Alsweiler et al., 2012). Written informed consent was obtained from a parent of each child. 
Babies were eligible for enrolment if they were born at <30 weeks gestational age (GA), or 
birth weight (BW) <1500g, and had become hyperglycaemic, defined as two consecutive 
BG>8.5 mmol/L
 
at least 4 hours apart. Babies were randomised when they became 
hyperglycaemic, which was usually 4-5 days postnatal age (PNA). Small for gestational age 
(SGA) was defined as less than the 10
th
 percentile on population based growth charts. Birth 
weight z scores were calculated based on a similar published data cohort (Beeby et al., 1996).  
Of the 88 babies recruited to the trial, 41 were of GA<32 weeks and had sufficient plasma 
from 1 or more of the samples for further retrospective analysis, totalling 54 samples taken at 
a median of 7 days after study randomisation. Of these 41 babies, 20 were from the TGC 
group, contributing 25 samples. Median BW and GA was 839g and 27 weeks respectively. 
Demographic details are given in Table 4.1. 
Nutritional intake, BG, growth and insulin infusions were recorded. Parenteral nutrition was 
commenced within the first day after birth and enteral feeds with small amounts of breast 
milk were usually started in the first one to two days after birth. Lactose is comprised of both 
glucose and galactose, which are of approximately equal molar mass, with only glucose 
directly contributing to BG concentration. Therefore, glucose appearance from lactose was 
estimated as half the available lactose.  
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Table 4.1: Characteristics of babies randomised to the HINT trial whose plasma 
samples were analysed for plasma C-Peptide concentrations.  Numbers are presented as 
median [IQR] or number (% of total). CRIB 2: Clinical Risk Index for Babies. 
Characteristic Value 
Total patients 41 
Control group 21 
 Tight Glycaemic Control group 20 
Male (%) 20 (49%) 
Multiple Birth 11 (27%) 
Antenatal glucocorticoid exposure 39 (95%) 
Maternal diabetes 1 (2%) 
Gestational age, weeks 27.2 [26.2 - 28.7] 
Birth weight (grams) 839 [735 – 1000] 
Birth weight Z score -0.19[-1.03 - 0.14] 
Small for gestational age 6 (15%) 
CRIB 2 score 12 [10-14] 
Ethnicity  
   Asian 9 (22%) 
   Caucasian 11 (27%) 
   Maori 17 (41%) 
   Pacific Island 4 (10%) 
 
Blood samples were taken at randomisation (DOR=0), 7 and 14 days post-randomisation 
(DOR=7 and DOR=14 respectively), and at 36 weeks GA. Plasma insulin, insulin-like 
growth factor 1 (IGF I), and glucose concentrations were measured, and remaining plasma 
samples were frozen. BG measures were taken when clinically indicated and determined 
using a glucose oxidase method (ABL 700, Radiometer Ltd, Copenhagen, Denmark). Plasma 
insulin concentrations were measured on an Azsym system auto-analyzer (Abbott 
Laboratories, Abbott Park, IL) (Alsweiler et al., 2012). Retrospective C-peptide analysis was 
carried out on samples with sufficient remaining plasma from samples taken 0-15 days after 
randomisation at a GA <32 weeks. Plasma C-peptide concentrations were determined using 
immunometric assays (Elecsys 2010, Roche Diagnostics, Germany).  
4.2.2 C-peptide Model  
Plasma  C-peptide concentrations were used to estimate insulin secretion, using a well-
accepted 2 compartment kinetics model: (Van Cauter et al., 1992) 
  
  
                 (4.1) 
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         (4.2) 
where C is the amount of C-peptide in the central compartment comprising of plasma and 
tissues in rapid equilibrium with the plasma, and Y is the amount of C-peptide in the 
peripheral extra vascular compartment. C-peptide and insulin are secreted in equimolar 
amounts into the central compartment at rate S. Transport of C-peptide from the central to the 
peripheral compartment, and back, is described by k1 and k2. Irreversible renal clearance of 
C-peptide from the central compartment via the kidney is modelled by k3 (Van Cauter et al., 
1992).  
Sampling constraints due to limited blood volume in this cohort mean frequent, serial 
measurements of C-peptide, as used in adult studies, were not clinically or ethically possible. 
A steady-state assumption can be made to enable deconvolution of the insulin secretion rate 
from measured C-peptide concentrations. Under this steady-state assumption, it follows from 
Equation 4.2 that the rate of C-peptide entering and leaving the peripheral compartment must 
be equal. Hence, substituting this equality into Equation 4.1 and rearranging yields:  
       (4.3) 
Equation 4.3 holds whether C is an absolute amount [pmol] or concentration [pmol/L]. Since 
insulin is secreted in equimolar quantities with C-peptide, under steady state conditions the 
rate of secretion of insulin is directly proportional to the measured concentration of C-peptide 
in the central compartment.  
4.2.3 C-peptide Kinetic Parameters in Preterm Neonates 
Since no studies have been performed in preterm or term neonates to determine C-peptide 
kinetics, adult data and methodology (Polonsky et al., 1986, Van Cauter et al., 1992) were 
used as an approximation, given that the fundamental physiological kinetics and functionality 
are also no different. The reported values and ranges for each of the kinetic parameters of 
Equations 4.1 and 4.2 are given in Table 4.2.  
A short half life of 4.95 min and a fraction, F, of 0.76 was used based on non-obese and non-
diabetic adult data. The long half life thus was calculated using (Van Cauter et al., 1992): 
                                                (4.4) 
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Table 4.2: Kinetic C-peptide parameter ranges in adults. Data sources: (Bier, 1998, 
Eaton et al., 1980, Van Cauter et al., 1992). All values are mean ± SEM 
 
Patient 
Cohort 
Short 
half life 
[min] 
Long 
half life 
[min] 
Fraction 
F 
k1  
[min
-1
] 
k2  
[min
-1
] 
k3 
 [min
-1
] 
Eaton et 
al, 1980 
Normal 
n=20 
- - - 
0.047 
± 0.002 
0.035 
± 0.002 
0.049 
± 0.001 
Van 
Cauter et 
al, 1992 
Normal 
n=111 
4.95 
± 1.04 
32.4 
± 5.0 
0.76 
± 0.04 
0.053 
± 0.002 
0.051 
± 0.001 
0.062 
± 0.001 
Obese 
n=53 
4.55 
± 1.23 
34.6 
± 5.9 
0.78 
± 0.04 
0.067 
± 0.003 
0.051 
± 0.002 
0.065 
± 0.013 
Polonsky 
et al, 
1986 
Normal 
n=10 
- - - 
0.057 
± 0.006 
0.054 
± 0.006 
0.06 
± 0.002 
Diabetic 
n=7 
- - - 
0.037 
± 0.004 
0.031 
± 0.004 
0.057 
± 0.002 
 
Equation 4.4 yields an estimated long half-life of 29.2 minutes for newborns (Polonsky et al., 
1986). The kinetic parameters were then individually calculated using these cohort specific 
values, as per (Van Cauter et al., 1992): 
               (4.5) 
    
   
  
 (4.6) 
                 (4.7) 
where a = log(2)/(short half life), and b = log(2)/(long half life). The resulting calculated 
value for    for all neonates was     0.0644 min
-1
. This value is within the reported normal 
clearance rates from other well known studies, shown in Table 4.2. 
4.2.4 Trend Analysis 
Endogenous insulin secretion was calculated for each sample using Equations 4.3 – 4.7. 
Results were analysed with respect to patient BW, weight, GA, the DOR, CRIB2 score, 
maternal cortisol treatments, sex, multiple birth, and ethnicity, to determine if there were any 
trends within sub cohorts with these characteristics. Insulin secretion was also examined with 
respect to species or interventions previously reported in several prior studies in the literature 
to affect insulin secretion (Andronikou and Hanning, 1987, Cser and Milner, 1975, Grasso et 
al., 1975, Grasso et al., 1990, Grasso et al., 1973, Grasso et al., 1968, Grasso et al., 1970, 
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Reitano et al., 1978), namely BG, glucose, and protein intake. Linear models were fit using 
Matlab
®‟s lsqnonlin function.  
4.2.5 Statistical Analysis 
Results are presented as median (IQR) or number (%) as appropriate. Statistical analyses 
were carried out in Matlab
®
. Non-parametric data were log transformed to approximate 
normal distributions and compared using the Student‟s t-test (ttest2). Binary outcomes, such 
as survival and multiple births, were tested using the Fishers exact test. The Lilliefors test 
(lillietest) was used to assess the results of the transformations. P-values < 0.05 were 
considered statistically significant.  
4.3 Results 
4.3.1 Insulin Secretion and Clinical Characteristics  
Across all samples the median BG and plasma insulin were 7.5 mmol/L and 14.3 mU/L, and 
the median insulin secretion was 8.2 mU/kg/L/min, as shown in Table 4.3. BG, plasma 
insulin, plasma C-peptide concentrations and insulin secretion decreased following 
randomisation (Figure 4.1).  
 
 
Table 4.3: Insulin secretion and plasma glucose, insulin, IGF-1, C-peptide and cortisol 
concentrations. Numbers are presented as median [IQR].  
Characteristic Value 
Number of Samples 54 
Day after randomisation  7 [0 – 14] 
BG, mmol/L 7.5 [5.1 – 10.5] 
Plasma insulin concentration, mU/L
 
14.3 [8.5 – 26.2] 
Plasma IGF I concentration, nmol/L
 
0.80 [0.47 – 1.12] 
Plasma C-peptide concentration, 
nmol/L
 2.3 [1.1 – 4.2] 
Cortisol at randomisation, nmol/L
 
278.7 [251.1 – 416.6] 
Insulin secretion, mU/kg/L/min
 
8.2 [3.5 – 17.8] 
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Figure 4.1: Blood glucose, plasma insulin and C-peptide concentrations and insulin 
secretion at the time of randomisation to the HINT trial and 7-14 days later. Blood 
glucose (A), plasma insulin (B), and plasma C-Peptide concentrations and insulin 
secretion (C) from samples taken at randomisation (DOR=1; black), and on days 7 or 14 
after randomisation (DOR>1; grey). Data are median (IQR). 
 
There was no difference between TGC and control groups in BG (5.8 [4.8 - 11.0] vs. 8.0 [5.3 
- 10.6] mmol/L, p=0.27), plasma insulin concentration (14.3 [8.0 - 27.6] vs. 14.3 [8.2 - 27.6] 
mU/L, p=0.75), plasma IGF-1 (0.76 [0.46 – 1.14] vs. 0.93 [0.51 – 1.22] nmol/mL, p=0.83), 
C-peptide concentration (0.51 [0.24 - 1.19] vs. 0.98 [0.42 - 1.56] mmol/L, p=0.09), or insulin 
secretion (6.0 [3.1 - 11.8] vs. 11.1 [3.9 - 18.1] mU/kg/L/min, p=0.16). There were no 
differences in BG, plasma insulin concentrations, and insulin secretion with ethnicity 
(p≥0.29). There was not a statistically significant correlation between insulin secretion and 
CRIB 2 score (r
2
=0.04, p=0.33) or plasma cortisol concentration at randomisation (r
2
=0.05, 
p=0.30). 
Weight at time of sample and insulin secretion were not strongly correlated (R
2
=0.1). There 
was no clear trend of insulin secretion with GA. The median insulin secretion tended to be 
higher in neonates of lower GA at randomisation, or with lower weight, but this group had 
significantly higher BG than at post-randomisation (DOR>0) (Figure 4.1, p<0.005). 
Separating the cohort into two groups based on gestational age with a cut-off of 26 weeks, 
gave the greatest significant difference in insulin secretion (GA>26 weeks: 4.9 [3.0 - 9.8], 
GA ≤ 26 weeks: 9.8 [3.8 - 19.9] mU/kg/L/min) based on GA (p=0.03), and the IQR is lower 
for the GA>26 group, showing lower variability.  
Weight at time of sample and insulin secretion were not strongly correlated (R
2
=0.1). There 
was no clear trend of insulin secretion with GA. The median insulin secretion tended to be 
higher in neonates of lower gestational age at randomisation, or with lower weight, but this 
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group had significantly higher BG than at post-randomisation (DOR>0) (Figure 4.1, 
p<0.005). Separating the cohort into two groups based on GA with a cut-off of 26 weeks, 
gave the greatest significant difference in insulin secretion (GA>26 weeks: 4.9 [3.0 - 9.8], 
GA ≤ 26 weeks: 9.8 [3.8 - 19.9] mU/kg/L/min, p=0.03), and the IQR is lower for the GA>26 
group, showing lower variability as well.  
Of 54 samples, 41 were from singleton births. More babies from non-singleton birth were 
male (70% vs. 39%), but both groups were similar in GA, weight, PNA and CRIB 2 score 
than babies from singleton birth (p≥ 0.69). BG was significantly higher in the singleton group 
(8.6 [5.6 - 11.1] vs. 5.5 [4.8 - 7.5] mmol/L, p=0.03), but insulin secretion was not 
significantly different in babies from singleton compared with non-singleton births (9.1 [3.7 - 
19.4] vs. 5.1[3.2 - 10.2]  mU/kg/L/min, p=0.28). 
Table 4.4: Clinical characteristics, nutritional data and plasma insulin and c-peptide 
concentrations in boys and girls. Data are presented as median [IQR] or n(%). PN is 
parenteral nutrition, and EN is enteral nutrition. TGC is the tight glucose control 
group. Nutrition data  is a daily total for the day the sample was taken. 
Characteristic 
Sex 
Boys Girls p 
n 25 29 - 
Randomised to TGC 15 (60) 10 (33) - 
Gestational Age (GA) [wks] 26 [26-27] 26 [25-26.5] 0.98 
Weight [g] 930 [750-1043] 815 [700-979] 0.17 
Z score 0.03 [-0.76 – 0.11] 0.05 [-0.88 – 0.13] 0.72 
SGA 3 (12) 4 (14) - 
Multiple birth 9 (36) 4 (14) 0.06 
Post Natal Age (PNA) [d] 9 [3.5-17] 11 [4.5-17] 0.81 
Maternal Diabetes 1 (4) 0 1.0 
CRIB 2 score 12 [11-14] 12 [10-13] 0.99 
Died 4 (16) 2 (7) 0.27 
BG [mmol/L] 6.9 [5.5-10.2] 7.6 [4.9-10.8] 0.61 
Plasma Insulin [mU/L] 14 [6.8 – 26] 16 [8.9 – 7] 0.30 
IGF I [nmol/L] 0.96 [0.54 – 1.31] 0.72 [0.45 – 1.06] 0.33 
C-peptide [mmol/L] 0.51 [0.16-0.90] 1.09 [0.46-1.64] 0.005 
Insulin Secretion [mU/L/kg/min] 4.7 [2.1-8.3] 11.7 [5.3 – 18.7] 0.003 
PN glucose [g/day] 4.6 [0-8.8] 3.6 [0-8.6] 0.34 
EN lactose [g/day] 2.1 [0.6-11.9] 6.5 [0.5-14.8] 0.42 
Protein intake [g/day] 3.2 [2.5-4.0] 2.8 [2.5-3.8] 0.52 
Average dextrose intake 
[mg/kg/min] 
9.4 [7.7-11.1] 9.3 [7.8 – 11.8] 0.79 
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Insulin secretion was higher in girls (Table 4.4). This difference was seen both at 
randomisation (18.0 [13.3-27.1] vs. 6.7 [3.5 - 9.4] mU/kg/L/min, p=0.01) and post 
randomisation (8.2 [4.8 - 13.0] vs. 3.6 [1.2 - 7.6] mU/kg/L/min, p=0.03). There was no 
significant difference in insulin secretion between TGC and control groups for either sex 
(girls: 12.5 [4.9 - 20.4] vs. 11.7 [8.0 - 17.4] mU/kg/L/min, p=0.81; boys: 4.7 [1.8 - 7.3] vs. 
6.5 [2.2 - 11.5] mU/kg/L/min, p=0.48). BG, plasma insulin concentration, nutrition amount or 
delivery method were not significantly different between the sexes (Table 4, p≥0.34).  
4.3.2 The Effect of Nutrition and Insulin on Insulin secretion 
Neither protein intake nor total dextrose intake for the day significantly affected the rate of 
insulin secretion (Figure 4.2). Adjusting for BG at the time of the sample did not affect this 
result, with high and low protein intakes being equally scattered with respect to BG and 
insulin secretion rate.  
 
    a)       b) 
 
    c)       d) 
Figure 4.2: Endogenous insulin secretion and blood glucose with respect to protein (a & 
b) and total dextrose intake (c & d) on the day the sample was taken. In parts a) and c) 
data points are scaled in size by the magnitude of nutritional intake, with data points 
from infants with a larger mass of intake being larger in size. 
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There was a positive and expected relationship between plasma insulin concentration and 
insulin secretion, but it was weak (R
2
=0.36), as shown in Figure 4.3b. There was also no clear 
relationship between both BG and plasma insulin with insulin secretion (Figure 4.3a). Insulin 
secretion was lower at the time of samples taken during an insulin infusion (n=13) than when 
not on insulin infusion (3.7 [1.8 - 6.9]  vs. 9.8 [4.7-17.8] mU/kg/min, p=0.02) with no 
statistically significant effect on BG (insulin infusion: 6.9 [5.4 - 9.5] mmol/L vs. not on 
insulin: 7.6 [5.0 - 11.1] mmol/L, p=0.46) or plasma insulin concentration (insulin infusion; 
19.9 [9.2 - 26.7] mU/L vs. not on insulin; 13.2 [6.6 - 27.1]  mU/L, p=0.25). Thus, none of 
these effects, as evident in Figure 4.3, had a clear, significant trend. 
4.3.3 Insulin Secretion and Blood Glucose Concentration 
There was a weak relationship between insulin secretion and BG (Figure 4.4). This 
relationship was stronger in female babies, with a weak correlation for males.  The difference 
between the sexes in insulin secretion was true over the entire BG range (p < 0.005), with no 
statistically significant difference between clinical characteristics (p ≥ 0.17), plasma insulin 
concentration (p=0.30), or nutrition regimes (p ≥ 0.34). Thus, Figure 4.4 also shows separate 
male and female models for secretion in these cohorts, as well as an overall cohort model.  
 
     
     a)      b) 
Figure 4.3: Endogenous insulin secretion with a) BG and plasma insulin concentration, 
and b) plasma insulin. In parts a) data points are scaled in size by the magnitude of 
plasma insulin, with larger data points representing samples with higher plasma insulin 
concentration. Open (o) purple and closed (●) red circles denote results from infants not 
receiving and receiving exogenous insulin respectively at the time of sampling.  
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These sex based insulin secretion models are defined in Equation 4.8: 
      
                      
                     
  
              
        
 (4.8) 
where 4.2 and 2.2 mU/kg/L/min are the lower bounds on insulin secretion in Figure 4.4. 
The whole cohort model in Figure 4.4 is defined: 
                            (4.9) 
Multiple linear regression models that accounted for combinations of GA, weight, postnatal 
age, BG, dextrose intake and exogenous insulin were not able to predict insulin secretion. In 
particular, weak correlations of R
2 ≤ 0.2 indicate the small role of these variables. Thus, these 
models do not benefit from these added clinical variables.  
 
Figure 4.4: Models of endogenous insulin secretion as a function of BG over the whole 
cohort and male and female sub cohorts. A total of 5 data points from 54 total (9%) 
were excluded from the analysis as outliers based on a 2-3 fold difference with other 
data points of similar BG. Some of these data points were from heavier and older 
patients of GA>29 weeks. However, 2 were from 26 week old male and female neonates. 
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4.4 Discussion 
4.4.1 Insulin Secretion and Sex 
Insulin secretion in girls was higher than that in boys, despite similar clinical characteristics, 
plasma insulin and BG concentrations, and no sex difference in the incidence of neonatal 
hyperglycaemia in babies eligible for the HINT trial (Alsweiler et al., 2012). The effect of sex 
on insulin secretion, as measured by C-peptide concentrations, has not been reported 
previously in preterm babies (Mitanchez-Mokhtari et al., 2004, Sosenko et al., 2007, 
Tsubahara et al., 2012) or children.  
There was a positive relationship between BG concentration and insulin secretion rate. 
Higher insulin secretion at higher BG concentrations has been reported previously in preterm 
babies (Adam et al., 1969a) and is supported by research that shows that a reduction in 
plasma glucose concentration in hyperglycaemic preterm infants is accompanied by a 
reduction in insulin secretion (Mitanchez-Mokhtari et al., 2004). This correlation was 
stronger in females, perhaps suggesting that the male sub cohort was sicker or had higher C-
peptide clearance.  Insulin secretion was similar between males and females at the lower end 
of the basal BG range, but the linear model fitted to the female sub cohort had a larger slope 
in Figure 4.4, indicating heightened pancreatic response to changes in BG level. Higher 
insulin secretion in the females at comparable plasma insulin concentrations could also 
indicate higher insulin clearances. Glomerular filtration rate (GFR) was not available in these 
preterm babies, which would have allowed determination of sexual dimorphism in renal 
clearance of C-peptide. However, GFR has not been observed to be different between the 
sexes in preterm babies previously (Rhodin et al., 2009).   
Differences in insulin concentrations and SI between the sexes have previously been 
observed during infancy and later in life. Higher plasma insulin concentrations have been 
observed in girls born at term (Ibanez et al., 2008), and plasma IGF-1 concentrations were 
also higher in baby girls (Ibanez et al., 2008). Women have been shown to have higher 
insulin sensitivity (Mathai et al., 2012), and post-pubertal, pre-menopausal women are less 
likely than men to develop diabetes, although this trend reverses after menopause (Liu and 
Mauvais-Jarvis, 2010). Potentially, the sex differences in insulin secretion seen in our study 
could be due to sex hormones, as oestrogen protects against Beta cell apoptosis in mice (Le 
May et al., 2006) and oestrogen replacement therapy reduces the incidence of Type 2 diabetes 
in post-menopausal women (Margolis et al., 2004). However in a study looking at age and 
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sex differences in glucose and insulin metabolism, sex differences in insulin secretion in 
adults was not observed (Basu et al., 2006). 
Preterm birth is associated with higher mortality (Stevenson et al., 2000), and poorer 
neurodevelopmental outcome (Henderson-Smart et al., 2006) in boys than girls.  Animal 
studies have shown that in utero interventions, such as alterations of maternal diet, result in 
sexual dimorphism of cardiovascular risk factors, such as insulin resistance and raised blood 
pressure (Aiken and Ozanne, 2013). Recent studies have also shown sexual dimorphism in 
cardiovascular risk factors after preterm birth in both animal models and human studies 
(Berry et al., 2013, Feldt et al., 2007, Kaseva et al., 2014). Girls may respond differently to 
antenatal glucocorticoids, or preterm birth, than boys. Insulin sensitivity is reduced in 
children born preterm (Hofman et al., 2004) and adults (Dalziel et al., 2005) exposed to 
antenatal glucocorticoids. Placental 11-hydroxysteroid dehydrogenase-2 activity following 
antenatal betamethasone is greater in girls than boys (Stark et al., 2009), which may reduce 
the ability of betamethasone to increase insulin sensitivity in girls. As nearly all babies in this 
study were exposed to antenatal glucocorticoids it was not possible to analyse the effect of 
antenatal glucocorticoids on insulin secretion. Equally, this consistent exposure also indicated 
that the results were not biased. 
4.4.2 Insulin Secretion and Exogenous Insulin 
There was a positive correlation between endogenous insulin secretion and plasma insulin. 
However, causation and response is hard to separate from this data. Infants in this post-hoc 
analysis were evenly distributed between control and TGC cohorts in the original HINT study 
(Alsweiler et al., 2012). There are too few data points to conclusively refute or determine 
models for suppressed insulin secretion in the presence of exogenous insulin, but there was 
increased insulin secretion in the absence of an exogenous insulin infusion. Male and female 
infants were evenly spread between the exogenous insulin and no exogenous insulin groups, 
indicating sex was not responsible for this difference, and vice versa. These data points are 
tightly clustered with respect to BG, and are thus heavily influenced by one or two points at 
extremes in BG. In addition, endogenous insulin secretion was not significantly suppressed in 
the presence of increasing exogenous insulin infusion, as might be expected (Ruotsalainen et 
al., 1996). 
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4.4.3 Comparison to Literature 
This study determined insulin secretion, calculated from plasma C-Peptide concentrations, in 
hyperglycaemic preterm babies randomised to tight glycaemic control or standard care. This 
study used C-peptide measurements, data that relatively few studies have reported for this 
population (Mitanchez-Mokhtari et al., 2004, Sosenko et al., 2007, Tsubahara et al., 2012). C-
peptide concentration is a more accurate indicator of insulin secretion than plasma insulin 
concentration due to its simple clearance kinetics. In particular, C-peptide is only cleared 
through the kidney, in contrast to the multiple clearance paths of insulin (Van Cauter et al., 
1992). 
Surprisingly, no differentiation of insulin secretion rates was seen between differing levels of 
protein or glucose intake in the neonates, as seen in Figure 4.2. An increase in plasma insulin 
concentrations in response to a glucose stimulus is well documented in preterm babies 
(Andronikou and Hanning, 1987, Grasso et al., 1975, Grasso et al., 1990, Grasso et al., 1973, 
Nakai et al., 1976). In addition, it has been observed that plasma insulin concentrations are 
higher after a glucose stimulus in the presence of amino acids, such as theophylline 
theophylline (Cser and Milner, 1975, Grasso et al., 1973, Grasso et al., 1968, Grasso et al., 
1970, Salle and Ruiton-Ugliengo, 1977), or glucose priming (Grasso et al., 1975). Potentially, 
these results reflect the differing physiological stress and degree of prematurity. Some 
neonates showed high insulin secretion rates with medium-high protein intakes, as would be 
expected, and it is possible that if a pancreas is compromised due to prematurity, or for any 
reason, then the presence of protein is unlikely to affect endogenous insulin secretion. Again, 
a more detailed prospective study would be required to verify this possibility. 
There was no statistically significant difference in insulin secretion between babies fed 
enterally or parenterally, indicating that enteral feeds may not increase insulin secretion in 
preterm babies. Previous studies have observed higher fasting and post-feed concentrations of 
glucagon-like peptide-1, which has an incretin effect in term and preterm babies (Padidela et 
al., 2009), but there are no data available on the effect of this on insulin secretion in preterm 
babies. In this study, we were unable to further investigate the effect of nutrition on insulin 
secretion in preterm babies due to the comparison of glucose (parenteral) and lactose (enteral 
–lactose is broken down into glucose and galactose), and the availability of daily totals of 
these sugars only. Moreover, babies receiving predominantly enteral feeds were more likely 
to be older than babies on parenteral feed.  
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4.4.4 Glucose-Insulin Physiology 
The regulation of BG is complex and involves both the liver and the pancreas. Unfortunately, 
little information is available in this cohort to describe the interactions of these organs and 
comprehensively describe their contribution to glycaemic regulation. In adults, insulin 
secretion by the pancreas is regulated by plasma insulin and BG, as well as hormones such as 
glucagon, cortisol and adrenaline (Bessey and Lowe, 1993, Deibert and DeFronzo, 1980, 
Gelfand et al., 1984). Stress can also affect secretion (Black et al., 1982), generally through 
these aforementioned hormones.The variability seen in the secretion dynamics in this 
neonatal cohort is thus unsurprising when it is considered that their glycaemic response is 
affected by stress, age (Sunehag et al., 1996b), and hormones in the blood, as well as being 
affected by prematurity.  
Multiple linear regression using GA, weight, postnatal age, and exogenous insulin as 
predictor variables did not significantly alter insulin secretion predictability. The individual 
effect of each of these factors is impossible to isolate, and very complicated models that 
could not be specified easily at the bedside, if at all, would be required to successfully model 
insulin secretion to a higher degree of accuracy. Much of the variability observed in this data 
can probably be attributed to stress or prematurity, and the data available was insufficient to 
give an indication of insulin sensitivity between morbidity groups in the cohort.   
4.4.5 Limitations 
The major assumption required for the calculation of insulin secretion is that of steady state 
kinetics, an assumption which is considered necessary due to sampling limitations. This 
assumption limits the studies ability to capture dynamic changes in SI (Bier, 1998). However, 
it is reasonable given the steady glucose infusion. Importantly, the extremely limited blood 
volume of extremely preterm babies means it is not possible to take the repeated C-peptide 
measurements during a glucose tolerance test used in adults to describe dynamic insulin 
kinetics and secretion with high resolution.  
This sampling limitation has two implications. The first is that because detailed information 
on preterm neonatal metabolism is not currently available, approximations on C-peptide 
kinetic parameters must be made from adult human data. If the resulting insulin secretion is 
also calculated using k3 kinetic values that are approximately 2 standard deviations (k3 = 
[0.05, 0.07]) from the normal kinetics reported in Table 4.2, and the neonatal cohort falls 
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within the observed adult range in healthy and unhealthy cohorts, then the insulin secretion 
could be in error by up to ~20%. However, changing the population constant kinetic 
parameters does not change any of the results or trends observed, and only shifts these trends. 
In addition, it is not possible in this cohort to determine patient-specific values.  For the 
purposes of model based control, the k3 parameter used is thus sufficient. Finally, any scale 
inaccuracies are absorbed and scale the time varying patient-specific SI parameter (Le 
Compte et al., 2010a) without significantly altering control outputs.   
The second implication is that the insulin secretion models generated in this study are valid in 
the context of quasi-static clinical conditions. This assumption is reasonable in babies fed 
predominantly via parenteral infusions that do not tend to change dramatically from hour to 
hour. In addition, given the limited blood sampling in typical clinical contexts, it is 
potentially dangerous to try and accurately model what cannot be clinically measured, 
especially with uncertainty around timing and delivery of feeds and pump based infusions.  
4.5 Summary 
C-peptide concentrations have been used from blood samples from very preterm neonates in 
intensive care to estimate steady state endogenous insulin secretion in this cohort, where 
previous studies have relied on plasma insulin concentrations alone. In this study, it was 
found that female neonates had a stronger endogenous insulin secretion relationship with BG 
than their male counterparts, and that overall, BG was the best predictor for endogenous 
insulin secretion. A linear model of insulin secretion based on BG and sex has thus been 
created. Insulin secretion was observed to be lower in the presence of exogenous insulin, but 
data was insufficient to be conclusive. The difference in secretion by sex is a unique result 
that can impact both control and physiologic understanding of this not well, nor easily 
studied, cohort.  
4.6 Acknowledgements 
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Chapter 5: Modelling Insulin Clearance and Degradation 
5.1 Introduction 
The previous chapter used a unique set of plasma C-peptide concentrations and well 
established models of C-peptide dynamics to determine and model insulin secretion in a very 
premature infant cohort. In this chapter plasma C-peptide and insulin concentrations will be 
used alongside results from an analysis of data from the literature to determine rate constants 
for model-based insulin clearance pathways. 
Insulin is cleared through a number of pathways, including clearance by the liver, kidneys, 
and peripheral degradation. In the adult, around 50% of peripheral insulin is removed by the 
kidneys via glomerular filtration, and proximal tubal re-absorption and degradation 
(Duckworth et al., 1998).  Liver clearance of insulin occurs in two main processes, a first pass 
hepatic clearance of endogenously secreted insulin and a more general clearance of insulin 
from circulating blood. Hepatic (liver) insulin clearance is variable and incompletely 
understood. It involves receptor-mediated processes resulting in saturation of clearance at 
high insulin concentrations (Duckworth et al., 1998, Duckworth et al., 1988).  
Insulin degradation by cells is a complex, receptor-mediated process. Receptor bound insulin 
can either be released back into the extracellular fluid space or internalised by the cell 
(Duckworth et al., 1998). Internalised insulin may be returned to the extracellular fluid space 
or degraded within the cell though several mechanisms. Insulin can also be internalised by a 
cell via pinocytosis, the pinching of the cell membrane to form a vesicle within the cell. At 
high insulin concentrations insulin stimulates higher rates of pinocytosis (Duckworth et al., 
1998).  
Thus, insulin clearance pathways are complex and vary with insulin concentration. Extremely 
detailed physiological models would be required to capture the specifics of each clearance 
mechanism. Even in adults, such data is rarely available.  
This chapter expands on previous models of insulin kinetics in premature infants (Le Compte 
et al., 2010a) to model separate insulin clearance pathways. Each pathway has a single 
clearance parameter associated with it, and saturation effects of receptor-mediated processes 
are modelled.  
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5.2 Methods 
5.2.1 Modelling Insulin Dynamics 
Plasma (I) and interstitial (Q) insulin kinetics in the premature neonate will be modelled with 
the following equations: 
      
      
         
                       
      
       
                   
(5.1) 
      
  
  
               
    
         
 (5.2) 
where    (units: 1/min) is hepatic clearance of insulin,     (units: L/mU) is the saturation of 
this clearance, and    (unit-less fraction) is the first pass hepatic clearance of insulin secreted 
into the portal vein by the pancreas. Kidney clearance is determined by    (units: min
-1
),    
(units: min
-1
) is the diffusion of insulin between the plasma and interstitial compartments, and 
   (units min
-1
) is the clearance of insulin via cellular degradation. Insulin degradation by 
cells is dependent on binding of insulin to insulin receptors, so is saturated by the receptor 
binding saturation term    (units: L/mU). Exogenous insulin delivery (IV infusion or bolus, 
units mU/min) is       , and the distribution volumes of insulin in the plasma and interstitial 
compartments are approximated by plasma and interstitial fluid volumes,    and    (units: 
L/kg) respectively.  
Equations 5.1 and 5.2 are structurally similar the ICING model, defined in Chapter 3, 
Equations 3.7 and 3.8. One difference is that Equation 3.8 has been modified to ensure 
consistency in the transfer of insulin between compartments with different distribution 
volumes, as shown in Equation 5.2. These distribution volumes are approximated by the fluid 
volumes of each compartment, and are now denoted    and   . These fluid volumes are in 
units of L/kg to reflect the significant difference between premature infants of different sizes. 
Insulin secretion,        has also been made body mass (       dependent and is no longer 
divided by distribution volume to ensure dimensional consistency with the new secretion 
model (mU/L/kg/min) developed in Chapter 4.  
Saturation of liver clearance of insulin cannot be measured in premature infants, or indirectly 
determined in this analysis. Thus, the adult value of                is used (Hann et al., 
2005, Le Compte et al., 2010a, Lin et al., 2011). In neonates saturation of insulin-mediated 
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glucose uptake by cells, a receptor-mediated process, has been reported to have little or no 
saturation in neonates (Farrag et al., 1997). As a result, insulin degradation by cells is also 
assumed to have no practical saturation (     .  
5.2.2 Clinical Data 
The clinical data used in this analysis is the same as was used in Chapter 4, and more details 
can be found in Section 2.4.1 and Table 4.1. In particular, the plasma C-peptide and insulin 
concentrations from the clinical blood samples are used alongside results from an analysis of 
the literature to examine insulin clearances. In this analysis, insulin secretion was directly 
determined from the C-peptide concentrations according to the analysis in Chapter 4. 
5.2.3 Determining Insulin Clearances 
Insulin clearance kinetics are determined using the model based method of (Pielmeier et al., 
2010a). C-peptide kinetics were defined in Equations 4.1 and 4.2. Assuming the forward and 
reverse diffusive properties of C-peptide between the two compartments are the same, and 
with C and Y in concentrations [pmol/L] rather than in absolute amounts [pmol] (as 
originally presented in (Van Cauter et al., 1992)), then Equations 4.1 and 4.2 in Chapter 4 can 
be re-written:  
  
  
                   (5.3) 
  
  
     
  
  
      (5.4) 
Here C and Y are concentrations [pmol/L] and the rate constants      and      correspond to 
parameters in the original Van Cauter model: 
          (5.5) 
          (5.6) 
The rate parameter      denotes the rate transport of C-peptide from the central to the 
peripheral compartment. The transport of C-peptide into the interstitial compartment is scaled 
by the difference in volumes of distribution in the central plasma (  ) and interstitial (  ) 
compartments. The parameter      denotes irreversible removal of C-peptide from central 
compartment via the kidney.  
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Since no studies have been performed in preterm or term neonates to determine  C-peptide 
kinetics, adult data and methodology (Polonsky et al., 1986, Van Cauter et al., 1992) was 
used as a reasonable approximation as the kinetic compartments and their functional 
physiology are the same. The values for these parameters are given in Table 5.1, and were 
derived using Equations 4.4 - 4.7. All parameters fall within reported adult ranges (Polonsky 
et al., 1986, Van Cauter et al., 1992). 
If the same steady state conditions are assumed as in Chapter 4, Equations 5.3 and 5.4 
simplify to: 
              (5.7) 
where Equation 5.7 is the same as Equation 4.3, as expected. 
Table 5.1: C-peptide model parameter values from Equations 4.4-4.7 
Parameter Value [1/min] 
k1 0.0478 
k2 0.0516 
k3 0.0644 
 
Assuming similar diffusive properties between insulin and C-peptide, the diffusion constant 
for insulin between the plasma and interstitial compartments,   , can be estimated as the C-
peptide transfer rate,     , scaled by molar mass (Pielmeier et al., 2010a): 
        
  
  
   
  
  
 (5.8) 
where            and           are the molecular masses of C-Peptide and Insulin, 
respectively. 
To determine the clearance of insulin in the interstitial compartment,   , steady state is 
assumed and Equation 5.2 re-arranged to yield: 
      
  
  
 
   
   
    (5.9) 
In adults, studies indicate that the steady state interstitial to plasma insulin ratio (Qss/Iss ) is 
between 0.4 and 0.6 (Gudbjornsdottir et al., 2003, Sjostrand et al., 2005, Sjostrand et al., 
1999, Sjostrand et al., 2000). Therefore, in this study, a ratio of 0.5 is assumed. 
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If steady state conditions are also applied to Equation 5.1, then the sum of the kidney and 
liver clearances can be estimated: 
       
              
      
  
          
   
 
(5.10) 
First pass insulin clearance by the liver is estimated using the adult value of          (Lin 
et al., 2011, Lotz et al., 2008). It is also estimated that 30-80% of insulin in the systemic 
circulation is removed by the kidneys (Rabkin et al., 1984). Renal clearance of insulin occurs 
via two pathways, glomerular filtration and absorption from the peritubular capillaries. 
Glomerular filtration compromises about 60% of total insulin clearance by the kidney 
(Rabkin et al., 1984).  
Creatinine or inulin clearances are two common approaches used to estimate glomerular 
filtration rate (GFR). The rate of GFR for insulin is approximately 90% that of inulin 
determined GFR (Maack et al., 1979).  As such, total insulin clearance via the kidney can be 
estimated: 
    
 
  
 
       
    
 (5.11) 
where GFR is in units of ml/min, and divided by 0.6 to approximate total renal clearance 
based on the proportion due to GFR. The distribution volume of insulin in the central 
compartment,   , is assumed to be the total volume of blood plasma,   . Finally, GFR can be 
estimated from (Coulthard, 1985): 
                          (5.12) 
where     the birth is weight, and     is the postnatal age in weeks. Using Equations 5.10, 
and 5.11 and 5.12, kidney and liver clearance of insulin can now be differentiated. 
5.2.4 Determination of Fluid Distribution Volumes 
Distribution volumes of glucose and insulin have not been determined for premature infants. 
To approximate these distribution volumes, the distribution volume of insulin in the central 
compartment is assumed to be the plasma fluid volume (  ). The distribution volume in the 
peripheral insulin compartment is assumed to be equal to the interstitial fluid volume (  ). 
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Previously, it was indirectly assumed that interstitial and blood plasma fluid volumes of 
distribution for insulin were essentially equal  (Le Compte et al., 2010a), as in Equations 3.2 
and 3.3. This assumption is not necessarily correct for neonates, and a literature search was 
carried out on PubMed to determine how plasma and interstitial fluid volumes change over 
time or between patients. As interstitial fluid volume is the extracellular fluid volume (ECV) 
minus the plasma volume (  ), extracellular fluid volumes were also included in the search.  
Key search terms included: plasma, extracellular, interstitial, fluid volume, and neonate. 
Exclusion criteria included lack of reported values, or non-human or adult fluid volumes. In 
premature and term infants, fluid volumes are strongly correlated with weight. Fluid volumes 
were thus analysed in units of mL/kg, as presented by the studies. Results were plotted 
against postnatal age and reported standard deviations were included as error bars. Model 
fitting was carried out in Matlab
®
 using the plot fitting toolbox. 
5.3 Results 
5.3.1 Fluid Volumes 
Fluid volumes are well reported in preterm neonates, and 10 studies were found using the 
given search terms with an average study cohort of GA < 33 weeks and BW < 2kg. Of these, 
7 reported ECV values (Bauer et al., 1991, Ekblad et al., 1991, Heimler et al., 1993, Modi et 
al., 2000a, Shaffer et al., 1987, Shaffer et al., 1991, Shaffer and Meade, 1989b) and 4 
reported    (Bauer et al., 1991, Cassady, 1966, Leipala et al., 2003, Usher and Lind, 1965). 
Figure 5.1 shows that ECV drops significantly over the first 1-2 weeks PNA, and after that 
remains relatively constant. Although a lot of variation is seen between study mean values, 
most studies fall within one standard deviation of each other. 
A power law function (R
2
 = 0.44) was fitted to capture the rapid decrease in ECV over the 
first few days and subsequent ECV plateau: 
                  (5.13) 
where PNA is postnatal age in days. 
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Figure  5.1: Decrease of extracellular volume (ECV) with postnatal age. Vertical Error 
bars are 1 standard deviation; horizontal error bars cover the range of study days. For 
the Modi et al. data, the median and range is plotted. 
 
Figure 5.2: Plasma and blood volume changes over time. Data used in this analysis is 
from patients with BW<2KG, sourced from Usher and Lind (1965).  
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Figure 5.2 shows that Plasma volume does not significantly change over the first couple of 
weeks of life. While Ussher and Lind (Usher and Lind, 1965) show a very slight decrease 
over time (R
2
 = 0.04), Bauer et al. (1991) shows a slight increase. Therefore,    may be 
assumed to remain essentially constant over time, giving an average plasma volume is 47 
mL/kg. The interstitial fluid volume may thus be defined: 
           
           (5.14) 
Thus, interstitial fluid volume, with units of mL/kg, can be modelled to decrease with 
increasing postnatal age.   
5.3.2 Insulin Clearance Parameters 
The results from the evaluation of Equations 5.8-5.12, using C-peptide data to estimate 
insulin secretion, are presented in Table 5.2 and Figure 5.3. It should be noted that nC is 
scaled by the ratio of plasma volume to interstitial volume (  /  ). The parameter nK is made 
patient specific and depends on a birth weight and postnatal age dependent model of GFR, 
according to Equation 5.11.  The distribution of patient specific values for liver clearance, nL, 
is shown in Figure 5.3, with a median clearance of 0.39 min
-1
. 
 
 
Table 5.2: Clearance Parameters based on HINT C-peptide analysis and physiological ranges in 
adult subjects. Unless otherwise stated, results are presented as Median [IQR] 
Parameter 
Preterm 
infant value 
[1/min] 
Adult ICING 
model value 
[1/min] 
Adult range  
Median [Range]  
(Lotz et al., 2008) 
[1/min] 
nI 0.025       
0.28 [0.22-0.36] [L/min] 
0.0052 [0.0041 – 0.0119] [1/min]* 
nK 
0.021 
[0.020-0.22] 
0.054 0.15 [0.1-0.21] 
nL 
0.39 
[0.15-0.70] 
0.158 0.06 [0.064-0.53] 
  
  
  
    
   
   
    0.025       - 
* From Pretty et al. (2014) 
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Figure 5.3: Model based liver clearance parameters derived from plasma C-peptide and 
insulin concentrations. 
 
5.3.3 Summary of Insulin Model 
The developed insulin kinetic model is now defined: 
      
      
         
                       
      
       
                   
(5.15) 
      
  
  
               
    
         
 (5.16) 
The parameters of the insulin kinetics model presented in Equations 5.1 and 5.2 are defined: 
 Liver clearance:         , and          
 Diffusion between compartments:          
 Insulin degradation:       
  
  
 
   
   
    
 Kidney clearance:     
 
  
 
       
    
 
Here GFR and fluid volumes are defined: 
 Glomerular filtration:                          
 Plasma volumes:           /kg 
 Interstitial fluid volume:            
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5.4 Discussion 
This study presents a more physiologically descriptive insulin model for the purposes of 
glycaemic control. In particular, it focuses on the kinetics of insulin. Previously, the total 
insulin clearance was modelled by a single clearance parameter in Equation 3.2, determined 
from literature data and minimisation of model fitting error. Different clearance pathways 
have been segregated, adding a degradation term to the interstitial compartment, saturable 
liver clearance, and kidney clearance.  
Most of the insulin clearance parameters lie within the reported physiological range for adults 
(Table 5.2). Insulin diffusion between the plasma and peripheral compartments,   , is an 
order of magnitude faster than the adult ICING model, but is lower than the    
            in adults reported by Lotz et al. (2008). It is higher than the IQR of Pretty et 
al. (2014), but within the  full reported range. Given that that the ICING model value for    
was chosen based on extensive grid search and fitting error minimisation (Lin et al., 2011), 
and that the value reported by Lotz et al. (2008) was found in fasted adults on low insulin, it 
is likely that the true physiological value is somewhere in between. That this parameter is 
slightly lower in premature infants could be explained by prematurity, or reflect assumptions 
made in this analysis, or both.  
Previous work examining insulin transport between blood plasma and the interstitial space in 
adults has been focused more on determining the mechanism of transport than quantifying 
transport rate. Trans-capillary insulin diffusion has been identified as one of the rate limiting 
steps of insulin action (Chiu et al., 2008, Hamilton-Wessler et al., 2002), and is not saturated 
(Hamilton-Wessler et al., 2002, Steil et al., 1996), suggesting diffusion-based or similar 
modes of transport. Two studies suggest that insulin transport between plasma and interstitial 
fluid has a half life of 30-90 minutes (Hamilton-Wessler et al., 2002, Miles et al., 1995), 
suggesting that the summation of nI and nC is between 0.007-0.023 min
-1
. There is thus large 
variability in reported clearance and transport of insulin. This variability could reflect 
assumptions such as the rate parameter being independent of insulin concentration, or 
unknown physiological interactions and limitations on insulin transport which impact study 
design and results.  
Birth weight and age based modelling of plasma volumes and GFR allow inter-compartment 
transport and renal clearances to be patient-appropriate. This approach is in contrast to the 
adult case, where these volumes are held constant. In addition, during the first week of life 
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there is significant weight loss in the premature infant as the extracellular fluid compartment 
contracts. Modelling this contraction will prevent long term bias in identified SI profiles, thus 
providing more accurate SI estimates.  
Insulin degradation is being modelled as a process that is unsaturated at high insulin 
concentrations. Farrag et al. (1997) observed insulin mediated glucose uptake was not 
saturated with insulin concentration. Insulin mediated glucose uptake is a receptor-mediated 
process, and receptor-bound insulin is either released back into the extracellular space, or 
internalised by the cell (Duckworth et al., 1998). As such, the same saturation parameter is 
applied to both insulin-mediated glucose uptake and insulin degradation. In this case it has 
been set to zero, due to the lack of observed saturation of insulin-mediated glucose uptake.  
Many of the study limitations are similar to those discussed in Chapter 4. In particular, the 
intermittent nature of the blood sampling in this extremely fragile cohort means that the 
assumption of steady state conditions was necessary. Thus, an assumption of approximate 
clinical steady state conditions underlies both the insulin secretion model, and insulin 
clearances. This means that the model is less likely to be transiently accurate around times of 
rapid change, for example large changes in exogenous insulin infusion. Given that insulin 
infusions change clinically every 3-6 hours, and no exogenous insulin boluses are used, this 
assumption appears reasonable in this clinical cohort. 
 5.5 Summary 
Clinical data with plasma C-peptide and plasma insulin concentrations was used with an 
analysis of results reported in the literature to model insulin clearance dynamics. Insulin is 
cleared by several main pathways, including the liver, the kidneys, and peripheral 
degradation. Insulin clearance parameters were determined for very premature infants and 
results were within the range reported in literature. Saturation of liver clearance at high 
insulin concentration was modelled. Insulin-mediated glucose uptake has been observed to be 
unsaturated with insulin in premature infants. As this receptor-mediated process is related to 
insulin degradation, insulin degradation was assumed to be unsaturated.  
Distribution volumes of insulin in the plasma and interstitial compartments were assumed to 
be equal to the fluid volumes of these compartments. The extracellular fluid compartment 
contracts significantly during the first week of life, while plasma volume remains relatively 
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constant. Fluid volumes in neonates are reported as mL/kg, and as such the models derived 
here for plasma and interstitial fluid volumes enable calculation of these fluid volumes in a 
patient appropriate manner, based on age and weight. 
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Chapter 6: Modelling Endogenous Glucose Production 
 
Chapters 4 and 5 analysed insulin secretion and clearance kinetics. Chapter 6 is the first of 
two chapters concerned with modelling glucose metabolism. This chapter examines 
variability around endogenous glucose production (EGP), and attempts to quantify some of 
this variability through modelling. 
6.1 Introduction 
EGP is the formation of glucose by the body from substrates. It is a physiological function 
that normally assists in self-regulation of BG levels and the avoidance of hypoglycaemia. It 
encapsulates two main metabolic processes: (1) gluconeogenesis, a metabolic pathway 
generating glucose from non-carbohydrate carbon substrates; and (2) glycogenolysis, by 
which the body generates glucose through the breakdown of glycogen to glucose. 
EGP can be measured by tracer studies (e.g. (Hovorka et al., 2002, Kalhan et al., 1986, Vicini 
et al., 1997)). However, because of the inherent fragility of the extremely low birth weight 
(ELBW) cohort, the true fasting rate of EGP cannot be explicitly determined experimentally 
in this way. This introduces significant uncertainty to metabolic models that rely on this 
value. Studies measuring unfasted EGP are relatively few for this cohort, and in general. 
What data there is in the literature for similar cohorts must be extrapolated. In addition, inter-
patient variability has led to significant variation between results and conclusions in these 
studies. 
Studies have attempted to quantify the variability of EGP, but with mixed results. 
Gluconeogensis has been shown to persist in premature infants receiving total parenteral 
nutrition (TPN) (Chacko and Sunehag, 2010). EGP has been shown to remain unaffected by 
amino acid administration (Diderholm et al., 1999, Poindexter et al., 2001, Van Kempen et 
al., 2003a), but lipids have been shown to support (Sunehag, 2003a) or enhance (Van 
Kempen et al., 2006) EGP. Glycerol has been shown to enhance gluconeogenesis (Sunehag, 
2003b) and to be a principle gluconeogenetic substrate (Sunehag et al., 1996b, Sunehag et al., 
1999b). Furthermore, the extremely preterm infant is capable of generating glycerol at a rate 
similar to much larger, full term infants (Sunehag et al., 1996b, Sunehag et al., 1993).  
Preterm infants have been shown to produce glucose at a rate similar to (Sunehag et al., 
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1996b, Sunehag et al., 1993) or exceeding (Chacko and Sunehag, 2010, Keshen et al., 1997, 
Tyrala et al., 1994) that of full term infants, or adults. There is also evidence of some 
relationship between GA and EGP (Chacko and Sunehag, 2010) and/or weight and EGP 
(Sunehag, 2003a). Overall, EGP is hard to measure and poorly understood in this premature 
infant cohort.  
6.2 Methods 
The analysis in this chapter utilises both literature review and clinical data. A literature 
review was carried out to examine reported values and trends for EGP. From identified 
trends, EGP models were created, and their efficacy analysed with respect to model fit to 
clinical data and control outcomes in simulation. EGP population constants based on 
literature distributions were also used to examine the effect of EGP on control in a clinical 
patient cohort, across the entire range of possible EGP values. These methods are 
summarised in Figure 6.1, and the overall goal is to find a best fit and realistic model. 
 
 
Figure 6.1: Methodological approach to analysis, modelling, analysis, and evaluation of 
models of EGP in very premature infants.  
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To evaluate the best model in the context of glycaemic control in the VLBW cohort, two 
approaches were used. The first was fit to clinical data, which evaluates the ability of a given 
model to capture clinically observed BG dynamics. The second was control performance, 
which evaluated the clinical safety of models with similar fit to clinical data using virtual 
trials. The second approach is required because, within physiological thresholds, EGP and SI 
trade off in the model. The second approach indirectly minimises SI variability and balances 
this minimisation with a focus on choosing an EGP value or model for safety in control.  
6.2.1 Literature Review 
A literature search was carried out using search criteria of “glucose”, “production”, 
“preterm”, and “neonate” in the PubMed database. Studies were excluded if they were 
associated with maternal or foetal diabetes, subjects were not human, subjects were full term 
or older, or studies were unrelated to glucose metabolism. Studies were chosen from the 
remaining literature on the basis that they reported sufficient data, including the rate of EGP, 
BG, BW< 2 kg, GA < 32 weeks, and glucose infusion (GI) feed regimes. A total of 177 data 
points were collected from 21 studies. Study methods and primary conclusions are 
summarised in Table 6.1, and cohort demographics are summarised in Table 6.2. Of these 
studies, 7 (33%) also reported plasma glucagon, and 8 (38%) reported plasma insulin. 
EGP was analysed for trends with respect to BW, GA, GI and BG, as well as glucagon and 
plasma insulin where available. A linear function was then fit using least squares for EGP 
versus GI, the strongest correlated pair of parameters. A piecewise linear function was also 
used to describe the suppression of EGP with increasing BG. The piecewise linear model was 
chosen because of high inter-patient variability in the data.  
6.2.2 Model Fit to Clinical Data 
The clinical patient cohort outlined in Table 6.2, consists of data from 21 retrospective 
patients (25 patient episodes, 3098 hours, 943 BG measurements) and 40 patients (54 patient 
episodes, 5014 hours, 1632 BG measurements) from prospective BG control studies in 
neonatal intensive care using STAR (Le Compte et al., 2009, Le Compte et al., 2012).  
Patients who received no insulin, or had no BG measurements, for more than 8 hours 
between treatments were separated into multiple patient episodes. Patient episodes were 
separated by more than 24 hours, and were at least 4 BG measures in length. 
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Table 6.1 Overview of literature studies in endogenous glucose production in premature 
infants 
Study 
Methods 
Study Conclusion(s) 
Tracers 
Tracer Infusion 
duration 
Hertz et al. 
(1993) 
[6-6-d2] glucose 
Primer dose: 5min 
Study period 4 
hours 
Clinically stable, extremely premature infants 
suppress glucose production and increase glucose 
utilization in response to increased glucose infusion. 
Increasing the rate of glucose delivery results in no 
change in whole body proteolysis in these infants. 
Sunehag et 
al. (1993) 
[6-6-d2] glucose 
 
Primer dose: 
10min 
Study period: 2 
hours 
Infants born at GA <28 weeks have a capacity to 
produce glucose on their 1
st
 day of life at rates close 
to or even exceeding those reported in term infants. 
Sunehag et 
al. (1994b) 
[6-6-d2] glucose 
Primer dose: 5min 
Study length:  
160-180 min 
Very immature newborn infants have an incomplete 
and varying capacity to respond to glucose infusion 
with suppression of glucose production. 
Insulin seems to be more important than plasma 
glucose in the regulation of glucose homeostasis in 
these infants. 
Tyrala et 
al. (1994) 
[6-6-d2] glucose 
 
Primer dose: 1min 
Study length: 2 
hours 
Infants who weigh <1100g utilise 3-4 times more 
glucose per kg of body weight than adults, reflecting 
their higher brain to body weight ratio. 
EGP provided only ~ 3
rd
 of the glucose required 
Sunehag et 
al. (1996b) 
[6-6-d2] glucose, 
[2-
13
C] glycerol 
Primed 
2 hours 
Extremely preterm infants are capable of generating 
glycerol at a rate within the range reported for term 
and near term newborns. 
The infants were also capable of converting part of 
this glycerol to glucose, providing a contribution to 
hepatic glucose production comparable to that found 
in more mature newborns. 
Keshen et 
al. (1997) 
[U-
13
C ] glucose 
 
4 hour 
Neonates whose birth weights are less than 1200g 
have a particularly high glucose production rate, 
secondary to enhanced gluconeogenesis. 
Sunehag et 
al. (1997) 
[U-
13
C ] glucose 
[2-
13
C] glycerol 
10 hours. 
During TPN gluconeogenesis accounts for 1/4 - 1/3 of 
glucose rate of appearance after 8-10 Hrs of reduced 
glucose supply. 
Sunehag et 
al. (1998) 
[U-
13
C ] glucose 
[2-
13
C] glycerol 
8 hours 
In VLBW infants receiving TPN, gluconeogenesis is 
maintained equally well by endogenous or exogenous 
amino acid supply. 
Diderholm 
et al. 
(1999) 
[6-6-d2] glucose 
[2-
13
C] glycerol 
 
3.5 hours 
No significant change in plasma glycerol 
concentrations, glycerol production, and the fraction 
of glycerol converted to glucose after theophylline 
administration. The percentage of glucose derived 
from glycerol increased. 
Sunehag et 
al. (1999b) 
[U-
13
C] glucose 
[2-
13
C] glycerol 
[6-6-d2] glucose 
11 hours 
VLBW infants receiving TPN, normoglycemia was 
maintained during reduced glucose infusion by 
glucose production primarily derived from 
gluconeogenesis. Glycerol was the principal 
gluconeogenic substrate. 
Farrag and 
Cowett 
(2000) 
N/A N/A 
Adult-like response to insulin requires maturation 
beyond the neonatal period. 
Ontogeny of glucose utilisation responsiveness to 
insulin occurs before that of glucose production. 
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 ... Table 6.1 continued 
Study 
Methods 
Study Conclusion(s) 
Tracers 
Tracer Infusion 
duration 
Poindexter 
et al. (2001) 
[6-6-d2] glucose 
+ unlabeled 
glucose 
3 hour study 
In response to amino acid infusion rates of 
endogenous glucose production were unchanged. 
Sunehag 
(2003b) 
[U-
13
C] glucose 8 hours 
In very premature infants, parenteral glycerol 
enhances gluconeogenesis and attenuates time 
dependent decrease in glucose production. 
Sunehag 
(2003a) 
[2-
13
C] glycerol 10 hours 
In parenterally fed very premature infants, lipids play 
a primary role in supporting gluconeogenesis. 
Van 
Kempen et 
al. (2003b) 
[6-6-d2] glucose 
[2-
13
C] glycerol 
6 hours 
Preterm infants can only partly compensate a decline 
in exogenous glucose supply by increasing 
endogenous glucose production rate. 
The ability to maintain the plasma glucose 
concentration after a decrease in exogenous supply is 
better preserved in infants >30 wk owing to more 
efficient adaptation of peripheral glucose utilization. 
Van 
Kempen et 
al. (2003a) 
[6-6-d2] glucose 
[2-
13
C] glycerol 
6 hours baseline 
(unlabeled) 
infusion 
Study length: 3 
hours 
Administration of alanine does not stimulate 
gluconeogenesis in preterm infants. 
van Kempen 
et al. 
(2005b) 
[6-6-d2] glucose 
[2-
13
C] glycerol 
6 hours baseline 
Study length: 1hr 
Increase in glucose production after glucagon was 
similar in appropriate for GA (AGA) and small for 
GA (SGA) infants, and mainly due to an increase in 
glycogenolysis. 
Based on the assumption that glycogenolysis is an 
indicator of liver glycogen content, this data does not 
support the hypothesis that liver glycogen content is 
lower in preterm SGA compared to AGA infants after 
the first postnatal day. 
van den 
Akker et al. 
(2006) 
[U-
13
C] glucose 
Study length: 6-7 
hours 
The anabolic state resulting from amino acid infusion 
in the immediate postnatal period resulted from 
increased protein synthesis and not decreased 
proteolysis. 
Energy required for additional protein synthesis was 
not derived from increased glucose oxidation 
Van 
Kempen et 
al. (2006) 
[6-6-d2] glucose 
[2-
13
C] glycerol 
9 hours 
Intralipid enhanced glucose production by increasing 
gluconeogenesis in preterm infants. 
Chacko and 
Sunehag 
(2010) 
[6-6-d2] glucose 
 
Primer 
2
H20 
Study Period: 8 
Hours 
Gluconeogenesis is sustained in preterm infants 
receiving routine TPN providing glucose at rates 
exceeding normal infant glucose turnover rates and 
accounts for the major part of residual glucose 
production. 
Gluconeogenesis is not affected by the glucose 
infusion rate or blood glucose concentration. 
Chacko et al. 
(2011) 
[U-
13
C] glucose 11 hours 
In extremely low birth weight infants receiving total 
parenteral nutrition, GNG is a continuous process 
that is not affected by infusion rates of glucose or 
concentrations of glucose or insulin. 
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Table 6.2:  Summary of patient metrics between the literature data and the clinical data 
cohorts 
 Cohort Medians 
Cohort 
Gestational 
Ages [weeks] 
Birth Weight 
[g] 
Blood Glucose 
[mmol/L] 
Hertz et al. (1993) 25.5 8900 6.1 
Sunehag et al. (1993) 26 796 3.5 
Sunehag et al. (1994b) 27 1196 4.8 
Tyrala et al. (1994) Range: 23-28 Mean: 858 5.7 
Sunehag et al. (1996b) 26 865 3.1 
Keshen et al. (1997) 28 1110 6.5 
Sunehag et al. (1997) Mean: 27 Mean: 1020 Mean 3.1 
Sunehag et al. (1998) 27.6 1060 3.8 
Diderholm et al. (1999) 28.5 1160 3.8 
Sunehag et al. (1999b) 27 1050 2.8 
Farrag and Cowett (2000) - 677 3.9 
Poindexter et al. (2001) 32 1500 4.8 
Sunehag (2003b) 28 1030 3.5 
Sunehag (2003a) 27.5 995 3.0 
Van Kempen et al. (2003b) 29.1 1140 3.9 
Van Kempen et al. (2003a) <32 AGA 3.9 
van Kempen et al. (2005b) 30.5 1244 4.6 
van den Akker et al. (2006) 27.4 946 5.4 
Van Kempen et al. (2006) 29.4 1335 4.2 
Chacko and Sunehag (2010) Mean: 26.5 Mean :955 Mean: 8.9 
Chacko et al. (2011) 25.4 820 4.1 
Median literature data [IQR] 27.5  [26-29] 1080 [921-1315] 4.1  [3.8 - 5.4] 
Median clinical data [IQR] 26.3 [25.0-27.8] 848 [636-940] 6.9 [6.2-7.9] 
P-value < 0.0001 < 0.0001 < 0.0001 
Virtual patients were created from clinical data through the identification of model-based SI 
profiles (See section 9.2). Once the SI profile was identified, model solutions were generated 
for G, I and Q (Matlab
®
, ode45). The model used to fit to clinical data was the insulin 
kinetics model developed in Chapters 4 and 5, with the BG model of Equation 3.1: 
                  
    
         
  
               
               
 
                  
               
 (6.1) 
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Parameter values for the population constants were from Le Compte et al (Le Compte et al., 
2010a), and are summarised in Table 6.3. 
Accuracy of model fit to clinical data was one metric used to evaluate the effect of the new 
EGP models. This fitting error is defined as the average percentage difference between the 
real and modelled BG levels at BG measurements. In addition, when using an integral based 
fitting method (Hann et al., 2005), the identified SI must remain positive to be physiologically 
correct; the lower limit was set to SI = 1x10
-7
 L/mU/min.
 
Where fitting error was poor, with modelled BG failing to reach clinical measurements, a 
negative SI had been forced to a lower limit of 1x10
-7
 L/mU/min. In such cases, Equation 6.1 
was re-arranged and EGP was identified for a perfect BG fit using SI = 1x10
-7
 L/mU/min. The 
resulting EGPmin values gave an indication of the magnitude of minimum EGP required to 
adequately fit clinical data under the assumption of minimum peripheral SI. These results 
should thus show the minimum level of inter-patient variability in EGP as it uses a minimal SI 
and only extreme cases seen by larger fitting errors. Thus, it is likely that differences in EGP 
were larger, but cannot be identified without further data that is currently unavailable.  
6.2.3 Control Based Analysis 
Generated models of EGP, as well as EGP as a population constant, were examined through 
simulation of glycaemic control using virtual SI profiles generated by the model fit process. 
The range of constant EGP values used can be found in Table 6.4, and represents the wide 
range of likely EGP values observed in the literature.  Percentiles of literature reported EGP 
were investigated, and other specific and relevant EGP values between the median and 95
th
 
percentile were included for completeness. 
 
Table 6.3: Glucose model parameters used in the EGP analysis 
Parameter Value 
   0.003  min
-1
 
   0 
           
GA based, as per Avery et al. 
(1994) 
    0.088  mmol/kg/min 
       14% of      [kg] 
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For each EGP model, SI profiles were identified for each patient (Section 9.3), and  whole 
cohort stochastic models were  generated (Le Compte et al., 2010b). Control was tested using 
clinically validated virtual trial methods (Chase et al., 2010a, Le Compte et al., 2009) and the 
control protocol simply selected insulin such that the predicted outcome likelihood of 
BG>4.4 mmol/L was  greater than or equal to 5%, as per the basic protocol in the adult ICU 
(Fisk et al., 2012).  A limit of 0.03 U/kg/hr was applied on the increase in insulin dose, as was 
applied by Le Compte et al (Le Compte et al., 2009). Control performance was measured by 
the percentage time in band (BG between 4.0-8.0 mmol/L), while the number of patients 
experiencing severe hypoglycaemic events (BG < 2.6 mmol/L) evaluated safety. 
 
Table 6.4: Values of constant EGP used to investigate effect on control 
Percentile EGP [mg/kg/min] 
5
th
 0.29 
25
th
 1.40 
50
th
 2.1 
75
th
 4.6 
95
th
 7.7 
Currently used [19]: 5.11 
Other EGP: 5.50, 6.00, 6.50, 7.00, and 7.50 
6.3 Results 
6.3.1 EGP and Patient Metrics 
Comparing reported values of EGP with BW and GA showed little or no correlation in Figure 
6.2. High inter-patient variability between similar patients across these studies is seen in the 
large scatter of EGP across all metrics. Similarly, as shown in Figure 6.3, there is no distinct 
correlation between BG and EGP, or plasma insulin and EGP. Across all literature studies, a 
suppression of EGP with increasing GI can be seen in Figure 6.3. However, at any given GI 
rate there is still significant variation in EGP, with no clear distribution with BW or GA. The 
piecewise linear trend of GI and EGP shown in Figure 6.3 is defined: 
         
                             
                                             
  (6.2) 
Where EGP and GI have units of mg/kg/min.  
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Figure 6.2: Relationships between endogenous glucose production (EGP) with birth 
weight (BW) and gestational age (GA). 
 
6.3.2 EGP and Glucagon 
Results in Figure 6.4 show large variation in EGP for any given  glucagon concentration, 
based on data from (Chacko et al., 2011, Cowett et al., 1983, Diderholm et al., 2007, 
Helander and Fandriks, 2014, Sunehag et al., 1994b, Van Kempen et al., 2003b). At low 
glucagon concentrations EGP is higher in neonates born at GA>=29 weeks, and seems to 
decrease with increasing glucagon concentration. For neonates born at GA<29 weeks, EGP is 
approximately constant across the entire plasma glucagon range.  
For any given plasma insulin concentration, plasma glucagon shows large variation, 
particularly with lower plasma insulin levels, as seen in Figure 6.5. There is no 
distinguishable and consistent trend in plasma glucagon levels with age, birth weight (not 
shown), or plasma insulin. Plasma glucagon levels drop with increasing blood glucose 
concentration in Figure 6.5a, as might be normally expected. In addition, plasma glucagon 
levels are seen to be higher with higher gestational age, with the same trend of decreasing 
plasma glucagon with increasing BG. As there was was no clear relationship between 
glucagon and EGP, no futher models were developed and tested in control. 
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Figure 6.3: Relationships between endogenous glucose production (EGP) with blood 
glucose (BG), plasma insulin, and glucose infusion rate (GI). 
 
Figure 6.4: Endogenous glucose production (EGP) and plasma glucagon concentration. 
Based on data from (Chacko et al., 2011, Cowett et al., 1983, Diderholm et al., 2007, 
Helander and Fandriks, 2014, Sunehag et al., 1994b, Van Kempen et al., 2003b). 
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a)                                                  b) 
Figure 6.5: Plasma glucagon and: a) blood glucose (BG) and b) plasma insulin 
concentration. Based on data from (Borgstrom et al., 1957, Chacko et al., 2011, Cowett 
et al., 1983, Diderholm et al., 2007, Heimler et al., 1993, O'Neill, 2003, Sunehag et al., 
1994a, Sunehag et al., 1994b, Tian et al., 2012) 
 
 
6.3.3 EGP and Blood Glucose 
Across all studies, EGP and BG are plotted in Figure 6.6, and show high variability across the 
glycaemic range. However, a sub-cohort of studies shows some degree of increase in EGP 
with BG, indicative of dysfunction due to stress response. These studies are plotted in Figure 
6.7a, with each study showing a different trend in the magnitude of EGP with respect to BG. 
All of these specific studies show high variation, as reflected in the R
2
 values from 0.2-0.5. If 
all the remaining studies are considered, a contrasting trend of suppression of EGP with 
increasing BG can be seen. This suppression exists to varying degrees among and between 
studies, as shown in Figure 6.7b. 
From Figure 6.7b a suppressed EGP with BG can be modelled.  The EGP variation with BG 
is modelled as: 
          
                                     
                            
                                       
  (6.3) 
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Figure 6.6: Endogenous glucose production (EGP) as a function of blood glucose (BG) 
over the literature cohort of 177 data points.  
 
 
 
Figure 6.7: Sub-cohorts of studies which show: a) increasing endogenous glucose 
production (EGP) with blood glucose (BG), and b) suppression of EGP with BG. 
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EGP has units of mg/kg/min and BG mmol/L. With the suppression of EGP with BG, there 
was a fitting error of  3.57% over the whole cohort. However, many patients had one or more 
instances where SI was constrained to a lower limit of SI = 1x10
-7
 L/mU/min without fitting 
the data, indicating insufficient EGP production in the model.  
To estimate patient specific EGP over these periods, the EGP was reverse calculated using an 
assumption of an absolute minimum SI = 1x10
-7
 L/mU/min, giving EGPmin in Figure 6.8. This 
is the lowest EGP required to fit the data assuming minimal insulin-mediated glucose 
removal. These minimum values suggest that EGP in hyperglycaemic infants is generally 
higher than the literature data for slightly heavier and non-hyperglycaemic (Table 6.2) 
infants, and is not suppressed by elevated BG, as might be expected in a stress response. 
EGPmin is also scattered across the cohort with a far wider spread than the literature data, 
indicating greater inter- and intra- patient variability than previously reported with no clear 
trend. 
 
 
 
Figure 6.8: Comparison of literature based model of endogenous glucose production 
(EGP) with blood glucose (BG) and the minimum EGP required for adequate fit to 
clinical data (EGPmin). 
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Table 6.5: Comparison of model fit and control performance across different 
endogenous glucose production (EGP) models. 
Case Fitting Control 
EGP 
[mg/kg/min] 
Fitting 
error 
% 
T
im
e 
in
 b
a
n
d
 
(4
.0
 -
 8
.0
 m
m
o
l/
L
) 
H
y
p
er
g
ly
ca
em
ic
 
(B
G
 >
 1
0
 m
m
o
l/
L
) 
M
il
d
 h
y
p
o
g
ly
ca
em
ic
 
(B
G
 <
 4
.0
 m
m
o
l/
L
) 
S
ev
er
e 
h
y
p
o
g
ly
ca
em
ic
 
#
 B
G
 <
 2
.6
 m
m
o
l/
L
 
Suppressed 
EGP(BG) 
3.57 
EGP too low to sustain modelled BG levels, indicating 
inability of the EGP model to replicate clinical results. 0.3 (5
th
) 4.26 
1.40 (25
th
) 2.93 
2.1 (50
th
) 2.64 66.7 13.4 1.2 2 
4.20 2.40 69.3 12.6 1.0 2 
4.6 (75
th
) 2.39 69.8 12.5 1.0 2 
5.11* 2.38 70.8 11.7 1.0 1 
5.50 2.38 70.3 11.9 1.1 1 
6.00 2.37 70.8 11.6 1.1 1 
6.50 2.37 70.8 11.7 1.2 1 
7.00 2.37 70.8 11.7 1.2 1 
7.50 2.36 71.4 11.4 1.2 0 
7.7 (95
th
) 2.36 71.3 11.6 1.2 1 
EGP(GI(t)) 2.58 67.1 13.2 1.0 2 
* Currently in use with EGP = 5.11 mg/kg/min  
 
6.3.4 Control Analysis of EGP 
The fitting and virtual trial control performance metric results for different EGP models are 
shown in Table 6.5. EGP as a function of GI and EGP as a function of BG both performed 
worse than the currently used constant EGP = 5.11 mg/kg/min (Le Compte et al., 2010a). In 
the first case, fitting error was increased, and in both cases the number of patients with 
hypoglycaemic events increased.  
Due to high variation in EGP in Figures 6.6 and 6.7, a range of constant EGP values were 
investigated. Table 6.5 shows that EGP values below 2 mg/kg/min had high fitting error due 
to insufficient EGP to reach clinically measured BG levels, and during simulation EGP was 
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insufficient to maintain a positive BG. Increasing EGP decreased fitting error and increased 
the performance and safety of STAR model based glycaemic control. However, all average 
fitting errors for EGP > 2 mg/kg/min are within measurement error of 1-2% for blood gas 
analysers. Thus, compared to BG values in Figure 6.6, the current value of EGP = 5.11 
mg/kg/min appears reasonable. From a control standpoint, increasing EGP beyond this value 
increases control, with EGP = 6.0 mg/kg/min providing a best compromise between a likely 
physiological value and improved control. Beyond this value, the small percentage 
improvements in Table 6.5 are unlikely to be clinically significant. 
6.4 Discussion 
6.4.1 Study Results 
The piecewise linear models of suppressed EGP with increasing BG shown in Figure 6.8, and 
EGP with GI, shown in Figure 6.3, resulted in poor fitting and control performance. These 
poor results are primarily because EGP values in the literature were too low during 
hyperglycaemia to sustain the BG values measured clinically in the data used in this research. 
They suggest that hyperglycaemic ELBW premature infants are more greatly stressed than 
the cohorts studied in the literature. This assumption matches the statistical differences in 
Table 6.2. Hence, they often fail to suppress or otherwise regulate EGP with BG or GI, 
compared to normal infants.  
In particular, literature data and EGPmin data points did not overlap, as shown in Figure 6.8. 
The BG data from the literature studies in Table 6.2 and Figure 6.8 were in the normal range. 
Thus, as noted, it is likely that the majority of these infants were healthy, and therefore 
representative of normal EGP dynamics. In contrast, the clinical data is based on 
hyperglycaemic infants in the NICU, with higher average BG levels, suggesting this cohort is 
less healthy. This result implies that EGP may be higher in these preterm and hyperglycaemic 
infants, which is physiologically intuitive as BG is likely high, at least in part, due to elevated 
or unsuppressed EGP due to stress of their condition. These differences mimic the adult ICU 
situation (Capes et al., 2000, McCowen et al., 2001), which would again suggest that 
hyperglycaemic infants have less ability to suppress EGP with high BG or GI. 
In support of these outcomes, the clinical data patients are typically younger (lower GA), 
lighter (lower BW), and generally start hyperglycaemic, unlike the literature data. Clinical 
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data had a median starting BG of 9.8 [IQR: 8.3–12.3] mmol/L, compared to the literature 
median BG of 4.1 [IQR: 3.8–5.4] mmol/L. These statistics, summarised in Table 6.2, reflect a 
limitation in the use of literature data to describe EGP model in hyperglycaemic ELBW 
infants. However, no other data for EGP in this or any similar cohort exists, due to the 
practical difficulty of measuring EGP in this cohort. Thus, the literature data provides the 
only valid basis for extrapolation, despite its limitations.  
Figure 6.7a suggests that some neonates are at higher BG levels because of a physiological 
inability to regulate EGP. However, the regulation of BG is overall a complex function of 
EGP, endogenous insulin secretion, insulin therapy, and nutritional treatment. Thus, it is 
extremely difficult to define a direct cause and effect relationship between BG and a single 
variable EGP. This difficulty is partially reflected in the low R
2
 values in Figure 6.7a. Higher 
EGP with increased BG, as seen in the sub-cohort of studies in Figure 6.7a, was not modelled 
as this model formulation created a positive feedback system within the simulation software, 
which inhibited the controller‟s ability to regulate BG to a target band. It was also not 
reflective of a majority of the literature, or the presumed stress state behaviour of the specific 
ELBW cohort examined here. 
While glucagon was seen to decrease with increasing BG, as would be expected 
physiologically, EGP also decreased with increasing glucagon, which is counter to known or 
expected physiological response. As a result, further models considering glucagon were not 
created or tested in control. This outcome potentially suggests that while the pancreas is able 
to suppress glucagon production with elevated BG to some degree, the liver is not yet able to 
respond fully to the EGP stimulus.  
As the overall result of this study, it can be concluded that a population constant of EGP = 
6.0 mg/kg/min is adequate for use in model-based control.  This population constant model 
best accounts for, and reflects, uncertainty due to variability between patients. Increases in 
controller performance seen in virtual trials using higher assumed EGP values are unlikely to 
be clinically significant. 
6.4.2 Comparison to Literature 
No strong relationship was found in a range of literature reports between EGP and BW, 
plasma insulin, or GA. Keshen et al. (1997) have reported decreasing EGP with increasing 
body weight in babies less than 31 weeks GA, and with a PNA of 4-9 days. However, this 
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single result remains unconfirmed by any other study in the literature examined, and was 
contradicted by the findings of Chacko and Sunehag (2010) in a study with a similar patient 
cohort. Van Kempen et al. (2003b) reported that the ability of neonates to maintain basal BG 
levels with a decrease in exogenous insulin is greater in neonates older than 30 weeks GA. 
However, no studies have specifically investigated EGP over a range of GA, although 
preterm infant EGP has been shown to be similar or exceed that of term infants (Sunehag et 
al., 1996a, Sunehag et al., 1993). 
Some studies conclude that glucose production has been regulated by BG levels (Hertz et al., 
1993, Kalhan et al., 1986), but the majority report the reverse (Chacko et al., 2011, Chacko 
and Sunehag, 2010, Cowett et al., 1983, van Goudoever et al., 1993). Preterm infants display 
varying ability to suppress EGP with increasing glucose infusion, with complete (Hertz et al., 
1993),  incomplete (Sunehag et al., 1994b, Van Kempen et al., 2003b), and failed (Chacko 
and Sunehag, 2010) suppression reported. Although one study suggests that insulin plays an 
important role in EGP regulation (Sunehag et al., 1994b), other studies show that EGP is not 
suppressed by plasma insulin levels (Chacko et al., 2011, Chacko and Sunehag, 2010, 
Sunehag et al., 1993, van Goudoever et al., 1993). Hence, there is significant variability in 
fundamental physiological responses between EGP in these main hormonal and demographic 
characteristics. 
6.4.3 Study Limitations 
A study in adults by Tigas et al. (2002) suggests that using an isotope infusion period of 5 
hours or longer can reduce error in EGP measurements by at least 80% due to the time 
required for isotopes and substrates to equilibrate. As a result, some of the studies undertaken 
before 2002, where infusion periods tended to be shorter than 5 hours, may have inherent 
error in EGP. However, using only literature reported results with an infusion period of 5 
hours or greater (Table 6.1)  (Chacko et al., 2011, Chacko and Sunehag, 2010, Sunehag et al., 
1997, Sunehag et al., 1999a, Sunehag, 2003b, Sunehag, 2003a, Sunehag et al., 1998, van den 
Akker et al., 2006, Van Kempen et al., 2003b, Van Kempen et al., 2006)  changed none of the 
trends  seen for EGP, and did little or nothing to reduce the variation in EGP seem across all 
metrics. Thus, for the data available, this issue was not a factor. 
Similarly to EGP, CNS glucose uptake is also a population constant based on literature data 
(See Equation 6.1). It is possible that CNS in this population is lower, which would be 
reflected in this study as a higher EGP compared to the value of CNS = 0.088 mmol/kg/min 
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(15.8 mg/kg/min) assumed. In addition, a higher EGP term could result from a need for 
reduced endogenous insulin production. Hence, the values here are relative to these 
parameters and assumptions. 
Finally, this analysis is only relevant in the context of this model. The same model 
framework and in-silico control modelling approach has been validated in adult cases where 
much more independent data is available (Chase et al., 2010a). Thus, it is felt that the overall 
results showing enhanced EGP with elevated BG are realistic and valid, especially given the 
limited data available or possible for this particular cohort. 
6.5 Summary 
A wide range of literature studies have been found that report EGP in the very premature 
cohort. The studies themselves are divided and often contradictory in their conclusions, and 
no definitive relationship between EGP and BG, plasma insulin, or patient metrics, such as 
weight and GA, exists. Over all studies, EGP was shown to be highly variable between 
patients and studies. One consistent trend was that EGP was seen to decrease with increasing 
glucose infusion over all the literature studies examined. Additionally, two trends were seen 
with glucose production and BG. The first saw higher EGP at higher BG, and the second saw 
suppression of glucose production at higher BG. Both of these latter tends are physiologically 
reasonable. However, given all this variability, STAR glycaemic control was still found to 
perform best when EGP was modelled as a population constant, with EGP = 6.0 mg/kg/min 
providing a good balance between control performance and the likely physiological range. 
Finally, a model-based analysis indicated that hyperglycaemic ELBW infants produce 
glucose at a higher rate than healthy counterparts. 
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Chapter 7: Modelling Non Insulin-Mediated Central 
Nervous Glucose Uptake 
 
 
 
 
 
 
 
 
 
 
7.1 Introduction 
Glucose utilisation in the body has insulin dependent and insulin independent pathways. 
Cellular uptake of glucose is achieved via 5 types of glucose transporters (GLUT), of which 
only GLUT4, which achieves glucose uptake in muscle and adipose tissue, is insulin 
dependent. The GLUT 1 transporter is found in all cells, but plays a significant role in 
allowing rapid diffusion of glucose into the brain. The rate of glucose uptake by the brain is 
relatively constant (Gruetter et al., 1998). The GLUT2 transport is mainly found in liver and 
pancreatic cells, and plays a role in cellular monitoring of glucose concentrations (Tirone and 
Brunicardi, 2001, Triplitt, 2012). GLUT3 mediates uni-directional glucose and sodium 
uptake in neurons, kidneys, and the intestine (Tirone and Brunicardi, 2001, Triplitt, 2012).  
Non-insulin mediated cellular glucose uptake in this thesis is simplified to central nervous 
system (CNS) uptake and other uptake. This approach lumps the effects of GLUT 2 and 
GLUT3 into one parameter,    in Equation 6.1. This chapter will focus on CNS uptake and, 
in particular, its variation with brain mass.  
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7.2 Methods 
7.2.1 Central Nervous System Uptake 
Only two studies in premature infants have directly examined cerebral glucose metabolism in 
premature infants (Kinnala et al., 1996, Powers et al., 1998). The median value of the study 
by (Powers et al., 1998) was used as a population constant by Le Compte et al. (Le Compte, 
2009, Le Compte et al., 2010a). The study by (Kinnala et al., 1996) examines cerebral 
metabolism in older premature infants (32-56+ weeks since conception), and is thus beyond 
the scope of this study as significant development and changes will have occurred over that 
period. As the CNS parameter directly trades off with EGP in the model, the sensitivity of 
this parameter and its effect on control has been indirectly examined in the previous chapter. 
This analysis will instead focus on the modification of the weight based CNS glucose uptake 
constant, which has units of mmol/kg/min, through improved modelling and estimation of 
brain mass. 
7.2.2 Other Non-Insulin Mediated Glucose Uptake 
In Equation 6.1, the expression          is used to capture non insulin mediated glucose 
removal via the kidneys, intestine, pancreas, and liver. As the insulin-mediated glucose 
uptake expression,        is structurally similar to this non-insulin mediated glucose uptake 
expression, both patient specific    and    cannot be uniquely determined at the same time 
(Hann et al., 2005). The    term is assumed to be adequately modelled by the adult value of 
         min
-1
, given a lack of non-insulin mediated glucose data specific to premature 
neonatal physiology.  
7.2.3 Brain Mass Estimation 
Two methods of estimation of brain mass are examined here. The first treats brain mass as a 
fixed proportion of body weight, and the second uses head circumference. 
Proportion of body mass 
Previous work by Le Compte et al utilised brain mass as constant proportion of body mass 
(Le Compte et al., 2008, Le Compte, 2009). This proportion was estimated using data from 
Ho et al. (1981), where body and brain mass is reported over a range of preterm infant sub 
cohorts defined by sex and ethnicity. Ethnicity was defined simply as 'black' and 'white', with 
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no other details provided. Sub-Cohort characteristics and brain-to-body mass ratios are given 
in Table 7.1. 
Table 7.1: Mean statistics on body and brain mass. Data sourced from Ho et al. (1981) 
Ethnicity Sex 
Gestational 
Age (wk) 
      
(g) 
       
(g) 
      
       
(g/g) 
Black 
Female 27.3 958 139 0.145 
Male 28.4 1151 157 0.136 
White 
Female 29.2 1258 165 0.131 
Male 30.4 1434 190 0.132 
 
A brain-to-body mass ratio of 0.140 was determined from the reported results for the cohort 
with the lowest GA (GA 27 - 28 weeks, ethnicity 'black'). This value is reflective of the ratio 
of 0.136 obtained if the entire cohort is used. As the hyperglycaemic neonatal cohort seen in 
previous work has lower gestational age and weight than that of Ho et al. (1981), it is likely 
that this ratio is slightly higher than 0.14. The body mass based method, denoted the BM 
model, for brain mass estimation is thus defined: 
                  (7.1) 
 
Head circumference and brain mass 
Head circumference may be a more accurate indicator of brain mass than body mass alone, 
given that brain-to-body mass ratio changes with GA (Dobbing and Sands, 1973) (Table 7.2). 
A model relating head circumference to brain mass has been proposed by (Cooke et al., 
1977). The model was derived from post-mortem analysis of 485 premature infants of GA 
18-43 weeks. Small-for-gestational-age (SGA) infants are accounted for using a different 
parameter set to those that were appropriate-for-gestational-age (AGA). This separation was 
the result of SGA infants having a statistically higher brain mass for their GA than AGA 
infants (Cooke et al., 1977). 
The brain mass and head circumference model from (Cooke et al., 1977), denoted here as the 
HC model, is defined: 
         
    (7.2) 
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where   is the head circumference in centimetres and        is the brain mass in grams. The 
remaining parameters given are in Table 7.2. 
Table 7.2: Parameters in HC model. Data sourced from (Cooke et al., 1977) 
Cohort     
Appropriate-for-Gestational-Age 3.001 0.0093 
Small-for-Gestational-Age 3.225 0.0048 
 
7.2.4 Patient Data 
Glycaemic control records from 88 patients enrolled in the HINT glycaemic control trial 
(Alsweiler et al., 2012), previously detailed in Section 4.21, were used to generate virtual 
patients. Patient episodes were created from infants who received insulin therapy and had 5 
or more consecutive BG measurements, with a maximum of 8 hours between measurements. 
A patient episode was not included if no head circumference measurements were taken 
during the episode, or within 24 hours before the start of an episode.  
A total of 48 patients were selected, totalling 82 episodes, and patient demographics are given 
in Table 7.3. The 82 virtual patient episodes constituted 7032h of care, with 1881 BG 
measurements (mean 3.7 h/intervention). None of the mothers of patients in the study 
experienced maternal diabetes. Of the 48 patients, 17 experienced intra-ventricular 
haemorrhage (IVH), all of whom were AGA infants. IVH was rated on a scale of 1–5 in order 
of increasing severity, where the 17 patients had a median [IQR] IVH score of 2 [1–3.5] 
(Alsweiler et al., 2012).  
Detailed information about insulin treatments and BG measurements were recorded.  
Nutritional input was both parenteral and enteral. Parenteral sources of glucose included 
TPN, dextrose infusions, and dextrose within medications. Enteral feeds were started as early 
as possible in this trial, and consisted of formula and/or breast milk, depending on breast milk 
availability. Nutrition was recorded as daily totals, so feed timing and changes in nutrition 
within a 24 hour period were not detailed. It was thus assumed that the daily glucose total 
was delivered as a constant parenteral and/or enteral infusion over 24 hours, which is 
acceptable given this analysis concerns the constant model value, CNS. 
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Table 7.3: Median [IQR] cohort demographics 
Characteristic Value 
Birth Weight (g) 750 [678–894] 
GA at birth (weeks) 25.0 [24.0–26.5] 
Age at start of trial (days) 4 [2–7] 
Ethnicity (%) 
 
   NZ European 28 
   Māori 35 
   Pacific Islander 6 
   Asian 10 
 
SGA infants were defined as patients at or below the 10
th
 percentile of weight for their GA 
using growth charts from New South Wales, Australia (Beeby et al., 1996)  that are used in 
New Zealand NICUs. Of the entire cohort, 5 of 48 patients were SGA, corresponding to 7 of 
82 patient episodes. In addition, 4 of the 5 SGA patients were asymmetric SGA, as 
determined by the Ponderal index (Vik et al., 1997). Due to the small SGA cohort, 
asymmetric and symmetric patients are not analysed separately. 
7.2.5 Analyses 
As the true brain mass could not be measured, the different methods for estimating brain 
mass were first compared against each other, and then analysed using a control based 
analysis, similar to that in Chapter 6. SI was fitted from clinical data (See section 9.2), 
creating virtual patients, using both brain mass estimation models. Glucose and insulin 
kinetics were modelled using the insulin kinetics model developed in Chapters 4 and 5, and 
the population constant for EGP determined in Chapter 6. BG model parameters are 
summarised in Table 7.4. For each brain mass model a stochastic model forecasting SI was 
created (Le Compte et al., 2010b, Lin et al., 2006).  
Table 7.4: Glucose model parameters used in the EGP analysis 
Parameter Value 
   0.003  [min
-1
] 
   0 
           GA based, as per (Avery et al., 1994) 
    0.088  mmol/kg/min (15.8 kg/kg/min) 
    0.033 mmol/kg/min (6.0 mg/kg/min) 
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Virtual trials were used to assess the sensitivity of control based outcomes to brain mass 
estimation methods. The control protocol used was that detailed in Section 6.2.3. 
Measurement interval was set to 4 hours. As the 'true' brain mass is unknown, four simulation 
cases are considered, and these are detailed in Table 7.5. Comparison of control outcomes is 
made using nonparametric statistics. Distributed data are compared using the Wilcoxon rank-
sum (also known as the Mann–Whitney U test: Matlab®, ranksum). Values of        are 
considered statistically significant. 
 
Table 7.5: Combinations of assumed model and controller-perceived model used in 
virtual trials 
 
SI profile in Control 
HC-fit control BM-fit control 
SI profile in 
Simulation 
HC-fit 
virtual 
profile 
A. 
Assume HC gives the 
best estimate, and 
control with it. 
B. 
Assume HC gives the 
best estimate, but 
control with BM 
BM-fit 
virtual 
profile 
C. 
Assume      gives the 
best estimate, but control 
with HC. 
D. 
Assume BM gives the 
best estimate, and 
control with it. 
 
7.3 Results 
7.3.1 Brain Mass Model Comparison 
The median [IQR] brain mass estimated using the BM model, based on a body mass was 112 
[973 – 129] g. In comparison, the median [IQR] brain mass estimated using the HC model, 
based on head circumference, was 121 [102 – 144] g. Estimations of brain mass from the BM 
and HC models are compared in a Bland–Altman plot in Figure 7.1. The figure shows a bias 
towards the BM model estimating a significantly lower value for        (       ). The 
median difference (       (BM) -       (HC)) was  9.8 g, with an IQR of [ 19.6, 0.9] g.  
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Figure 7.1: Comparison of BM and HC model estimations for brain mass, highlighting 
SGA infants. 
 
The bias towards a much lower estimation of brain mass via body mass proportion is stronger 
in the SGA patients.  These SGA infants have a median difference of  34g, with an IQR of 
[ 40,  28] g (       ). As a result, the distinction between AGA and SGA infants that 
Cooke et al. (1977) required for their HC model may also be necessary when using a body 
mass estimate. 
In Figure 7.2 the data points from Figure 7.1 are further differentiated by their mass for GA 
percentile bands. The downward bias is present across all centiles and average brain masses, 
indicating that       estimations of brain mass tend to be lower than HC brain mass 
estimations. This result indicates that the body mass and head circumference methods 
represent significantly different measures of brain mass. 
7.3.2 Effect on Model-Based Insulin Sensitivity  
Patients are fit to the NICING model to generate SI profiles for virtual patients using both 
models for brain mass estimation. The resulting SI profiles identified are summarised in 
Table 7.6. The median SI value is 1.1% lower using the BM model. However, this difference 
is not significant (p=0.47).  
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Figure 7.2: Comparison of BM and HC model estimations for brain mass at different 
birth weight percentiles 
 
For the SGA group, the BM model fit SI was 2.9% lower than the HC model fit SI, 
suggesting that model selection for brain mass estimation has greater impact in infants at the 
lower extremity of birth mass outcomes. This difference is not significant (p=0.57), but may 
still yield significantly different insulin interventions in model-based control.  
SI is significantly higher in the SGA cohort, irrespective of the brain mass estimation model 
used (p<0.001). However, variability is a much more important factor in glycaemic control 
and forecasting than absolute SI (Chase et al., 2011b, Le Compte et al., 2010b), particularly 
for safety from hypoglycaemia. The IQR for SI in SGA infants is wider, suggesting that they 
are more variable and thus more difficult to control. 
 
Table 7.6: Deviations in SI profiles under different models 
 
Entire cohort SGA only P-value 
   with      model (Med 
[IQR]) (mL/mU/min) 
14.1 [6.7 – 23.9] e-4 18.7 [4.8 – 34.2] e-4 
P<0.001 
   with HC model (Med 
[IQR]) (mL/mU/min) 
14.2 [6.8 – 24.1] e-4 19.3 [5.1 – 35.1] e-4 
P<0.001 
p-value 0.47 0.57  
%     (Med) 1.1 [0.5 – 1.8] 2.9 [2.7 – 4.0] 
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7.3.3 Effect on Control 
Results for virtual trials across the entire cohort are shown in Table 7.7. BG outcomes are not 
significantly altered between control situations A-D, with no difference in safety from 
hypoglycaemia (%BG<2.6) and negligible difference in performance assessed by the % time 
in band (% BG within the 4.0 -8.0 mmol/L band). 
While median insulin rates remained similar between simulations, the IQR differs. Assuming 
that the HC model provides a more accurate indication of brain mass than the BM model, 
using the HC model in control results in smaller changes in insulin infusion rate (compare A 
to B in Table 7.7).  Overall, control is slightly better if the BM model is used in control 
(compare A-B and C-D in Table 7.7). However, these improvements are not likely to be 
clinically observable. 
Control is also assessed for the SGA cohort only, shown in Table 7.8. Time in band is not 
improved by using the HC model to estimate brain mass. This simulation of 7 patient 
episodes included 166 BG measurements over 622h (9% of total cohort hours).  Time in band 
for this group is significantly lower across all simulations, indicating another underlying 
reason for difficulty in control. It is worth noting that SGA infant data (N = 7), contributing 
only 9% of total hours, is reasonably sparse and thus more greatly influenced by outlying 
patients, rather than indicating a lesser performance. 
 
Table 7.7: Control interventions and outcomes from virtual trials for the entire cohort. 
Whole cohort 
statistics 
A. 
Simulate 
HC, 
Control HC 
B. 
Simulate 
HC, 
Control 
      
C. 
Simulate 
     , 
Control HC 
D. 
Simulate      
Control       
Median insulin rate 
[IQR] (U/kg/hr): 
0.04 
[0.03–0.06] 
0.04 
[0.02– 0.07] 
0.04 
[0.02– 0.07] 
0.04 
[0.03–0.07] 
% BG within 4.0–
8.0 mmol/L 
62.1 62.4 62.2 62.5 
% BG > 10 mmol/L 13.3 13.2 13.3 13.2 
% BG < 4.0 mmol/L 1.1 1.1 1.1 1.1 
% BG < 2.6 mmol/L 0.1 0.1 0.1 0.1 
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Table 7.8: Control interventions and outcomes from virtual trials for the SGA cohort 
Whole cohort 
statistics 
A. 
Simulate 
HC, 
Control 
HC 
B. 
Simulate 
HC, 
Control 
      
C. 
Simulate 
     , 
Control HC 
D. 
Simulate 
     , 
Control 
      
Median insulin rate 
[IQR] (U/kg/hr): 
0.05 
[0.00–0.10] 
0.05 
[0.00–0.10] 
0.05 
[0.00–0.10] 
0.05 
[0.00–0.09] 
% BG within  
4.0–8.0 mmol/L 
42.9 42.9 43.1 45.6 
% BG > 10 mmol/L 28.9 28.9 30.0 28.9 
% BG < 4.0 mmol/L 2.2 2.2 2.2 1.9 
% BG < 2.6 mmol/L 0.3 0.3 0.3 0.3 
 
 
The matched difference in insulin interventions between Cases A-B and A-D are shown in 
Figure 7.3 and summarised in Table 7.9. Comparing A–B shows the difference between doses 
for either controller method, assuming that the HC model is true in simulation, while using 
HC (Case A) or mbody (Case B) in model-based control. Comparing A–D shows the difference 
between best-case model selections, with no mismatch between virtual patient and controller 
model. For both comparisons, Case A is most likely to give equal or slightly more insulin 
(94.6 – 100% across comparisons and sub cohorts).  
 
Table 7.9: Comparison of insulin interventions in simulation 
Case 
comparison 
Cohort 
Percentage of interventions 
Lower than A Equal Higher than A 
A –B AGA 0.3 99.4 0.3 
SGA 0.0 100.0 0.0 
A - D AGA 1.7 95.8 2.5 
SGA 4.0 89.6 6.4 
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Figure 7.3: Matched insulin interventions by birth weight cohort for a) cases A vs. B, 
and b) cases A vs. D 
0 0.05 0.1 0.15 0.2 0.25
0
0.05
0.1
0.15
0.2
0.25
Case A: Sim HC, control HC
Insulin infusion (U/kg/hr)
a)
C
a
s
e
 B
: 
S
im
 H
C
, 
c
o
n
tr
o
l 
m
b
o
d
y
In
s
u
li
n
 i
n
fu
s
io
n
 (
U
/k
g
/h
r)
 
 
AGA
SGA
0 0.05 0.1 0.15 0.2 0.25
0
0.05
0.1
0.15
0.2
0.25
Case A: Sim HC, control HC
Insulin infusion (U/kg/hr)
b)
C
a
s
e
 D
: 
S
im
 m
b
o
d
y
, 
c
o
n
tr
o
l 
m
b
o
d
y
In
s
u
li
n
 i
n
fu
s
io
n
 (
U
/k
g
/h
r)
 
 
AGA
SGA
104 
   
7.4 Discussion 
The HC model resulted in higher estimations of brain mass than a simple body mass based 
model. This effect was seen more clearly in infants that were SGA. Across the entire cohort, 
parameter changes in SI were clinically negligible. Control performance remained relatively 
unchanged or slightly worse when using the HC model for control decisions. This result was 
independent of which model was used in simulation of the virtual patient. Using the HC 
model resulted in more insulin being recommended for the same glycaemic outcomes, 
indicating that insulin was used less effectively.  
The introduction of the Cooke method using HC would require an additional input for clinical 
staff when starting glycaemic control. Adding complexity to clinical protocols may increase 
clinical burden and potential for error (Aragon, 2006, Chase et al., 2008b). As a result, this 
analysis indicates that there is no control or clinical benefits to be gained from using the HC 
model instead of a body mass based model in this glycaemic control system. 
Virtual trial performance is slightly worse than seen in Chapter 6. This result is likely because 
the data acquired from the HINT trial has some longer periods between interventions than 
those for which NICING was designed. In addition, the treatment of daily nutrition totals as 
constant parenteral or enteral infusions also degrades data quality. These differences can 
increase identified SI variability compared to the unknown reality and make control in virtual 
trials harder than would be seen clinically. However, in each case, these virtual trials are 
comparing the patients and cohort as their own control, thus eliminating this factor.  
As the comparative accuracy of both the HC and body mass models is not known it would be 
beneficial to have an objective study compare the two models against a more accurate 
method. Head circumference data has not yet been analyzed for patients undergoing STAR at 
Christchurch Women‟s Hospital NICU, or any other cohort with more frequent BG 
measurement, which eliminated other sources of clinical data in this analysis.  
The discrepancies observed between SGA and AGA infants are of interest. However, more 
data on SGA infants is necessary to claim robust conclusions. In particular, this investigation 
was not able to distinguish differences in symmetric and asymmetric SGA infants due to lack 
of data. As SGA infants are the most affected by model choice, this distinction may be of 
clinical use. Particularly as SGA infants were more insulin sensitive and variable in this small 
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cohort analysis. This difference, if verified, could increase risk in dosing. Future research 
should investigate these cohorts in greater detail.  
Overall, the HC model is much more likely to be physiologically accurate. This outcome is 
due to the nature of the measurement and because the method is derived from a cohort of the 
same demographics it will be used on. However, metabolically its impact may not necessarily 
affect clinical outcomes in model-based insulin control.  
7.5 Summary 
The HC model resulted in higher estimations of brain mass than a simple body mass based 
model. This effect was seen more clearly in infants that were SGA. However, model based SI 
was not significantly different when fitted when the different brain mass estimation models in 
both SGA and AGA cohorts. A control based analysis showed that body mass based 
estimation of brain mass performed better. Thus, there is no control or clinical benefits to be 
gained from using the head circumference model instead of a body mass based model in this 
glycaemic control system. The SGA cohort has higher and more variable model-based SI, so 
potential differences in brain mass proportions between SGA and AGA infants are of interest 
to improve control. While this analysis showed no benefit in the use of head circumference 
based estimates, more data is needed for more comprehensive analysis. 
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Chapter 8: Modelling Intestinal Glucose Absorption  
 
8.1 Introduction 
Postnatal growth restriction is a problem in premature infants, and in extremely low birth 
weight (ELBW) infants in particular (Clark et al., 2003b). The American Academy of 
Paediatrics suggests that nutrition goals should aim to achieve a postnatal growth rate 
approximating that of a normal foetus of the same GA (American Academy of Pediatrics 
Committee on Nutrition, 1985, Cooke, 2003). This nutrition can be delivered via parenteral 
or enteral routes, and there is significant debate in literature around appropriate onset and 
clinical procedure for enteral feed initiation (Karagol et al., 2013). 
Enteral feeding of milk causes changes in gut structure and function, even in very premature 
infants (Aynsley-Green, 1983). These changes in gut structure and function include changes 
in gut motility,  enzyme secretion, absorptive capacity, and endocrine response  to nutrient 
absorption (Aynsley-Green, 1983). Early enteral feeding has been shown to decrease gut 
atrophy (breakdown of tissues) and increase intestinal permeability (Rouwet et al., 2002), as 
well as decreasing the incidence of sepsis (Flidel-Rimon et al., 2004).  
In contrast to these positives, historically, there have been concerns about early enteral 
feeding causing necrotising enterocolitis (NEC) (Cakmak Celik et al., 2007, Ramani and 
Ambalavanan, 2013). However, many studies and randomised  control trials have 
demonstrated no increase in the risk of NEC with early enteral feeding (Cakmak Celik et al., 
2007, Caple et al., 2004, Hamilton et al., 2014, Karagol et al., 2013, Krishnamurthy et al., 
2010, Rayyis et al., 1999).  
Therefore, enteral feeding is very common in many neonatal intensive care units (Cormack et 
al., 2013, Patole and Muller, 2004, Ramani and Ambalavanan, 2013). As such, a model of 
glucose appearance from enteral feeds is necessary for tight glycaemic control. This chapter 
uses retrospective continuous glucose monitor (CGM) data in term and premature infants to 
model the appearance of glucose in the blood from enteral nutrition. In particular, the half-life 
of gastric absorption of glucose from the gut into the bloodstream is determined to better 
model glucose metabolism in the preterm neonate, and thus improve glycaemic control. 
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8.2 Methods 
CGM traces reflecting glucose appearance from enteral nutrition administration were used to 
estimate gut absorption of glucose in premature and term infants. De-identified CGM data 
was available from premature and term infants in two clinical cohorts, one from a Neonatal 
Unit in Budapest, Hungary, and the second from a study carried out in New Zealand  (Harris 
et al., 2013). Results were compared to estimates derived from reported gut absorption values 
in independent perfusion studies. 
8.2.1 Adaptation of the NICING Glucose-Insulin Model for Older Neonates 
The NICING model of glucose-insulin dynamics developed in Chapters 4 to 7 was used. This 
model has been developed for very premature infants, but is considered sufficiently reflective 
of premature and term infant physiology for use here in premature and term infants. The only 
points of change were that CNS uptake and fluid compartment values were allowed to change 
with GA and PNA, according to the literature-based models shown in Figures 8.1 and 8.2. 
Endogenous glucose production (EGP) was explored based on an expansion of the literature 
search of Chapter 6 for very preterm infants, but the median EGP was not found to differ  
consistently with GA, so EGP was maintained at the constant value of EGP = 6.0 
mg/kg/.min. 
 
Figure 8.1: Increasing CNS uptake with increasing conceptual gestational age (CGA), 
where CGA = GA + PNA/7. Data sources:  (Kinnala et al., 1996, Powers et al., 1998).  
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Figure 8.2: Extracellular fluid volume (ECV) with gestational and postnatal age. A drop 
in ECV in the first week following birth is observed across a wide range of studies, and 
is most prominent in the more premature infants. An ECV volume model is generated 
using a linear model derived from Avery et al. (1994) to give ECV(PNA=0). 
ECV(PNA>0) is described by a proportional drop off based on two long term studies of 
ECV in very preterm (~28 weeks) (Shaffer et al., 1986)  and term (~ 40 weeks) (Friis-
Hansen, 1954) infants. All data sources: (Coran et al., 1984, Friis-Hansen, 1954, Modi et 
al., 2000b, Shaffer et al., 1986, Shaffer and Meade, 1989a) 
 
8.2.2 The Gut Model 
The gut model comprises two compartments, P1 and P2, denoting glucose in the stomach and 
intestine, respectively, which is a typical approach for these dynamics. The amount [mmol] of 
glucose in the stomach, P1, is defined: 
                (8.1) 
Glucose is delivered to the stomach as glucose or glucose based sugar, and is denoted Pex. 
Lactose is made up of glucose and galactose in roughly equal molar weight, and since 
galactose does not contribute directly to BG levels it was ignored. A value of d1= 0.035 min
-1
, 
corresponding to a half life of 20 min is the rate of gastric emptying of glucose from the 
stomach into the gut (Le Compte et al., 2010a). The amount of glucose in the gut, P2 [mmol], 
is defined: 
                           (8.2) 
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Where d2 [1/min] is the rate of uptake from the gut into the blood, and          
mmol/L/min is an upper limit on this rate in adults (Lin et al., 2011).  
8.2.3 Parameter Identification 
The rate constant of glucose uptake from the gut into the bloodstream, d2, was the parameter 
of interest. SI and glucose appearance from the gut trade off mathematically, so the fitting 
process was iterative. The parameter d1 was left constant as it also trades off with d2, and d1 = 
0.035 min
-1
 (corresponding to a 20 minute half life) is a reasonably acceptable value.  
The NICING and gut models were initially fit using the adult value of d2 = 0.006 min
-1
 (Lin 
et al., 2011) to get a    trace. The optimal d2 values for each feed were then found using a 
grid search to minimise RMS fitting error over the range d2 = 0.001:0.060 min
-1
. This process 
was iterated to update the    trace using the median d2 value from the previous iteration. 
Iterations were continued until d2 changed by less than 0.001 (3 decimal places, 2-3 
iterations).  
Several factors made parameter identification difficult. First, enteral feeds were recorded as 
having been given „on the hour,‟ whereas in clinical practice the actual time of feeds is 
somewhere near this mark. For this reason, delivery time of the feed was varied by up to 20 
minutes either side of the hour, and the d2 with the lowest fitting error to the associated peak 
in the CGM data was selected. Second, feed duration was uncertain, and could vary between 
5 and 20 minutes. While, for some patients, a reasonable estimate of feed time could be made 
based on delivery method, in other cases this estimate was not possible. Across the entire 
cohort the delivery duration was assumed a constant 12 minutes, and sensitivity of d2 to 
delivery time was evaluated separately. 
The parameter d2 was analysed with respect to PNA, GA, BW, and total glucose content of 
feed to differentiate potential sources of variability between gut absorption in infants. 
Statistical comparisons are made using the non-parametric Mann-Whitney U test (Matlab
®
, 
ranksum). P-values at p<0.05 were considered significant.  
8.2.4 Feed Methods 
For the purpose of this investigation, enteral feeds were defined as any manually delivered 
(syringe/feeding tube) enteral nutritional intake delivered with duration of ~20min or less, 
involving expressed breast milk (EBM), nutritionally fortified EBM, or milk formula. 
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Breastfeeds were not considered due to uncertainty around the total fluid volume delivered, 
and rate of delivery. Enteral feeds delivered within 2 hours of a breastfeed, a change in 
parenteral (IV) nutrition, or oral dextrose gel use were discounted, to avoid any overlapping 
glucose appearance dynamics.  
8.2.5 Clinical Data Cohorts 
Budapest 
CGM (Guardian REAL-Time, Medtronic, Minimed, Northridge, California) traces from 4 
infants receiving 3 hourly enteral breast milk feeds of 20 mL or more were available from 
Semmelweise University, Department of Paediatrics, Hungary. Demographic data are in 
Table 8.1. According to the local ethical codes this analysis of retrospective CGM data is 
considered as a clinical data audit and the only ethics committee requirement was the 
depersonalization of the data collected. 
SUGAR-BABIES 
CGM traces (CGMS system gold, Medtronic, Minimed, Northridge, California) from 10 
Patients from a cohort of 237 infants who were part of the SUGAR-BABIES study (Harris et 
al., 2013) were analysed. The SUGAR-BABIES study was approved by the Northern Y 
Ethics Committee, New Zealand (Harris et al., 2013). 
 The selection criteria included patients that were given 5 or more feeds of volume 20 mL or 
more at least 2 hours apart, with a clear rise and peak in the CGM trace corresponding to the 
timing of an enteral feed. The patient cohort is summarised in Table 8.1. Feeds were 
delivered over 5-20 minutes, depending on the feed method, but administration time was not 
recorded.  
8.2.6 CGM Recalibration 
CGM data gives 5 minutely readings of interstitial glucose concentrations, which are 
assumed to be in equilibrium with BG concentrations. CGM data for the SUGAR-BABIES 
study data was recalibrated to blood gas measurements of BG concentration using the 
measured current (ISIG) values and method in Signal et al. (2012).  Recalibration was not 
carried out for the Budapest data, as not all necessary data was available. 
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Table 8.1: SUGAR-BABIES and Budapest patient cohort characteristics. 
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Feed type administered 
 (for samples fitted) 
Budapest 
1 36 3240 N/A 26 days Breast Milk 
2 40 4150 N/A 55 days Breast Milk 
3 39 3920 N/A 15 days Breast Milk 
4 40 5150 N/A 17 days Breast Milk 
SUGAR-BABIES 
1 39 3220 1.3 16.2 hrs Term formula 
2 36 2050 1.7 2.0 hrs Preterm formula 
3 38 2370 1.5 6.8 hrs 
Mostly Term formula (2 
mixed milk and formula) 
4 36 2810 1.3 <1 hrs Term formula  
5 35 2260 0.7 <1 hrs 
Mostly Term formula (1 
mixed milk and formula) 
6 31 1306 21.3 3.7 hrs Breast milk 
7 36 2140 4.4 1.7 hrs Term formula 
8 36 2135 3.5 6.5 hrs Term formula 
9 35 2450 0.5 <1 hrs Term formula 
10 33 2770 27.3 5.7 hrs Breast milk 
 
8.2.7 Reported Absorption Rates for Comparison 
Glucose absorption rates for short intestinal sections were found in literature. These 
absorption rates were transformed into 'whole compartment' glucose absorption rates by 
assuming a linear glucose gradient down the gut, and integrating to give total glucose present 
in the gut [mmol]. This assumed model is shown schematically in Figure 8.3. 
Assuming the glucose concentration profile is roughly linear (Borgstrom et al., 1957) in the 
gut 
             (8.3) 
Where     is the local glucose concentration,      is the glucose concentration at the start of 
the gut,   is position along the gut, and m is a constant.  
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Figure 8.3: Linear glucose concentration across the small intestine. 
 
Glucose is absorbed over a approximate length of  Lg = 3m (Borgstrom et al., 1957), and  
intestinal radius is r=0.013m for adults (Helander and Fandriks, 2014). Small intestinal length 
in premature infants gives Lg=0.145m (Touloukian and Smith, 1983) and r=0.007m for 
infants (O'Neill, 2003). If at the Lg end the glucose concentration is P2 ≈ 0, then m is defined: 
  
    
  
 (8.4) 
The total absorption of glucose from the gut [mmol/min] is defined:  
    
  
 
         (8.5) 
Where P2 is the total glucose in the gut, and is equal to the integral of the glucose 
concentration across the gut. The parameter c is the cross sectional area of the gut (c=π r2). 
Thus, the total absorption across a given gut length, Ls, of the perfusion study is defined: 
    
  
 
             
  
 
 (8.6) 
Equation 8.6 can be integrated to give: 
    
  
 
                 
  
 
 
  (8.7) 
To find d2, Equation 8.7 can be rearranged: 
    
    
  
 
             
   
  
 (8.8) 
Equation 8.8 allows estimation of    from intestinal glucose absorption studies in literature. 
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8.3 Results 
8.3.1 Intestinal Glucose Absorption Constants from CGM Data 
The calculated glucose absorption rate constant for all CGM data cohorts was d2  = 0.014 
[0.008 - 0.022] min
-1
, corresponding to an absorption half life 50 [31 -86] min. Of the 
Budapest cohort, a d2 solution was converged to in 77 of 165 sets of feed data. The median 
rate constant for glucose uptake was 0.014 [0.008 - 0.018] min
-1
, corresponding to an 
absorption half life of 49 [39 - 86] min. Of the SUGAR-BABIES cohort, 178 sets of feed data 
across 10 patients converged to a solution, with a median [IQR] rate constant for glucose 
uptake of d2 = 0.018 [0.012 - 0.026] min
-1
, which corresponds to an absorption half life of 39 
[27 - 58] min. In the SUGAR-BABIES cohort a further 140 sets of feed data were not used 
due to small feed size, failure to converge to a solution, failure of the feed to appear in the 
CGM trace, or a delay in the rise of BG indicating a more than 30 minute discrepancy 
between the recorded feed time and the given feed time. 
Median and IQR varied between patients (Figure 8.4) with high variability over all patient 
metrics and no clear trend in d2 over PNA (R
2 
< 0.001), BW (R
2
= 0.03) or feed size (linear R
2
 
= 0.03).   
 
 
Figure 8.4: Per patient gut glucose absorption constants (d2) across the SUGAR-
BABIES and Budapest cohorts. 
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Table 8.2: Glucose absorption constants with gestational age (GA).  
Grouping by Gestational Age: 36 week cut off (excluding breast milk patients) 
 Rate absorption constant, d2 [min
-1
] 
 GA< 36 weeks GA = 36 weeks GA> 36 weeks GA>=36 weeks 
N patients 2 4 2 6 
N feeds 40 58 23 81 
Median 
[IQR] 
0.017 
[0.011- 0.024] 
0.015 
[0.008 - 0.020] 
0.018 
[0.012 - 0.022] 
0.018 
[0.010 - 0.020] 
p GA<36  <0.06 0.9 0.18 
GA=36   0.15 0.28 
 
In the SUGAR-BABIES data, for breast milk feeds (N=57), the median absorption rate 
constant was d2 = 0.026 [0.018 - 0.035] min
-1
 (absorption half life of 27 [20 - 39] min) 
compared to the formula feeds (N = 118) value of d2 = 0.018 [0.010 - 0.020] min
-1
 
(absorption half life of 39 [34 - 69] min), (p<0.001). The remaining 3 feeds were a mixture of 
breast milk and formula.  
The gut absorption rate constant was, in general, higher with lower gestational age, but the 
relationship was week (R
2
 = 0.05). In the SUGAR-BABIES formula fed data (Table 8.2), 
using 36 weeks as the cut off age for three groups, because they approximate tertiles by GA 
and patient feed density, the gut absorption constant was not significantly different between 
infants grouped by GA (p ≥ 0.06).  
Figure 8.5 shows model fit for a representative selection of CGM trace sections. It can be 
seen that the model achieves a qualitatively good fit in most cases. However, it cannot 
completely capture the peak and/or trough of the glucose appearance. In addition, there may 
to be un-modelled dynamics, unrecorded inputs, or sensor error in cases where multiple peaks 
are not captured.  
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Figure 8.5: Fitting error over a representative selection of CGM trace sections from 
SUGAR-BABIES data. The crosses (x) show CGM data, and the solid line (-) the model 
solution around the time of an enteral feed.  
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Figure 8.6: Fitting error across the d2 range for different feed administration periods. 
 
Sensitivity to the time over which the feed was administered was tested, and the results are 
shown in Figure 8.6. Fitting error does not differ significantly between different assumed 
administration times. Given that blood gas measures have an associated error of ~2%, from 
Figure 8.6 the optimum d2 can be estimated to lie between 0.011 and 0.024 min
-1
, 
corresponding to a half life of 30 - 70 minutes.  
The trade off between the gut model transport parameters d1 and d2 is shown in Figure 8.7. 
While there is a global minimum, the parameters trade off significantly within the middle of 
their likely physiological range. The global minimum exists in most cases at the upper end of 
the d1 parameter range, suggesting short gastric emptying times, shorter than reported 
elsewhere in literature. For example, in Figure 8.7 the global minimum occurs at d1 = 0.040, 
corresponding to a half life of 17 minutes. In contrast insulin sensitivity and d2 trade off to a 
much smaller degree (Figure 8.8), with relatively small change in SI  for a relatively large 
change in d2. 
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Figure 8.7: A typical error surface showing sensitivity and trade off of gastric emptying 
(d1 ) and gut absorption (d2) parameters for a two compartment gut model.  
 
Figure 8.8: A typical error surface showing sensitivity and trade off gut absorption (d2) 
and insulin sensitivity (SI) parameters for a two compartment gut model.  
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8.3.2 Comparison to Reported Absorptions 
Gut absorption rates were found in the literature for both adults (Modigliani and Bernier, 
1971) and infants (Shulman, 1999) . These values were converted from a 'per study gut 
length' rate to a whole compartment rate constant, and the results are shown in Table 8.3. The 
average gut absorption rate constant is higher than the d2 value determined here using CGM 
data. However, it is approximately the same order of magnitude. 
 
Table 8.3: Intestinal glucose absorption rate constants derived from literature. Glucose 
infusion (Pex) rate, initial glucose concentration (P2s), and absorption rates (Rab) found 
are used to derive a whole compartment absorption rate constant (d2) using Equation 
8.8. 
 
Adults 
Study 
Pex 
[mmol/min] 
P2s 
[mmol/L] 
    
  
 
 
[mmol/min/25cm] 
d2 [1/min] 
Modigliani 
and 
Bernier 
(1971) 
0.5 66 0.472 0.056 
1.1 133 0.728 0.043 
2.1 260 0.82 0.025 
0.7 66 0.459 0.054 
1.3 133 0.763 0.045 
2.0 200 0.841 0.033 
2.6 260 1.019 0.030 
1.0 66 0.585 0.069 
2.0 133 0.885 0.052 
3.0 200 0.971 0.038 
3.9 260 0.999 0.030 
1.3 66 0.719 0.085 
2.7 133 0.913 0.053 
4.0 200 1.091 0.042 
5.2 260 1.042 0.031 
Median 
[IQR] 
2.0 
[1.2 - 2.8] 
133 
[100 - 230] 
0.841 
[0.723 - 0.985] 
0.043 
[0.032 - 
0.054] 
Preterm 
Infants 
(<37 
weeks) 
Study 
Pex 
[mmol/min] 
P2s 
[mmol/L] 
    
  
 
 
[mmol/min/15cm] 
d2 [1/min] 
Shulman 
(1999) 
0.001 1 0.6 0.047 
0.01 10 3.6 0.028 
0.1 100 27.9 0.022 
Median 0.01 10 3.6 0.028 
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8.4 Discussion 
8.4.1 CGM Derived Results 
GCM data was used in a first ever analysis to estimate whole gut absorption of glucose in 
premature infants using a 2 compartment gut model. The median gut absorption rate constant 
was d2=0.014 min
-1
, which corresponds to an absorption half life (time for half of total 
glucose to be absorbed) of 50 minutes. This value is twice as fast as the half life of 100 
minutes used in the adult intensive care case. The glucose absorption rate constant was not 
found to differ significantly with GA.  This result suggests that prematurity may not be a 
significant factor in glucose absorption, a result counter to expectations. 
The median gut absorption constant here is of the same order as that calculated from adult 
and infant literature data (0.031 min
-1
 and 0.028 min
-1
 respectively, from Table 8.3), but 
slightly lower. This outcome seems to indicate the results derived from CGM data are 
physiologically likely, and that gut absorption in premature and term infants in intensive care 
may be lower than that in the literature for healthier infants due to their critically ill state, or 
feed composition differences (Bourlieu et al., 2014). 
The practical insignificance of differences between absorption rate constants over GA and 
between the SUGAR-BABIES data and slightly older Budapest patients (Table 8.1) is further 
highlighted when blood gas error is considered. Figure 8.5 shows the RMS error is less than 
around 2% between d2 = 0.011 and 0.023 min
-1
 (half life 30-63min), suggesting a wide valid 
range from which the glucose absorption can be selected. Almost all median values from 
Table 8.2 fall within this range, thus suggesting any observed differences between groups 
may result from chance measurement error. 
Insulin sensitivity and glucose absorption in the gut trade off to a small degree. However, SI 
is relatively insensitive to changes in the gut absorption constant d2 (Figure 8.8). These 
results suggest that it is the total glucose absorbed rather than the rate that it is absorbed at 
that has the biggest influence on insulin sensitivity, and while a faster d2 improves model fit 
to the more measurement dense CGM data, variability in d2 does not significantly influence 
glycaemic control.    
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8.4.2 Contributions of Gastric Emptying and Feed Composition 
A gastric emptying half life of 20 minutes (d1=0.035 min
-1
) was used. This value is within the 
range of 17 – 60 minutes reported in the review by Bourlieu et al. (2014), where high 
variation in the rate of gastric emptying was seen within and between studies. If higher 
gastric emptying half lives of 30-40 minutes were used, fitting error increased (see Figure 
8.7), as the width of the modelled glucose appearance exceeded that observed in the CGM 
data. This result suggests that, although d1 and d2 trade off to a large extent, there is a lower 
limit on d1. Gastric emptying is higher in premature infants than term infants Bourlieu et al. 
(2014), so while in this analysis a gastric emptying half life of 20 minutes was appropriate for 
term and premature infants, a longer half life of 30-45 minutes (Bourlieu et al., 2014) may be 
more appropriate in very and/or extremely premature infants.  
For the SUGAR-BABIES cohort infants feed formula had higher glucose absorption half 
lives, which is a bias likely resulting, at least in part, from the assumption of a constant 
gastric emptying over the entire cohort. Gastric emptying is dependent on the enteral milk 
feed composition and caloric composition, and gastric emptying of human milk feeds is 
observed to be faster than that of formula milk feeds (Bourlieu et al., 2014). However, as 
fitting error increased with a higher gastric emptying time, it is also possible that milk 
composition can affect glucose absorption and/or the two compartment model is unable to 
adequately capture some of the GCM observed gastric dynamics.  
In contrast, the glucose absorption rate constant for the breast milk fed Budapest cohort was 
lower than both the formula fed and breast milk fed cohorts. This constant could be lower due 
to the inability to recalibrate the CGM data, smaller cohort size (4 infants vs. 10 in the 
SUGAR-BABIES cohort), or cohort specific differences. However, the resultant median and 
inter-quartile range for this cohort falls within the 2% error region of Figure 8.5, indicating it 
may not be possible to separate these effects from sensor noise or blood gas measurements. 
Given the wide range of possible glucose absorption rate constant values within the 2% error 
threshold, the study median of d2 = 0.014 1/min is a reasonable approximation of glucose 
absorption dynamics across a wide range of premature infants. This value is also a reasonable 
approximation of glucose absorption in very premature infants, in lieu of more gestational 
age specific data. However, since gastric emptying is known to be slower in very premature 
infants, the gastric emptying rate constant d1 can be tailored to this cohort with a value of d1 
= 0.017 min
-1
, corresponding to a gastric emptying half life of 40 minutes.   
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8.4.3 Study Limitations 
There are several limitations to this study. First, CGM data is well known for both sensor 
noise and drift (Castle and Ward, 2010, Facchinetti et al., 2014, Facchinetti et al., 2010, 
Kuure-Kinsey et al., 2006). For each feed, the initial glucose value used was the initial CGM 
BG value, rather than the model fit up to that point, which minimised the effect of sensor 
drift. In addition, CGM values for the SUGAR-BABIES cohort were recalibrated according 
to the method of Signal et al. (2012), which improves the correlation between sensor data and 
BG measures. Around 44% (140) of the total feeds in the data failed to converge to a solution 
or failed to display a clear peak in the CGM data around the time expected from the feed. As 
a result, the results in this paper should be considered indicative only of glucose absorption, 
with glucose absorption being variable over time and between patients, as might be expected 
in any case. 
Additionally, infants were selected for this study primarily based on feed volume and number 
of feeds. Thus, infants that were likely to display the largest feed related spikes in CGM data 
were chosen, and so the gut absorption constants found may best reflect relatively large feeds 
and/or faster absorption, the latter of which could skew model-based results. Table 8.3 shows 
that the glucose uptake rate is not in direct proportion to the gut glucose concentration. The 
results in this paper display no trend and high variability with feed size and glucose 
concentration, and thus do not confirm, but also, do not rule out, different gut absorption 
constants that vary with different feed sizes. 
A third potential limitation is the use of the NICING model developed for very low birth 
weight premature infants, in premature and term infants. Fluid volumes and central nervous 
system uptake were tailored to the infants in this study based on their gestational and 
postnatal age. Without the relatively rare data to tailor insulin clearances and secretion to this 
older cohort, the NICING model was considered to be sufficiently reflective of neonatal 
physiology for the purposes of this study. 
Finally, the CGM data in this study is from older infants than those the gut absorption model 
is being designed for. This difference is perhaps partly offset through the use of the NICING 
model. However, given the lack of such CGM data being available for very or extremely 
premature infants, the results are considered more indicative of premature infant gut glucose 
absorption than that of adult ICU patients. Thus, these results are sufficient for an estimation 
123 
 
of the gut glucose absorption rate constant, but should be interpreted with caution outside the 
context of this study and the NICING model. 
8. 5. Summary 
CGM data has been used to estimate the half life, and therefore the rate constant, of glucose 
absorption from the gut to the bloodstream. The median gut absorption rate constant was d2 = 
0.014 min
-1
, which corresponds to an absorption half life of 50 minutes. The glucose 
absorption constant was found to be higher in formula fed infants than breast milk fed infants 
in the SUGAR-BABIES cohort. However, this constant was lower in the breast milk fed 
Budapest cohort in comparison to both breast milk and formula fed SUGAR-BABIES 
cohorts. Given the range in d2 = 0.011 – 0.024 min
-1
 within the 2% measurement error 
threshold, the median value of d2 =0.014 min
-1
 is a reasonable approximation for a whole-
cohort value, given the limitations of the study. 
The gastric emptying rate constant was set to d1 = 0.035 min
-1
 (20 minutes half life) for this 
analysis in term and premature infants, which is at the lower end of the range reported in 
literature.  Increasing the half life of gastric emptying increased fitting error in this analysis.  
Given that gastric emptying is slower in very low birth weight premature infants, it is 
recommended that the gastric emptying constant be set to d1 = 0.017 min
-1
  (40 minutes half 
life). It could also be varied with formula type. 
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Chapter 9: Model Summary 
 
 
 
 
 
 
Chapters 3 to 8 have attempted to better capture inter- and intra- patient metabolic variability 
through better modelling of metabolic processes. This task was done using available data 
from the extremely fragile very premature infant cohort, and the focus has been on 
developing models to much better capture and describe glucose-insulin kinetics in a clinical 
setting using common bedside measures. This new model is known as the Neonatal Intensive 
Care Insulin-Glucose-Nutrition (NICING model). 
The NICING model differs from its predecessor, developed by (Le Compte, 2009), in several 
important aspects: 
 An insulin secretion model has been developed specifically for the 
very/extremely premature infant cohort (Chapter 4). 
 Insulin clearance pathways have been differentiated, and model parameters are 
made specific to the very/extremely premature infant (Chapter 5). 
 Differing compartment distribution volumes for insulin are now taken into 
account  between the interstitial fluid space and blood plasma (Chapter 5). 
 Endogenous glucose production was extensively investigated, but remains a 
population constant, as discussed in Chapter 6. 
 The previous model of glucose absorption via the gut has been replaced with a 
new model that conserves mass. Model parameters based on premature/term 
infant data have been identified (Chapter 8). 
This short chapter summarises the modal equations and parameters in one place. 
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9.1 Neonatal Intensive Care Insulin-Glucose-Nutrition (NICING) model 
9.1.1 Insulin 
Insulin kinetics are modelled via two compartments, plasma insulin (I) and interstitial insulin 
(Q), described: 
      
      
         
                       
      
       
                   
(9.1) 
      
  
  
               
    
         
 (9.2) 
Insulin secretion is modelled as a piecewise linear function of blood glucose concentration 
(G) that differs with infant sex: 
      
                      
                     
  
              
        
 (9.3) 
Patient specific and/or time varying insulin clearance parameters are defined: 
      
  
  
 
   
   
    (9.4) 
                 
        
 
 (9.5) 
    
 
  
 
       
    
 (9.6) 
PNA is postnatal age in days. Insulin distribution volumes in the plasma  and interstitial 
compartments are approximated by plasma (    and interstitial (    fluid volumes 
respectively. These volumes are estimated as: 
              (9.7) 
           
           (9.8) 
All parameter descriptions and values can be found in Table 9.1. 
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Table 9.1: Insulin kinetic parameters 
Parameter Corresponding physiology Value 
   Saturation on liver clearance of insulin 0.0017 L/mU 
   Liver clearance of Insulin 0.39 min
-1 
   First pass liver clearance of insulin 0.67 
   Kidney clearance of insulin Variable – Eq. 9.6 
[min
-1
] 
   Diffusion of insulin between plasma an interstitial 
spaces 
0.025 min
-1
 
   Clearance and degradation of insulin from 
interstitial space 
Variable – Eq. 9.4 
[min
-1
] 
       Endogenous insulin secretion by pancreas Variable – Eq. 9.3 
[mU/L/kg/min] 
       Exogenous insulin therapy Variable input [mU /min] 
   Fluid volume of plasma 0.047 L/kg 
   Fluid volume of interstitial space Variable [L/kg] 
   Saturation on insulin receptor binding 0.0 L/mU 
      Body mass Variable [kg] 
    Post natal age Variable [days] 
 
9.1.2 Glucose 
Blood glucose concentration, G, is modelled: 
                  
    
         
  
               
               
 
                   
               
 
(9.9) 
where brain mass may be estimated as 14% of body mass. Further parameter descriptions and 
values can be found in Table 9.2. It should be noted that in the case of EGP and CNS 
parameter values are given in both mg/kg/min and mmol/kg/min. These values are consistent 
with each other (glucose has approx 180g/mol), and reflect differing clinical practice in 
measuring blood glucose in mmol/L and glucose delivery in mg/kg/min. As EGP and CNS 
are constants, there are no scaling or modelling issues associated with the conversion of 
literature/clinical data units of mg/kg/min to units of mmol/kg/min in Equation 9.9.  
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Table 9.2: Glucose kinetic parameters 
Parameter Corresponding physiology Value 
   Non-insulin mediated glucose uptake 0.003 min
-1 
   Whole body insulin sensitivity Variable [L/mU/min] 
   Saturation on insulin receptor binding 0.0 L/mU 
        Intravenous glucose delivery Variable [mmol/min] 
       Glucose absorption from gut Variable [mmol/min] 
           Distribution volume of glucose  Variable [L/kg] 
    
Endogenous glucose production 
0.033 mmol/kg/min 
(15.8 kg/kg/min)  
    
Glucose uptake by central nervous system 
0.088 mmol/kg/min 
(15.8 kg/kg/min) 
      Body mass Variable [kg] 
       Brain mass Variable [kg] 
 
9.1.3 Gut Model 
Glucose in the stomach,   , and gut,   , from enteral feeds is modelled by a two 
compartment model:  
                (9.10) 
                          (9.11) 
                      (9.12) 
Parameter values and descriptions are given in Table 9.3. It should be noted that as the data 
for the analysis in Chapter 8 was made available after clinical implementation of the model 
described in 9.1.1 and 9.1.2. As a result, the value for the glucose absorption constant    used 
in the clinical implementation was that used in the adult ICU (         min
-1
). Further 
parameter descriptions and values can be found in Table 9.3. 
Table 9.3: Glucose kinetic parameters 
Parameter Corresponding physiology Value 
   Gastric emptying of glucose from stomach to gut 0.017 min
-1
 
   Glucose absorption from gut to blood stream Old value: 0.007 min
-1
 
New value: 0.014 min
-1
 
     Maximum glucose absorption rate 6.0 mmol/min 
     Enteral feed rate Variable [mmol/min] 
       Rate of glucose appearance in blood stream from gut Variable [mmol/min] 
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9.2 Model Solution and Fitting 
Model solutions are generated from Equations 9.1, 9.2, 9.9, 9.10 and 9.11 to give G, I, Q, P1 
and P2 using numerical integration and Matlab
®
ode45 numerical solver. Patient-specific 
time-varying insulin sensitivity,   , is fit on an hour to hour basis using integral based fitting 
(Hann et al., 2005). This process involves the integration and re-arrangement of Equation 9.9 
to find   . If    is constant from hour    to     , then Equation 9.9 can be integrated and re-
arranged to give: 
   
     
            
    
  
       
               
               
 
                   
               
 
    
  
   
     
    
         
    
  
  
 (9.13) 
When fit over all hours in clinical data, a time-varying insulin sensitivity profile is generated. 
This forms the basis of a virtual patient in simulation, and is used to forecast future changes 
in insulin sensitivity in the STAR-framework (Section 3.4).  
Linear interpolation of BG measures provides a first estimate of G in equation 9.13. The 
identification process can be made iterative, with the substitution of each new model 
generated G profile into 9.13 to re-identify   . However, it was found that    was not 
significantly different between iterations, and an interpolated G profile is sufficient for 
parameter identification of   .  
9.3 Summary 
This chapter briefly presents the NICING model in its final form, along with all parameter 
values and sub-models. This form of the NICING model, with a noted exception in terms of 
the new gut model, will be used in the next few chapters to design and test a control protocol 
in virtual trials, and implement it in a clinical context. 
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Chapter 10: Protocol Development and Optimisation 
 
 
 
10.1 Introduction 
Chapter 2 discussed different clinical approaches to insulin therapy. Surveys have shown that 
insulin therapy clinical practice differs significantly between different neonatal intensive care 
units, with differing thresholds for hyperglycaemia and insulin therapy onset (Alsweiler et al., 
2007). Further, not all units have a protocol for dosing insulin (Alsweiler et al., 2007, Simeon 
and Gottesman, 1991). Insulin dosing protocols tend to be ad hoc, or insulin is titrated with 
BG level in a fixed or flexible protocol that, critically, ignores nutrition and insulin inputs. In 
addition, often a single glycaemia level is clinically targeted as the ideal, rather than a range 
of acceptable values, which doesn‟t account for intra-patient variability (Chase et al., 2011b). 
Stochastic models were outlined in Chapter 3, based on previous work (Le Compte, 2009, Le 
Compte et al., 2010b, Lin, 2007, Lin et al., 2006). Given a current insulin sensitivity (  ), a 
stochastic forecasting model then predicts the range of possible changes in SI over the 
coming intervention interval. From this range of SI values a range of resulting BG outcomes 
can be calculated for a given insulin intervention, as shown again in Figure 10.1. This 
calculation of a range of probable BG outcomes allows stochastic targeting protocols to 
utilise insulin therapy to actively target a desired target range or threshold with a specified 
level of hypoglycaemic, out of range, risk. The aim is to overlap these predicted BG 
outcomes with a clinically specified target range to maximise the likelihood of the BG levels 
in that range. This probabilistic target to range approach is unique in glycaemic control. 
There are several ways by which the desired overlap of outcomes and the targeted BG range 
can be achieved. These approaches typically use various percentiles of likely outcomes and 
targeted range thresholds or values. This chapter will analyse several different stochastic 
targeting protocols, with the aim of developing an optimised protocol for effective and safe 
use in neonatal intensive care. 
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Figure 10.1: Stochastic forecasting of insulin sensitivity (SI) and blood glucose (BG) 
outcomes. First a patients current SI is determined. Distributions of future insulin 
sensitivity are generated from stochastic models, and these are used to generate 
distributions of BG outcomes for a given insulin/nutrition treatment (usually 
characterised by the 5th, 50th, and 95th percentiles).  
 
10.2 Methods 
10.2.1 Stochastic Targeted Protocol Designs 
To determine a baseline SI, a 0.05 U/kg/hr insulin infusion is started and maintained for 2 
hours. This is a relatively low and safe dose to provide a second BG measurement. BG is then 
measured, SI determined, and the STAR protocol calculates the next insulin intervention. 
The previous STAR-NICU controller (Le Compte et al., 2009) checks  insulin doses until the 
50
th
  percentile BG prediction is 6.0 mmol/L (Le Compte et al., 2011). It then checks that 
95% of predicted BG levels BG ≥ 4.0 mmol/L, and reduces insulin if required to meet this 
constraint, allowing median BG to rise. To improve this approach, the following control 
approaches were tested:  
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PROTOCOL 1: Select the maximum allowable insulin infusion rate that causes the 5
th
 
percentile BG prediction to be equal to or greater than a specified lower BG limit. This 
approach limits the risk of BG less than a lower target to 5%, but does not target the median 
result. 
PROTOCOL 2: Select the maximum insulin infusion rate that places the 95
th
 percentile BG 
prediction on or below an upper BG limit. This approach is more aggressive and does not 
consider a lower limit, except implicitly through choice of the upper limit. 
PROTOCOL 3: As per Protocol 1, but giving an insulin bolus that yields a 5
th
 percentile BG 
on or above a specified lower limit in the first hour, followed by an infusion for the remaining 
time period so that the 5
th
 percentile BG remains on or above the specified lower limit at the 
end of the entire measurement interval.  
PROTOCOL 4: As per Protocol 4, but giving an insulin infusion, instead of a bolus, over the 
first hour. 
For each of the protocols a range of target values was tested. For Protocols 1, 3, and 4, the 5
th
 
percentile targets tested were 4.0, 4.2, 4.4, 4.8, and 5.0 mmol/L. For Protocol 2, the 95
th
 
percentile was tested on targets of 8.0, 9.0, 10.0, and 11.0 mmol/L. Protocols 3 and 4 allow 
more aggressive control where certainty is the greatest - in the first hour, immediately after SI 
is identified. Figure 10.2 systematically illustrates the four protocol approaches. 
In all protocols, if measured BG< 4.0 mmol/L, no insulin is given to for safety.  An upper 
limit is applied to the amount the insulin rate can increase between treatments to ensure 
control is not compromised by glucose meter error, or short perturbations from the neonate's 
normal glycaemic state. No attempt was made to regulate nutritional inputs, which were left 
to clinical choice, which is a major difference from the adult ICU. 
Insulin infusions are increased in steps of 0.01 U/kg/hr, with a maximum allowable insulin 
infusion of 0.3 U/kg/hr, and a minimum pump rate of 0.1 mL/hr (~0.03 U/kg/hr). Insulin 
concentration was simulated according to the weight measurements in the patient data set, 
and the following clinical formula for concentration from Christchurch Women‟s hospital: 
            
        
  
 
(10.1) 
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Figure 10.2: Stochastic targeting and treatment selection for Protocols 1-4. Dashed lines 
show the shape of the proposed insulin treatment from the current time, tn. It should be 
noted that Protocols 3 and 4 examine stochastic bounds at 1 and 4 hours due to the 
initial treatment given. 
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To improve the best protocol, a sensitivity analysis was carried out on the limit placed on the 
increase in insulin rate between treatments, and a tolerance was applied to the targeted value. 
Limits on the rate of insulin change can limit control over-response to short-term changes in 
observed sensitivity to insulin caused by measurement device error or rapid fluctuations in 
patient condition. The limit used by the STAR-NICU controller is set to a maximum 0.03 
U/kg/hr increase in insulin infusion. The effect of higher and lower limits was investigated, as 
well as variable, BG defined limits allowing greater changes at higher BG levels. These 
variable BG defined limits allowed a rate increase of 0.06 U/kg/hr for BG greater than a 
defined limit, maintained a limit on rate increase of 0.03 U/kg/hr within an intermediate 
range, and allowed a rate increase of 0.01 U/kg/hr below a defined BG limit, for safety 
reasons. 
10.2.2 Virtual Trial Methods 
The different protocols were tested using clinically validated virtual trial methods (Chase et 
al., 2010a). A virtual patient in this method consists of a SI profile fitted from clinical data 
using Integral-based fitting methods (Hann et al., 2005). As SI is treatment independent in the 
model ((Chase et al., 2010a) the known SI profile and NICING model can be used to describe 
what the BG response to insulin and nutrition would have been under different treatment 
doses. Model fit procedure is summarised in Section 9.2. 
Real time control can be simulated in virtual trials using these virtual patients. The control 
protocol is made blind to the known SI profile after the simulated 'current time.' Using the SI 
at that point, stochastic forecasting can be used to predict a range of likely SI outcomes, 
which in turn guide the control protocol to select an insulin dose. Once the control protocol 
has made its treatment selection, the known SI profile can be used to determine the BG 
response to this treatment up until the next simulated BG measurement. Measurement noise, 
timing errors, and other variability may also be included in the simulation. The process is 
repeated until the end of a virtual patient episode is reached. This process is summarised in 
Figure 10.3. 
10.2.3 Virtual Patient Data 
The virtual patient cohort consisted of those patients described in Section 6.2.2, and their 
clinical characteristics can be found repeated in Table 10.1. Virtual patients were created 
from retrospective data, and clinical data from infants who were treated using the STAR-
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NICU protocol.  Retrospective data is comprised of 22 patients totalling 25 episodes, who 
received insulin under a bedside titration protocol prior to STAR implementation in 2008. 
STAR-NICU data was collected from August 2008 to December 2012, where 40 premature 
infants totalling 53 episodes received insulin under the STAR-NICU protocol, as either a 
pilot trial or as a standard of care, and 22 of these have been previously reported (Le Compte 
et al., 2012).  
 
Figure 10.3: Virtual patient development and in silico simulation method. Virtual 
patients are created from clinical data (I), and then used in virtual trials (II) to test 
glycaemic outcomes of protocols. Figure sourced from (Chase et al., 2010a). 
 
Table 10.1: Clinical characteristics of virtual patient cohort 
Characteristic Retrospective STAR-NICU 
n Patients (n male) 22 (7) 40 (22) 
n Episodes 25 54 
Total Hours 3098 5014 
Number of BG measurements 943 1632 
Gestational Age [weeks] 27 [25-27] 26 [25-29] 
Weight [g] 
845 
[800-900] 
785 
[635-950] 
Post Natal Age [days] 3 [1-7] 3 [1-12] 
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10.2.4 Analyses and Performance Metrics 
Results were compared against the existing protocol. The following performance metrics 
were used: 
 SAFETY: number of severe hypoglycaemic events (BG<2.6 mmol/L), and 
hypoglycaemia (%BG<4.0 mmol/L and %BG<3.0mmol/L).  
 PERFORMANCE: %BG within the 4.0-8.0 mmol/L band, and hyperglycaemia 
(%BG>10.0 mmol/L). 
10.3 Results 
10.3.1 Comparison of Protocols 
Table 10.2 summarises the results for all 4 protocols. Protocol 2 was the most aggressive by 
design, and thus had higher hypoglycaemia. Protocol 2 has no guarantee of managing 
hypoglycaemic risk, making it unsuitable for further optimisation despite good performance 
at higher upper BG limits. In particular, in Figure 10.4, Protocol 2 has a similar distribution 
slope within the target range to the other protocols, but higher % BG below 4.0 mmol/L. 
Protocols 1, 3, and 4 yielded an overall similar performance, which is clearly shown in the 
overlap of the cumulative distribution curves in Figure 10.4.  
Protocol 1, 3, and 4 also performed in similar manner to the NICU-Protocol. This outcome 
indicates that in most cases, due to large prediction band width in the stochastic model, the 
NICU-Protocol was putting the 5
th
 percentile of BG outcomes on 4.0 mmol/L to ensure 
safety, rather than the 50
th
 percentile of BG outcomes on 6.0 mmol/L. This behaviour is seen 
in the similarities between the percentiles in Protocols 1 and the STAR-NICU protocol in 
Table 10.2. Thus, the STAR-NICU protocol is implicitly very similar to Protocol 1, even 
though it was not explicitly designed that way.  
The STAR-NICU protocol has 7% greater time in band and fewer episodes of hypoglycaemia 
(1 of 79 virtual patients vs. 8 of 54 clinical episodes) than the clinical data collected from the 
clinical use of the STAR-NICU protocol. The STAR-NICU protocol was implemented using 
the NICU model, previously detailed in Chapter 3, and stochastic models developed from 
NICU models SI traces. In addition, the stochastic models were based on a much smaller, 
retrospective, cohort (N=25). As such, the performance increase in simulation reflects the 
change in models more than the protocol itself. 
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Figure 10.4: Cumulative distributions of BG outcomes for Protocols 1 – 4. Distributions 
are presented for simulations marked † in Table 10.2. 
 
The results for the 5
th
 and 95
th
 percentile targeting approaches of Protocols 1- 4  reveal a 
typical prediction range of 4.5 – 5.5 mmol/L in size, which is larger than the 4.0 mmol/L 
width of the target range,. This large width limits the degree to which control to the target 
range can be achieved. This wide prediction range explains the drop from 14 to 1 
hypoglycaemic events in the Protocol 2 simulation results when the limit is raised to 9.0 
mmol/L. In this case, for a 95
th
 percentile BG targeted to  9.0 mmol/L, the 5
th
 percentile BG 
is commonly around 4.0-4.5 mmol/L, giving similar performance to Protocol 1. However, the 
more aggressive nature of Protocol 2 did not constrain the 5
th
 percentile BG to 4.0 mmol/L or 
higher, resulting in higher time in band, and higher %BG < 4.0 mmol/L.  
Protocols 3-4 showed little gain in preloading insulin to make use of greatest SI certainty, and 
required more clinical effort in terms of additional insulin interventions between BG 
measurements. All else equal, reducing workload and expectations also makes a protocol 
simpler and thus better with greater likelihood of good compliance (Chase et al., 2008b). 
Thus, Protocol 1 was selected for further optimisation as it balancing desired reductions in 
hyperglycaemia with reduced hypoglycaemic events and lower clinical effort.  
 
139 
 
T
a
b
le
 1
0
.2
: 
V
ir
tu
a
l 
tr
ia
l 
re
su
lt
s 
fo
r 
P
ro
to
co
ls
 1
-4
 
 
P
re
d
ic
ti
o
n
s 
9
5
th
 p
er
ce
n
ti
le
 
B
G
 
p
re
d
ic
ti
o
n
s 
N
/A
 
9
.5
 [
9
.1
 -
 1
0
.1
] 
9
.2
 [
8
.9
 -
 9
.8
] 
9
.6
 [
9
.1
 -
 1
0
.2
] 
9
.9
 [
9
.5
 -
 1
0
.7
] 
1
0
.5
 [
1
0
.0
 -
 1
1
.2
] 
1
0
.8
 [
1
0
.0
 -
 1
1
.4
] 
7
.9
 [
7
.8
 -
 8
.7
] 
8
.9
 [
8
.7
 -
 9
.0
] 
9
.8
 [
9
.6
 -
 9
.9
] 
1
0
.6
 [
1
0
.3
 -
 1
0
.8
] 
9
.1
 [
8
.7
 -
 9
.8
] 
9
.4
 [
8
.9
 -
 9
.8
] 
9
.6
 [
9
.2
 -
 1
0
.1
] 
1
0
.2
 [
9
.7
 -
 1
0
.9
] 
1
0
.5
 [
9
.8
 -
 1
1
.3
] 
9
.1
 [
8
.7
 -
 9
.8
] 
9
.4
 [
9
.0
 –
 1
0
.0
] 
9
.7
 [
9
.3
 -
 1
0
.3
] 
1
0
.3
 [
9
.8
 -
 1
0
.9
] 
1
0
.6
 [
1
0
.0
 -
 1
1
.3
8
] 
*
 C
li
n
ic
al
 i
m
p
le
m
en
ta
ti
o
n
 o
f 
th
e 
S
T
A
R
-N
IC
U
 p
ro
to
co
l 
u
se
d
 t
h
e 
N
IC
U
 m
o
d
el
 a
n
d
 o
ld
er
 s
to
ch
as
ti
c 
m
o
d
el
s.
 *
*
 S
im
u
la
te
d
 w
it
h
 t
h
e 
N
IC
IN
G
 m
o
d
el
 a
n
d
 
n
ew
 s
to
ch
as
ti
c 
m
o
d
el
s.
 †
 C
u
m
u
la
ti
v
e 
d
is
tr
ib
u
ti
o
n
s 
ar
e 
sh
o
w
n
 f
o
r 
th
es
e 
si
m
u
la
ti
o
n
s 
in
 F
ig
u
re
 1
0
.4
. 
 
5
th
 p
er
c
en
ti
le
 
B
G
 
p
re
d
ic
ti
o
n
s 
N
/A
 
4
.5
 [
4
.3
 -
 4
.7
] 
4
.3
 [
4
.2
 -
 4
.4
] 
4
.5
 [
4
.4
 -
 4
.6
] 
4
. 
7
 [
4
.6
 -
 4
.8
] 
5
.1
 [
5
.0
 -
 5
.3
] 
5
.4
 [
5
.2
 -
 5
. 
6
] 
3
.7
 [
3
.6
 -
 3
.9
] 
4
.2
 [
4
.0
 -
 4
.5
] 
4
.7
 [
4
.5
 –
 5
.0
] 
5
.3
 [
5
.0
 -
 5
.5
] 
4
.3
 [
4
.2
 -
 4
.4
] 
4
.4
 [
4
.4
 -
 4
.5
] 
4
.7
 [
4
.6
 -
 4
.8
] 
5
.0
 [
5
.0
 -
 5
.2
] 
5
.3
 [
5
.2
 -
 5
.5
] 
4
.3
 [
4
.2
 -
 4
.4
] 
4
.5
[4
.4
 -
 4
.6
] 
4
.7
 [
4
.6
 -
 4
.8
] 
5
.1
 [
5
.0
 -
 5
.3
] 
5
.3
 [
5
.2
- 
5
.5
] 
S
a
fe
ty
 
#
 
p
a
ti
en
ts
 
w
it
h
 
B
G
<
2
.6
 
8
 
1
 
2
 
1
 
1
 
1
 
0
 
1
4
 
1
 
0
 
0
 
1
 
1
 
1
 
1
 
0
 
1
 
1
 
1
 
0
 
1
 
%
B
G
 
<
3
.0
 
0
.7
 
0
.1
 
0
.2
 
0
.1
 
0
 
0
 
0
 
0
.7
 
0
.3
 
0
.1
 
0
 
0
.2
 
0
.1
 
0
 
0
 
0
 
0
.1
 
0
.1
 
0
 
0
 
0
 
%
B
G
 
<
4
.0
 
4
.6
 
1
.4
 
2
.1
 
1
.5
 
1
 
0
.5
 
0
.4
 
6
.7
 
3
.5
 
1
.8
 
0
.8
 
2
 
1
.5
 
1
.2
 
0
.5
 
0
.4
 
2
 
1
.5
 
1
 
0
.5
 
0
.4
 
P
er
fo
rm
a
n
ce
 
%
B
G
>
 
1
0
.0
 
1
1
.8
 
1
0
.3
 
9
.5
 
1
0
.7
 
1
1
.7
 
1
4
.8
 
1
6
.3
 
8
 
7
.9
 
9
.4
 
1
1
.5
 
9
.5
 
1
0
.6
 
1
1
8
 
1
4
.2
 
1
5
.6
 
9
.6
 
1
0
.6
 
1
1
.9
 
1
4
.9
 
1
6
.2
 
%
 
T
im
e 
in
 b
a
n
d
 
6
7
.2
 
7
4
.9
 
7
6
.1
 
7
3
.6
 
7
0
.7
 
6
2
.5
 
5
3
.4
 
7
6
.3
 
7
8
.5
 
7
3
.7
 
6
2
.9
 
7
6
.4
 
7
5
.2
 
7
2
.4
 
6
5
.5
 
6
0
.7
 
7
6
.4
 
7
4
 
7
1
.3
 
6
3
 
5
8
.5
 
M
ed
ia
n
 B
G
 
6
.6
 [
5
.5
 -
 8
.2
] 
6
.6
 [
5
.9
 –
 8
.0
] 
6
.4
 [
5
.6
 -
 7
.7
] 
6
.7
 [
5
.8
 –
 8
.0
] 
7
.0
 [
6
.1
 -
 8
.3
] 
7
.5
 [
6
.6
 -
 8
.8
] 
7
.7
 [
6
.8
 -
 9
.1
] 
5
.6
 [
4
.8
 –
 7
.0
] 
6
.1
 [
5
.3
 -
 7
.3
] 
6
.8
 [
5
.9
 –
 8
.0
] 
7
.5
 [
6
.5
 -
 8
.6
] 
6
.4
 [
5
.5
 -
 7
.7
] 
6
.6
 [
5
.7
 -
 7
.9
] 
6
.8
 [
6
.0
 -
 8
.1
] 
7
.3
 [
6
.4
 -
 8
.6
] 
7
.7
 [
6
.6
 -
 8
.8
] 
6
.4
 [
5
.5
 -
 7
.7
] 
6
.6
 [
5
.8
 –
 8
.0
] 
6
.9
 [
6
.0
 -
 8
.2
] 
7
.4
 [
6
.5
 -
 8
.7
] 
7
.6
 [
6
.7
 –
 9
.0
] 
 
T
a
rg
et
 
v
a
lu
e 
6
.0
 
4
.0
 
6
.0
 
4
.0
 
4
.0
†
 
4
.2
 
4
.4
 
4
.8
 
5
 
8
 
9
.0
†
 
1
0
 
1
1
 
4
.0
†
 
4
.2
 
4
.4
 
4
.8
 
5
 
4
.0
†
 
4
.2
 
4
.4
 
4
.8
 
5
 
T
a
rg
et
 
ty
p
e 
5
0
th
 
5
th
 
5
0
th
 
5
th
 
5
th
 
9
5
th
 
5
th
 
5
th
 
 N
IC
U
  
p
ro
to
co
l 
cl
in
ic
a
l 
d
a
ta
*
 
N
IC
U
 p
ro
to
co
l*
*
, 
†
 
P
ro
to
co
l 
1
 
P
ro
to
co
l 
2
 
P
ro
to
co
l 
3
 
P
ro
to
co
l 
4
 
140 
   
10.3.2 Sensitivity Analysis on Protocol 1 
Table 10.3 presents a sensitivity analysis on the limit on the increase in insulin and the 
tolerance on the lower limit. A lower limit of 4.4 mmol/L was chosen such that tolerances of 
-0.2 and -0.4 mmol/L would allow the insulin rate to be chosen such that the 5
th
 percentile 
prediction to be within 4.2 – 4.0 mmol/L or 4.0 – 4.4 mmol/L, rather than just greater than a 
specified lower BG limit.   
The limit on the amount by which the insulin rate can increase at any BG level was increased 
to 0.04, 0.05, and 0.06 U/kg/hr. This change improved time in band, but the incidence of 
severe hypoglycaemia was increased (results not shown). However, when the amount by 
which insulin was allowed to increase was varied with BG level this change, in addition to 
the tolerance on the lower limit, proved effective at increasing the % time in band to around 
77%, without increasing the %BG below 4.0 mmol/L. There is some small sensitivity around 
the BG value that the maximum increase insulin rate is applied. If these BG are lower, time in 
band is higher, but hypoglycaemia (%BG<3.0 mmol/L) is also higher. A lower tolerance 
value is theoretically marginally safer, with 1 less incident of severe hypoglycaemia across 
most of the limit combinations in Table 10.3.  
In all simulations the %BG<4.0 mmol/L was lower than a maximum acceptable limit of 5%. 
In addition, the similar and relatively consistent value of 0.1 % BG<3.0 mmol/L suggests that 
the 1 extra hypoglycaemic event in the higher tolerance simulations is within simulation 
noise (Chase et al., 2007, Chase et al., 2010a). 
10.3.3 Selected Protocol 
The best balance between performance (% time in band) and safety (% incidence of BG<3.0 
and number of episodes of hypoglycaemia) was achieved using a tolerance of 0.4 mmol/L, 
and using BG determined limits on the increase in insulin infusion rate. These limits allow 
insulin to increase by up to 0.06 U/kg at BG>9 mmol/L, increase by up to 0.03 U/kg/hr 
between 6.0 and 9.0 mmol/L, and increase by up to 0.01 U/kg/hr below 6 mmol/L. The 
lowest allowable insulin rate is chosen that results in a 5
th
 percentile BG prediction within the 
tolerance range of 4.0 – 4.4 mmol/L. If the 5th percentile BG is higher than this tolerance 
range with the maximal allowable insulin rate, then this maximum insulin rate is given. This 
optimised protocol will be denoted as the STAR-GRYPHON (STAR glycaemic regulation 
system to prevent hyper- and hypo- glycaemia in neonates) protocol.  
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Table 10.3: Virtual trial results for the optimisation of Protocol 1. 
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Targeting 
type: 5th 
on 4.4 
mmol/L 
-0.2 
5.0, 8.0 6.6 [5.8 - 7.8] 75.6 9.3 1.5 0.1 1 
6.0, 9.0 6.4 [5.6 - 7.7] 74.4 9.5 1.4 0.1 1 
6.5, 9.0 6.7 [5.8 - 7.9] 73.8 9.8 1.4 0.1 0 
6.0, 10.0 6.5 [5.6 - 7.7] 73.8 9.8 1.3 0.1 0 
7.0, 10.0 6.7 [5.9 - 8.0] 73.4 9.9 1.3 0.0 0 
7.0, 11.0 6.5 [5.7 - 7.8] 73.3 10.2 1.2 0.0 0 
-0.4 
5.0, 8.0 6.7 [5.9 - 8.0] 77.6 8.5 2.3 0.2 3 
6.0, 9.0 6.5 [5.7 - 7.8] 76.4 9.0 1.8 0.1 2 
6.5, 9.0 6.8 [5.9 - 8.0] 75.6 9.2 1.8 0.1 1 
6.0, 10.0 6.6 [5.7 - 7.9] 75.5 9.3 1.7 0.1 1 
7.0, 10.0 6.8 [5.9 - 8.0] 75.1 9.6 1.6 0.0 1 
7.0, 11.0 6.6 [5.7 - 7.9] 74.7 9.9 1.6 0.0 1 
 
10.4 Discussion 
Virtual trials have been used to optimise a STAR protocol, leading to the STAR-GRYPHON 
protocol for use in the NICU. Virtual trials using virtual patients derived from clinical data 
enable different protocols to be tested quickly and safely, without the undue cost and risk of 
extended clinical trials. This new protocol uses stochastic targeting to place the 5th percentile 
of predicted BG outcomes within tolerance of the lower BG limit of 4.4 mmol/L to maximize 
overlap between the range of possible BG outcomes and a clinically specified target band 
(4.0-8.0 mmol/L). Further, the maximum increase in insulin is limited based on BG level, so 
that as the risk of hypoglycaemia decreases, more aggressive insulin treatments can be 
utilised. This approach allows direct management, of both hyper- and hypo- glycaemic risk.  
Performance is better than the NICU-Protocol in simulation by 1.7%, which is lower than 
might be expected. However, due to the large band width resulting from the stochastic model, 
the NICU-Protocol puts the 5
th
 percentile of BG outcomes on 4.0 mmol/L to ensure safety, 
rather than the 50
th
 percentile of BG outcomes on 6.0 mmol/L. As a result the protocols are 
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similar in effect, with the STAR-GRYPHON protocol‟s advantage being in its relative 
simplicity and further optimisation for this cohort.  
In virtual trials, the STAR-NICU protocol has higher time in band and fewer episodes of 
hypoglycaemia than the clinical data collected from the clinical use of the STAR-NICU 
protocol. This performance increase reflects the change in model, as the previous STAR-
NICU protocol was implemented using the NICU model of Chapter 3, and different 
stochastic models based on the NICU model and less data. This relative increase in both 
performance and safety indicates that the NICING model is more effective at capturing 
relevant insulin-glucose physiology for the purposes of glycaemic control, thus narrowing 
stochastic forecasting bounds. It may also reflect the larger clinical population that the new 
stochastic models are based on. 
The %BG below 4.0 mmol/L was much lower than the theoretical maximum of 5%. This 
outcome reflects the conservative nature of population based models for estimating patient-
specific changes in SI. However, this conservativeness increases safety from hypoglycaemia, 
as many patients do not drop below 4.0 mmol/L. 
The effect of patient variability can be represented by the width of the 5
th
 - 95
th
 percentile 
range of likely BG outcomes, which is given for various protocols in Table 10.2 This range is 
usually 4.5-5.5 mmol/L in width, which is larger than the width of the target range. The 
ability to control tightly to this target range is therefore partially compromised. The width of 
this 5
th
-95
th
 percentile BG outcome range is larger at higher blood glucose levels, where wide 
prediction bands in SI are magnified by high BG and large recommended insulin dosage (see 
Equation 9.9).  
Limits on the maximum change in insulin rate enable more aggressive treatments to be given 
at higher BG. However, they also provide an improved degree of safety at lower BG, as 
allowable insulin rates are more restricted. This restriction helps moderate risk of 
hypoglycaemia due to sudden rises in SI when at low BG, as well as from over response to 
any significant measurement error which can occur.  
The slightly higher incidence of hypoglycaemia seen in Table 10.3 was due to sensitivity to a 
sudden large increase in virtual patients SI while the patient was at a BG of ~8.0 mmol/L or 
higher. In most cases these large SI spikes occur around large changes in the parenteral 
nutrition rate in the original clinical data. These spikes are likely unphysiological model 
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artefacts, and reflect error around the onset of these nutrition rate changes, delays due to dead 
space in the delivery tubing, or inability of the model to accurately capture rapid changes in 
BG due to these nutrition changes.  
Clinical limitations on performance are present in the form of restrictions on the number of 
BG measurements that can be taken in a set time period. Neonates have extremely limited 
blood volume, so the lower limit on measurement interval is 2 hours, with clinical preference 
being 3-4 hours and a preferred maximum of around 8 measurements per day. Hence, the 
control protocols are optimised for 4 hourly intervals, although 3 hourly intervals give better 
performance.  
10.5 Summary 
Virtual patients were created using clinical data, and were used in virtual trials to test and 
optimise a protocol for dosing insulin in very/extremely premature infants. The STAR-
GRYPHON protocol was developed, which uses stochastic targeting of predicted SI 
outcomes to generate a range of BG predictions for a given insulin dose. The protocol selects 
and insulin infusion rate such that the maximum possible likelihood of BG outcomes less 
than 4.0 mmol/L is 5%. Limits on the amount that the insulin infusion rate can increase 
between treatments are applied according to current BG, allowing more aggressive treatments 
when the current BG is above 9.0 mmol/L.  
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Chapter 11: Clinical results 
 
 
 
 
In Chapter 10 virtual trials were used to develop and optimise a protocol in silico. The final 
optimised protocol is known as STAR-GRYPHON. Chapter 11 presents clinical results from 
the use of the STAR-GRYPHON protocol in Christchurch Women‟s Hospital NICU. 
11.1 Introduction 
In this Chapter clinical results are presented from patients treated using the new NICING 
model summarised in Chapter 9 and the STAR-GRYPHON protocol developed in Chapter 10 
are presented. These results are compared to clinical results from previous work by (Le 
Compte et al., 2009). This previous work included a protocol, denoted here as the STAR-
NICU protocol that uses the NICU model previously described in Chapter 3.  
11.2 Methods 
11.2.1 Model Dynamics and Stochastic Forecasting 
The glucose-insulin metabolic models utilised by the STAR-GRYPHON protocol and the 
older STAR-NICU protocol were the NICING and NICU models, respectively. These are 
summarised in Chapters 9 and 3. In the case of the NICING model, the premature infant 
specific parameters for the gut model were not yet developed, so the adult ICU values of d1= 
0.035 min
-1
 and d2 = 0.007 min
-1
  (corresponding to half lives of 20min and 100min 
respectively) were used with the 2 compartment gut model.  
Likely future outcomes in SI were forecast in both protocols using the stochastic modelling 
method outlined in Chapter 3. Stochastic models were created based on clinical data from the 
retrospective cohort in the case of the STAR-NICU protocol, and the retrospective and 
STAR-NICU clinical cohorts in the case of the STAR-GRYPHON protocol. 
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11.2.2 Protocol Definition 
STAR-NICU Protocol: Target to Value 
The 50
th
 percentile of likely SI outcomes is used to determine the 50
th
 percentile of BG 
outcomes for defined insulin and nutrition inputs. An insulin rate is chosen, such that the 50th 
percentile of BG outcomes is placed on a median target of 6.0 mmol/L and the 5
th
 percentile 
of likely BG outcomes is greater than 4.0 mmol/L (Le Compte et al., 2009) (see Figure 
11.1a). If the second condition is not met, insulin is reduced until it is, and the 50
th
 percentile 
is allowed to be higher than the median target of 6.0 mmol/L. As added protection against 
noise or mis-measurement, the rate of change of insulin is limited to a maximum increase of 
0.03 U/kg/hr per treatment, but can be dropped to zero if required. The overall approach was 
designed to balance performance and hypoglycaemic risk relatively equally. As a target to 
value protocol it is similar to many clinical protocols, but with the added model-based 
assessment and management of risk. 
STAR-GRYPHON Protocol: Target to Range 
To determine baseline SI the infant is started on 0.05 U/kg/hr insulin infusion for 2 hours. 
From there, the protocol used clinically was the optimised STAR-GRYPHON protocol 
developed in Chapter 10. To summarise briefly, an allowable insulin rate is chosen such that 
the 5th percentile of BG outcomes is placed at the maximum possible value between 4.0- 4.4 
mmol/L, as shown in Figure 11.1. Adaptive limits on the amount by which the insulin rate is 
allowed to increase are applied. If current BG is greater than 9.0 mmol/L, insulin infusion can 
increase by up to 0.06 U/kg/hr. If BG is between 6.0-9.0 mmol/L it can increase by up to 0.03 
U/kg/hr, and if BG<6 mmol/L it can only increase by up to 0.02 U/kg/hr. Insulin infusion 
rates are allowed to decrease or be turned off at any time. 
11.2.3 Clinical Cohorts 
Data from hyperglycaemic (2 consecutive BG ≥ 10.0 mmol/L within 4-6 hours) premature 
neonates (GA<30 weeks, BW<1.5 kg) treated with insulin in Christchurch Women‟s Hospital 
NICU was obtained for three cohorts: 1) Retrospective bedside titration (pre August 2008); 2) 
the first STAR-NICU protocol (August 2008-December 2012); and 3) the optimised STAR-
GRYPHON protocol (January 2013-June 2014).  Pilot trials under the STAR-NICU protocol 
were approved by the Upper South A Regional Ethics Committee, New Zealand  
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Figure 11.1: Dosing protocols use the forecast ranges of likely BG outcomes to select an 
appropriate insulin dose. The STAR-NICU protocol (a) targeted the outcome median to 
6.0 mmol/L and checked that 95% of likely BG outcomes were greater than 4.0 mmol/L, 
whereas the STAR-GRYPHON protocol (b) dosed insulin such that 95% of likely 
outcomes were greater than 4.4 mmol/L. 
 
(ClinicalTrials.gov registration NCT01419873). From August 2010 onwards, STAR was 
implemented clinically as a standard of care. Glycaemic data was de-identified and stored 
automatically by the computer system for data audits on performance and safety, and to 
increase the population data set that the statistical models draw on.  
From January 2013 to June 2014, 13 premature infants totalling 16 episodes of insulin 
therapy received insulin under STAR-GRYPHON. The STAR-NICU cohort comprised of 
data from 40 premature infants totalling 61 episodes, who received insulin therapy under the 
STAR-NICU protocol, as either a pilot trial or as a standard of care, from August 2008 to 
December 2012. The first 22 patients in this cohort have been previously reported (Le 
Compte et al., 2012). Retrospective data was obtained for 22 patients, comprising 25 
glycaemic episodes, who received insulin under a bedside titration protocol prior to STAR 
implementation in 2008. Cohort characteristics are included in Table 11.1 in the results. 
a) 
b) 
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Figure 11.2: Clinical implementation of STAR glycaemic control. Clinical glycaemic 
control actions are used by the tablet to calculate and predict future changes in a 
patient’s insulin sensitivity. Insulin doses are then chosen based on likely future 
outcomes in blood glucose.  
 
A patient episode was defined as 12 hours or more of insulin therapy with at least 4 BG 
measures. Episodes are separated by at least 12 hours reflecting separate episodes of 
treatment and a full restart of the glycaemic control protocol. STAR was initially 
implemented using a PC computer based application, and more recently through the use of 
bedside tablet computers with a touch-screen interface.  
11.2.4 Clinical Implementation 
The clinical implementation cycle for the STAR protocol is shown in Figure 11.2. STAR-
GRYPHON was implemented as a tablet computer (Samsung Galay Tab 2, 10.1 inch) 
application with a specifically designed graphical user interface, part of which is shown in 
Figure 11.3. The user interface, calculations, and data storage were all coded in Java and 
implemented using the android operating system (Android version 4.0.4). Solver and forward 
simulation Java code was structured in a similar manner to the Matlab
®
 code used in virtual 
trials. A 4
th
 order Runge-Kutta ODE solver was written in java to mimic the action of ode45 
solver in Matlab
®
, which it did to 4 or 5 decimal places. Matlab simulations calling the Java 
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code for the protocol and model solvers were carried out to ensure consistency between 
simulation and real-world implementation.  
 The interface (see Figure 11.3) was set up to ensure clarity of current clinical inputs and 
confirmation of treatments given to minimise clinical error effects on insulin dose 
calculation. Insulin and nutrition records are reviewed and/or updated prior to the insulin dose 
calculation. This data and the current BG measure are used to calculate the current value of 
SI and recommend an insulin dosage based on SI forecasts using this value, as illustrated in 
Figure 11.1. Having recommended an insulin dosage, at the end of the measurement interval 
the next BG measurement is entered into the tablet, alongside any changes in nutrition or 
insulin, and another treatment is calculated.  
A neonate is taken off STAR when BG is in the target range (4-8 mmol/L), no insulin has 
been given for 6 hours, and/or the infant is determined to be glycaemically stable. An infant 
may be restarted as a new episode if hyperglycaemia recurs. 
Blood samples are taken from a central umbilical line, if available, or from heel pricks every 
2-4 hours. BG is determined using a Bayer 850 blood gas analyser (Bayer AG, Leverkusen, 
Germany). Insulin is always delivered as an infusion through the same line as the main 
dextrose fluids. Insulin concentration is calculated based on infant weight, such that 0.05 
U/kg/hr = 0.20 mL/hr. Infusions are given in steps of 0.01 U/kg/hr, delivered by the pump in 
to an resolution of 0.01 mL/hr. Delivery tubing is pre-soaked in the insulin solution for 15 
minutes to reduce the effect of insulin absorption by the tubing on glycaemic control. 
Nutrition rates are clinically determined, and are not normally adjusted for glycaemic control. 
All recent (last 3-4 hours) and planned future nutrition sources and rate changes are 
accounted for when determining insulin dosage. Typically, neonates receive the bulk of their 
nutrition via TPN with 10% dextrose, with a target total glucose delivery of 6-8mg/kg/min. 
Medications, such as dobutamine and morphine, may be infused with 5% dextrose or saline 
solutions, which are also accounted for in the model calculation. Enteral boluses of expressed 
breast milk (EBM) are used as soon as they are available, starting at 0.5mL every four hours, 
with increasing volume and frequency as tolerated. Milk formula may also be given enterally, 
and human milk fortifiers were sometimes added to EBM to increase caloric value. All this 
information was available to the model at the time of calculation. 
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Figure 11.3: STAR-GRYPHON graphical user interface for treatment calculation. 
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11.2.5 Analysis 
Model BG data is re-sampled hourly because where the measurement interval is different, re-
sampled statistics allow a fairer comparison between groups, as well as an indication of 
glycaemic behaviour between measurements. Re-sampled statistics use the model generated 
BG profile to estimate BG behaviour between measurements.  
Safety is evaluated by the number of patients with one or more hypoglycaemic events 
(BG<2.6 mmol/L) and the %BG below the lower target band value of 4.0 mmol/L. 
Performance is determined by the percentage time in a 4.0-8.0 mmol/L target band, and 
minimisation of hyperglycaemia by the %BG>10.0 mmol/L.  
Statistical comparisons of median values are made using the Mann-Whitney U test, and the 
Kolmogorov-Smirnov test to compare variability (Matlab
®
, ranksum, kstest2). The Fishers 
exact test was used to calculate the statistical significance of the number of patients with at 
least 1 hypoglycaemic episode. Statistical power, based on sample size for p=0.05, is 
calculated using the method presented in Whitley and Ball (2002). Statistical power was 
considered for 3 metrics: 1) per-patient percentage time in targeted range; 2) per-patient 
median BG, and 3) number of patients with hypoglycaemia. Consideration was taken of 
unequal cohort sized in comparison. 
11.3 Results 
11.3.1 Clinical Results 
Performance statistics for each cohort are given in Table 11.1. The STAR-GRYPHON 
protocol implementation saw re-sampled BG in the target band rise to 76.6% (72% of all BG 
measures), with no incidence of hypoglycaemia (BG<2.6). This outcome reflects an almost 
10% absolute increase in BG in the target band in comparison to STAR-NICU, and a 26% 
absolute increase with respect to retrospective data. Statistical power for percentage time in 
band statistics was >95% and 88% respectively for STAR-GRYPHON and STAR-NICU 
cohort comparisons to retrospective data.  
Median BG was lower for STAR-NICU and STAR-GRYPHON compared to retrospective 
data (6.6 & 6.9 mmol/L vs. 7.8 mmol/L, p=0.01 (power 74%) and p=0.09 (power 30%), 
respectively). Cumulative distributions of BG in Figure 11.4 are significantly different 
(p<0.005 for all comparisons), and are steeper for STAR-NICU and STAR-GRYPHON in 
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comparison to retrospective data. While STAR-GRYPHON had higher median BG than 
STAR-NICU, it had the steepest gradient, indicating the tightest range of clinical glycaemic 
outcomes. Notably, STAR-GRYPHON had much less BG<4.0 mmol/L (p=0.007 in 
comparison to retrospective data, and p<0.001 in comparison to STAR-NICU), with no 
incidence of hypoglycaemia. That there were no patients who experienced hypoglycaemia on 
the STAR-GRYPHON protocol was not statistically significant in comparison to STAR-
NICU (p=0.14) given the smaller patient numbers. For 80% statistical power and p=0.05 a 
total of at least 26 STAR-GRYPHON patients would be required. 
 
Table 11.1: Clinical results and glycaemic statistics by cohort. Data are given as Median 
[Inter-quartile range].  
 
Retro-
spective  
(R) 
STAR-
NICU 
(SN) 
STAR-
GRYPHON 
(SG) 
P value 
SN vs. 
R 
SG 
vs. R 
SG 
vs. SN 
n Patients (n male) 22 (7) 40 (22) 13 (8)    
n Episodes 25 54 16    
Total Hours 3098 5014 987    
Number of BG measurements 943 1632 270    
Gestational Age (GA) [weeks] 27 [25-27] 26 [25-29] 26 [26-27] 0.82 0.91 0.84 
Weight [g] 
845 
[800-900] 
785 
[635-950] 
908 
 [820-1030] 
0.66 0.24 0.25 
Post Natal Age  (PNA) [days] 3 [1-7] 3 [1-12] 3 [2-4] 0.42 0.94 0.45 
Measurement interval 
3.2 
[2.6 - 3.9] 
3.3 
[2.7 - 3.8] 
4.0  
[3.8-4.1] 
0.98 0.01 
<0.00
1 
Insulin rate [IQR] (U/kg/hr) 
0.03 
[0.02-0.06] 
0.04 
[0.02-0.08] 
0.05 
[0.04 - 0.07] 
0.06 0.002 0.02 
Total glucose delivery rate 
[IQR] (mg/kg/min) 
8.1 
[5.7 - 9.7] 
7.3 
[5.1- 8.5] 
7.7  
[7.1 - 8.6] 
0.50 0.81 0.84 
Hourly re-sampled statistics 
Median BG 
7.8 
[6.6- 9.1] 
6.6 
[5.5 - 8.2] 
6.9  
[6.1-7.9] 
<0.001 <0.001 <0.001 
% BG within 4.0 - 8.0 mmol/L 50.3 67.2 76.6 <0.001 <0.001 0.42 
% BG>10 mmol/L 17.7 11.8 5.6 0.01 0.005 0.42 
% BG<4.0 mmol/L 3.0 4.6 0.4 0.21 0.007 <0.001 
% BG<3.0 mmol/L 0.3 0.7 0 0.28 0.09 0.02 
Num episodes with BG <2.6 
(%) 
1 (4) 8 (13) 0 (0) 0.20 0.61 0.14 
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Figure 11.4: Blood glucose (BG) distributions for each patient cohort. The vertical axes 
denotes the proportion of BG measurements ≤ the given horizontal axe threshold, and 
the clinically targeted range is shaded.  
11.3.2 Comparison to Simulation 
The STAR-GRYPHON shows similar performance in clinical results to those predicted in 
simulation, with 76.6 vs. 76.4% time in band, respectively. However, the incidence of %BG 
<4.0 mmol/L is significantly lower than predicted in simulation (p=0.03). The incidence of 
hypoglycaemia (number of patients with at least 1 BG<2.6 mmol/L) and hyperglycaemia 
(%BG>10.0 mmol/L) is also lower than predicted in simulation, although not significantly so 
(p≥0.60). The cohort characteristics, such as weight, GA, and PNA are also similar (p≥0.16), 
as well as clinically delivered insulin and glucose. The median BG is higher in the clinical 
results than in simulation. The median measurement interval is the same as simulated. 
11.3.3 Per-patient Results 
Individual patient results for STAR-GRYPHON are given in Table 11.3. Performance varies 
between patients, with a general trend of increased performance with GA, but not necessarily 
BW. Patients 1 and 10 are very resistant to insulin to start with. The results for Patient 1, 
shown in Figure 11.5a, show that BG is greater than 7.5 mmol/L for the first 55-60 hours of 
glycaemic control, despite relatively high insulin doses. Insulin dose is still lower than the 
clinically imposed maximum dose of 0.3 U/kg/hr, as the BG prediction bands for this patient 
are wide, with the actual BG closer to the cohort-based 95
th
 percentile than the median. 
Hence, slightly higher BG results from wide stochastic model bounds at high insulin doses, 
and provides additional safety from hypoglycaemia. 
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Table 11.2:Virtual trial vs. Clinical results for the STAR-GRYPHON protocol. Data are 
given as Median [Inter-quartile range].  
 
Virtual Trial 
results 
Clinical results P value 
n Patients (n male) 62 (29) 13 (8)  
n Episodes 79 16  
Total Hours 7962 987  
Number of BG measurements 2109 270  
Gestational Age (GA) [weeks] 26 [25-28] 26 [26-27] 0.99 
Weight [g] 845 [635 – 940] 908 [820-1030] 0.16 
Post Natal Age (PNA) [days] 3 [1-8] 3 [2-4] 0.57 
Measurement interval 4.0 
4.0 
[3.8-4.1] 
- 
Insulin rate [IQR] (U/kg/hr) 0.05 [0.03 - 0.08] 0.05 [0.04 - 0.07] 0.80 
Total glucose delivery rate [IQR] 
(mg/kg/min) 
7.5 [5.4 - 9.2] 
7.7 
[7.1 - 8.6] 
0.70 
Hourly re-sampled statistics 
Median BG 6.5 [5.6 - 7.7] 6.9 [6.1-7.9] <0.001 
% BG within 4.0 - 8.0 mmol/L 76.4 76.6 0.44 
% BG>10 mmol/L 9.0 5.6 0.60 
% BG<4.0 mmol/L 1.8 0.4 0.03 
% BG<3.0 mmol/L 0.1 0.0 0.25 
Num episodes with BG <2.6 (%) 2 0 (0) 0.69 
 
A more typical patient is shown in Figure 11.5b. In this case BG is lowered quickly and 
remains in band for a high proportion of the remaining time. Insulin is continually modulated, 
even when BG is within band, in response to changing SI. Insulin is eventually turned off as 
SI rises.  
Compliance with the STAR-GRYPHON protocol was high. Over 16 patient episodes 
(totalling 272 treatments) there were 10 treatment instances of changes to the STAR-
GRYPHON protocol recommendations (3.6% of all treatments). Once (10%) insulin was 
given when it was recommended that it be turned off, and in 3 (30%) instances insulin was 
changed independently. In 6 instances (60%), insulin was overridden and turned off. In this 
last case, insulin was turned off in 4 instances (40%) at the end of a patient episode instead of 
maintaining the minimum allowable insulin infusion. This occurred twice consecutively 
(20%) within the same patient at a BG of 8.3 and 8.9 mmol/L, respectively, without further 
explanation. Compliance data was not available for the STAR-NICU protocol. 
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Table 11.3: Individual results and protocol compliance across the STAR-GRYPHON 
cohort. 
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1 96 (28) 15 9.8 56.5 0 0 10.3 64.2 2 
2 91 (22) 11.1 4.4 87.9 0 0 2.9 90.9 0 
3 25 (9) 10.7 3.8 69.2 1 0 4.2 85.7 0 
4 18 (6) 12.6 10.5 63.2 0 0 4.6 85.7 2 
5 88 (24) 8.0 0.0 90.4 0 0 N/A 91.7 0 
6 Ep. 1 67 (17) 11.4 6.3 75.0 0 0 0.6 76.2 0 
6 Ep. 2 24 (7) 11.3 20.0 60.0 0 0 0.9 62.5 1 
7 Ep. 1 29 (9) 12.0 10.3 58.6 0 0 6.3 77.3 2 
7 Ep. 2 58 (15) 11.6 1.7 79.7 1 0 8.3 94.0 1 
8 243 (66) 10.5 3.3 85.7 0 0 0.8 86.0 0 
9 63 (17) 10.2 3.1 78.1 0 0 2.7 82.0 0 
10 111(28) 11.6 9.9 58.6 0 0 19.5 71.4 1 
11 71 (17) 12.6 7.0 80.3 0 0 4.9 86.4 0 
12 50 (13) 10.9 3.1 88.0 0 0 6.8 91.7 0 
13 Ep. 1 19 (6) 11.7 18.2 54.5 1 0 3.2 85.7 0 
13 Ep. 2 20 (7) 11.8 5.0 90.0 0 0 0.2 94.7 1 
 
156 
   
 
a) 
 
b) 
Figure 11.5: STAR-GRYPHON clinical results for a) Patient 1, and b) Patient 2. Plots 
show blood glucose (BG), model-based insulin sensitivity (SI), and clinical insulin and 
nutrition treatments. 
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11.4 Discussion 
11.4.1 Protocol Performance 
The STAR-NICU and STAR-GRYPHON protocols increased the percentage of BG 
measurements within the target band of 4.0 – 8.0 mmol/L in comparison to retrospective data. 
In the case of the STAR-NICU protocol this result was predominantly due to the reduction of 
hyperglycaemia and lowering of the median patient BG, and results across an increased 
cohort of patients reflect those of early published pilot trials (Le Compte et al., 2012). STAR-
GRYPHON improves on the performance of STAR-NICU by further reducing 
hyperglycaemia, and significantly reducing the incidence of BG < 4.0 mmol/L (p<0.001). In 
addition, clinical workload, as reflected by the BG measurement interval, was reduced. Under 
the STAR-GYRPHON protocols there were no (0%) patients with at least one incidence of 
hypoglycaemia, but this was not statistically significant due to lower patient numbers. Figure 
11.4 shows a significantly steeper cumulative distribution of BG (p<0.005), indicating much 
tighter glycaemic control with greater safety from hypoglycaemia than either retrospective 
clinical data or STAR-NICU could achieve.  
A key difference in protocol between STAR-GRYPHON and STAR-NICU is a shift from 
targeting a median target BG to instead optimise the overlap of likely outcomes with a target 
band. In addition, adapted limits on the allowable increase in insulin infusion rate are applied, 
with greater restrictions in this increase at lower BG. In practice, high variability means that 
both protocols are very similar, except in their treatment of BG near the lower end of the 
normal range, where results show STAR-GRYPHON to be safer and more effective. This 
result was previously seen in simulation, and is discussed in Chapter 10. The greater 
difference in the percentage time in band in clinical results compared to the simulation results 
of Chapter 10 (9 vs. ~2%) reflects the contribution of the new NICING model to the 
tightening of control.  
The average delivery rate of insulin is higher under STAR-GRYPHON, while the median 
glucose rate was highest in the retrospective data. The glucose delivery rate was also most 
varied in the retrospective data, suggesting that to some extent nutrition was being modulated 
to control BG levels at that time. Glucose delivery rates are determined clinically, and were 
lower for patients under STAR-NICU and STAR-GRYPHON, but not statistically different. 
However, the lower median BG cannot solely be attributed to lower glucose delivery rate, as 
average insulin delivery rates are higher.  In addition, Chapter 10 shows that for the same 
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glucose delivery rates given clinically in the retrospective cohort, STAR-GRYPHON was 
expected to lower the median BG and increase the time in band, thus tightening control. 
Higher insulin rates, improved control, and lack hypoglycaemic incidences reflect STAR-
GRYPHON's ability to modulate insulin according to glycaemic response and overall patient 
condition. 
11.4.2 Comparison to Simulation 
The clinical performance of STAR is similar to what was predicted in simulation, with a 
percentage time in band of 76.6 in comparison to 76.4 (p=0.44). However, the %BG<4.0 is 
much lower (p=0.03). The lower incidence of hyperglycaemia suggests overall higher whole 
body SI than predicted by the stochastic models. In addition, lower hypoglycaemia indicates 
additional safety, and suggests that the stochastic models over predict both extremes in the 
clinical patients treated with STAR-GRYPHON to date.  
The median BG is lower in simulation than in the clinical results (6.5 vs. 6.9 mmol/L, 
p<0.001). This is due in part to the clinical tendency near the end of a glycaemic episode to 
override and turn insulin off, rather than maintain a minimum insulin rate, as notes in Section 
11.3.3. It could also reflect the conservative nature of stochastic forecasting in this cohort. 
11.4.3 Comparison to Literature Results 
As discussed in Chapter 2, the benefits of insulin therapy to promote increased glucose 
tolerance and weight gain have been well reported (Binder et al., 1989, Collins et al., 1991, 
Kanarek et al., 1991, Meetze et al., 1998, Ostertag et al., 1986, Pollak et al., 1978, Thabet et 
al., 2003, Vaucher et al., 1982), but few statistics are reported with respect to the quality of 
glycaemic control. Rates of hypoglycaemia, when discussed, are often reported as the 
percentage of all BG measures taken, and are typically less than 1% BG<2.2 or 2.6 mmol/L. 
Further, target ranges and definitions of hyper- and hypo- glycaemia vary across centres 
(Alsweiler et al., 2007) and between studies.  Thus, very little literature is available with 
which these STAR glycaemic control results can be compared. Such difficulties are further 
compounded by differences in practice and definition. However, limited comparisons can be 
made to the studies previously outlined in Chapter 2, Section 2.3. 
The HINT trial randomised control trial saw a doubling of the number of incidences of 
hypoglycaemia (58% of infants with one or more BG<2.6 mmol/L in the TGC group 
compared with 27% in the control group) is reported, despite the fact that around a third of 
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the control group ended up being treated with insulin as well (Alsweiler et al., 2012). 
Beardsall and colleagues (Beardsall et al., 2008) report a high rate of hypoglycaemia (defined 
as BG<2.6 mmol/L for more than 60 min when measured by continuous glucose monitor 
(CGM)), with 29% of infants receiving early insulin therapy experiencing one or more 
hypoglycaemic events compared with 17% in the control group.  In a study comparing insulin 
therapy between ELBW and LBW infants, Ng and colleagues (Ng et al., 2005) report that 
15% of ELBW and 11% of LBW infants had BG<2.6 mmol/L during their study. In 
comparison, in the STAR-NICU cohort 8/62 (13% of all episodes) had hypoglycaemic 
events, and STAR-GRYPHON to date has shown no (0 %) hypoglycaemic events, and no 
BG<3.5 mmol/L.  
The median BG from neonatal STAR was 6.6 [5.5 - 8.2] mmol/L for STAR-NICU and 6.9 
[6.1 - 7.9] mmol/L for STAR-GRYPHON, which is higher than the 6.2±1.4 mmol/L seen in 
the early insulin group of the NIRTURE trial and higher than the HINT TGC group median 
of mean daily glucose measure 5.8 [4.8-6.7] mmol/L. It should be noted that the glycaemic 
control statistics are only reported for study days 2-7 in the NIRTURE trial, ignoring earlier, 
potentially higher and more unstable BG values that can occur early in the stay. Comparison 
to Ng is made difficult as only the median [range] BG during insulin therapy is reported (12 
[6-24] mmol/L in the ELBW cohort, and 11 [7-19] mmol/L in the LBW cohort), which are 
much higher than those of STAR.  
11.4.4 Strengths and Limitations 
Compliance with STAR-GRYPHON was high (96.4%), and 4 of 10 of non-compliance 
events (40%)  were due to insulin being turned off when an infant was judged glycaemically 
stable near the end of an episode, instead of maintaining a minimum insulin rate. Another 
source of non-compliance was insulin rates being dropped between BG measures, in most 
cases because of a drop in nutrition rate. While, ideally, another BG measure would be taken 
and a revised treatment calculated, low blood volume means that clinical staff prefer to 
minimise BG measures.  
Statistically, STAR-GRYPHON achieves much better time in the clinically targeted band 
than the retrospective titration protocols. Although this result stems from a comparison of two 
patient cohorts of 16 and 25 episodes, respectively, the observed difference between in the 
mean per-patient percentage time in band for the two group‟s results is greater than the 
standard deviation, resulting in a statistical power of over 95%. Further, the median episode 
160 
   
length is 2-3 days, and if the statistical power calculation is repeated on proportions of total 
BG measurements, this power increases.   
Lower difference between groups and higher variability means that the statistical power is 
lower when retrospective and STAR-NICU results are compared. While the statistical power 
is lower when median BG is compared, tightness of control has more to do with distribution 
than a single median value, especially once the median BG is within the target range. While 
STAR-GRYPHON has much lower %BG<4.0 (p<0.001) and %BG<3.0 (p=0.02), at least 10 
more (at least 26 total) STAR-GRYPHON patients are needed to determine if the lack of 
patients with a hypoglycaemic episode is statistically significant.  
A strength of these clinical results is that performance and safety are defined by more than 
just average BG measurement and/or hypoglycaemic incidences. However, even the concept 
of percentage time in band has its limitations. Controversy exists as to the definition of hyper- 
and hypo- glycaemia, as well as appropriate target ranges (Alsweiler et al., 2007, Cornblath et 
al., 2000). In addition, differences in glycaemic behaviour and stability can exist within a 
target range. It has been shown that glycaemic variability may be a predictor for mortality in 
adult ICU patients (Krinsley, 2008). Further work needs to be done to better and more 
universally quantify glycaemic control performance and stability. 
One of the limitations of this study is that the results are based in a single hospital, the 
hospital from which the cohort for protocol design was sourced. Other studies have shown 
that protocol performance in other hospital cohorts can be lower. Currently, STAR-
GRYPHON is being used in three other hospitals, two in Auckland, New Zealand and one in 
Miskolc, Hungary. Future results will give a better indication of its performance across NICU 
cohorts and clinical practices, particularly as a function of compliance. 
The focus of this research is the achievement of tight glycaemic control in this cohort. This 
study does not attempt to show the effect of the use of insulin therapy to lower BG on 
outcomes, and would likely be underpowered to do so. If a follow up study on outcomes was 
carried out, it could perhaps examine outcomes and the tightness of control, but would likely 
require a much greater cohort. 
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11.5 Summary 
STAR is a model based glycaemic control framework for extremely premature infants. It has 
successfully been implemented as a standard of care at Christchurch Women‟s Hospital, New 
Zealand. The original implementation reduced hyperglycaemia and increased measurements 
in the targeted rang by 16%. Recent implementation of an optimised STAR-GRYPHON 
protocol has resulted in 76.6% of hourly re-sampled BG measurements in the target band 
(26% better than retrospective data and 9% better than original STAR NICU protocols), and 
no incidence of BG<3.5 mmol/L. Comparison with results from the literature is difficult due 
to the lack of glycaemic control statistics reported, but STAR seems to achieve better or 
comparable control to published studies with lower incidence of hypoglycaemia. Safer 
methods will allow further studies to focus on the long term impact on outcome and benefits 
of glycaemic control on ICU cohorts.  
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Chapter 12: Cohort Based Insulin Sensitivity Analysis 
 
 
 
 
12.1 Introduction 
Quantification of potential future variability in SI enables safe glycaemic control decisions to 
be made based on a patient‟s current metabolic state and potential future changes in this state 
(Chase et al., 2011b, Le Compte et al., 2010b, Le Compte et al., 2013). This variability is 
clearly evident in Figure 12.1, which shows the hour-hour (SIn vs. SIn+1) variation in model-
based SI obtained from an analysis of clinical data for preterm VLBW and ELBW neonates 
(Le Compte et al., 2010b). In particular, Figure 12.1 shows a stochastic model of SI, along 
with an example probability distribution at one SIn value, delineating the inter-quartile and 
90% ranges. 
In fact, the potential variation can be quite large. However, stochastic models are population 
or cohort based, and thus can be overly conservative for some neonates. Very wide stochastic 
forecasting bands can thus result in low doses of insulin and persistently high BG. Hence, if 
sub cohorts of patients with different SI behaviour can be identified, overall stochastic 
modelling and control can be tightened in an increasingly patient-specific or sub cohort-
specific fashion. 
This analysis will examine SI distributions between different patient cohorts. The aim is to 
create stochastic models of SI that not only better account for inter-patient variability over 
cohorts, but also capture intra-patient variability (per-patient) more accurately. The end-user 
goal is equally safe, more precise control. 
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Figure 12.1: Hourly insulin sensitivity variation data with probability bounds and 
example curve showing probability bounds. Source: (Le Compte et al., 2013) 
12.2 Methods 
12.2.1 Glycaemic and Stochastic Models 
The model used in this analysis is the same as the model presented in Chapter 9, excluding 
the newly developed gut model. SI profiles are fit using this model, and from these identified 
SI trajectories stochastic models are created. As the median measurement interval under 
STAR-GRYPHON is 4 hours, 4 hourly stochastic models are generated using matched SI 
pairs four hours apart,             . 
Stochastic models are constructed using 2D kernel density models applied to a data set of 
matched SI pairs (Lin, 2007, Lin et al., 2006). As a result, for each discrete SI value within 
the observed data range, a probability density function is generated. Over the entire SI range, 
models of 5
th
 and 95
th
 percentile outcomes can be generated. An example stochastic model, 
generated during this analysis, for 4 hourly predictions using clinical data from 95 patients is 
shown in Figure 12.2. 
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Figure 12.2: Stochastic model for 4 hourly predictions in insulin sensitivity (SI). The 
model was generated using SI fitted from 95 clinical patients, and shows the 5
th
, 25
th
, 
50
th
, 75
th
, and 95
th
 percentiles for observed changes in SI.  
 
The mathematics of stochastic models are described more fully elsewhere, (Le Compte et al., 
2010b, Lin, 2007, Lin et al., 2006), but the kernel density estimator can be modified by a 
constant c, which effectively adjusts the kernel bandwidth and the degree of smoothing over 
the data. It can be used to tune stochastic models to more accurately reflect the theoretical 
90% coverage of data by the 5
th
 and 95
th
 percentiles, or to smooth model fluctuations in areas 
of low data density. In this analysis c was set to 1.0. 
12.2.2 Clinical data cohorts 
SI profiles were fitted from clinical data using Equations 9.1 – 9.13. Three cohorts of 
glycaemic episodes were compared: 1) retrospective data (N=25); 2) clinical data from 
control under the STAR-NICU protocol (N=79); and 3) the most recent clinical data cohort 
treated under the STAR-GRYPHON protocol (N=16). These clinical cohorts were previously 
presented and discussed in Chapters 10 and 11.  Cohort characteristics and control statistics 
are repeated for clarity in Table 12.1. 
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Table 12.1: Summary characteristics and glycaemic control statistics for retrospective, 
STAR-NICU, and STAR-GRYPHON clinical cohorts. 
 
Retro-
spective  
(R) 
STAR-
NICU 
(SN) 
STAR-
GRYPHON 
(SG) 
P value 
SN vs. 
R 
SG vs. 
R 
SG vs. 
SN 
n Patients (n male) 22 (7) 40 (22) 13 (8)    
n Episodes 25 54 16    
Total Hours 3098 5014 987    
Number of BG measurements 943 1632 270    
Gestational Age [weeks] 27 [25-27] 26 [25-29] 26 [26-27] 0.82 0.91 0.84 
Weight [g] 
845 
[800-900] 
785 
[635-950] 
908 
 [820-1030] 
0.66 0.24 0.25 
Post Natal Age [days] 3 [1-7] 3 [1-12] 3 [2-4] 0.42 0.94 0.45 
Measurement interval 
3.2 
[2.6 - 3.9] 
3.3 
[2.7 - 3.8] 
4.0  
[3.8-4.1] 
0.98 0.01 <0.001 
Insulin rate [IQR] (U/kg/hr) 
0.03 
[0.02-0.06] 
0.04 
[0.02-0.08] 
0.05 
[0.04 - 0.07] 
0.06 0.002 0.02 
Total glucose delivery rate [IQR] 
(mg/kg/min) 
8.1 
[5.7 - 9.7] 
7.3 
[5.1- 8.5] 
7.7  
[7.1 - 8.6] 
0.50 0.81 0.84 
Hourly re-sampled statistics 
Median BG 
7.8 
[6.6- 9.1] 
6.6 
[5.5 - 8.2] 
6.9  
[6.1-7.9] 
<0.001 <0.001 <0.001 
% BG within 4.0 - 8.0 mmol/L 50.3 67.2 76.6 <0.001 <0.001 0.42 
% BG>10 mmol/L 17.7 11.8 5.6 0.01 0.005 0.42 
% BG<3.0 mmol/L 0.3 0.7 0 0.28 0.09 0.02 
 
12.2.3 Calculation of Stochastic Model Accuracy 
Performance of stochastic models was calculated on a whole cohort and per-patient basis. For 
each SI value obtained from clinical data, stochastic models were blinded to future SI, and 
used to generate 5
th
, 25
th
, 75
th
, and 95
th
 percentiles of predicted future SI outcomes. The 
actual SI outcome was then compared to predicted outcome percentiles, and the percentage of 
actual SI outcomes that fell within this range was calculated on a per-patient and whole 
cohort basis. Ideally, a perfect model would capture 90% of each individual patient‟s 
variations in the 5-95
th
 percentile interval, as well as the 90% of the variations of the cohort 
as a whole. Performance can also be assessed by the number of patients whose individual 
stochastic performance comes close to this ideal.  
A cross comparison analysis was carried out with different stochastic models generated from 
different patient cohorts. Relevance of stochastic models to different clinical cohorts was 
reflected in the percentage of SI values that fell within predicted 25
th
-75
th
 and 5
th
-95
th
 
outcome ranges.  
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12.2.4 Stochastic Forecasting in Prematurity and Gender Sub-Cohorts 
Three variables easily identified at the bedside are gender, BW and GA. Cumulative SI 
distributions are generated and compared for male and female infants, and for sub-cohorts in 
weight and GA by tertile. Variability in SI is also compared, where variability is reflected in 
the percentage change in SI from hour to hour, relative to the initial SI value of these matched 
pairs. 
A Kolmogorov–Smirnov (KS) test was used over a full range of possible BW and GA 
groupings to identify groups with the greatest differences in relative change in SI. This may 
allow stochastic models to be created based on significant BW or GA groupings.  
12.2.5 Statistical analysis 
The KS test is used to compare the differences in SI distributions (Matlab
®
, kstest2). The 
Mann-Whitney U test (Matlab
®
, ranksum) is used to compare data medians in cohort 
characteristics or glycaemic statistics. A p-value of 0.05 or less is considered statistically 
significant.  
12.3 Results 
12.3.1 Insulin Sensitivity Across Different Cohorts 
Table 12.2 shows the percentage of SI within the 5
th
-95
th
 and 25
th
-75
th
 percentile prediction 
ranges for different cohort and stochastic matrix combinations. As expected, when a 
stochastic matrix is tested against the cohort it was generated from ~ 90% of the predictions 
fall within the 5-95
th
 percentile range, with differences due to kernel smoothing or regions of 
lesser data. For these cohort and stochastic model combinations, the percentage of predictions 
within the 25
th
-75
th
 range is slightly higher than 50%. If the c value is changed to bring the 
percentage within the 25
th
-75
th
 percentile range  closer to 50%, then the percentage within the 
5
th
-95
th
 percentile range falls to around 85%.  
There is thus a trade-off in percentile distributions when creating the stochastic models. In 
particular, this trade-off indicates that the distributions are not perfectly matching the kernel 
density estimator. Since it is the 5
th
-95
th
 percentile range that drives predictions in the model-
based glycaemic control protocols of Chapter 10, stochastic matrices are tailored towards 
better coverage of the 5-95
th
 percentile range. 
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When a stochastic model is used with a different cohort from the one it was generated with, 
the percent of SI in the 5
th
-95
th
 and 25
th
-75
th
 percentile prediction ranges is lower, reflecting 
differences in SI behaviour within and between the three cohorts used. The retrospective and 
STAR-NICU cohorts are essentially similar, shown by the 86-91% of SI in the 5
th
-95
th
 
percentile prediction range. However, this similarity is not true in the case of the STAR-
GRYPHON cohort. 
Table 12.2: Whole cohort percentage of SI predictions within the 25
th
-75
th
 and 5
th
-95
th
 
percentile prediction ranges. 
 Stochastic Model population 
  Retro-
spective 
(N=25) 
STAR-
NICU 
(N=54) 
Retrospective 
and STAR-
NICU (N=79) 
STAR-
GRYPHON 
(N=16) 
All 
cohort
s 
(N=95) 
Cohort 
coverage: 
% time 
in 5
th
-95
th
 
range 
Retrospective 
90.0 85.4 88.1 69.4 87.3 
STAR-NICU 
91.1 87.2 90.0 66.4 89.2 
Retrospective 
and STAR-
NICU 
90.7 86.5 89.3 67.6 88.4 
STAR-
GRYPHON 96.3 94.9 96.0 89.0 95.4 
All cohorts 
91.3 87.4 90.0 69.9 89.2 
 Stochastic Model population 
  Retro-
spective 
(N=25) 
STAR-
NICU 
(N=54) 
Retrospective 
and STAR-
NICU (N=79) 
STAR-
GRYPHON 
(N=16) 
All 
cohorts 
N=(95) 
Cohort 
coverage: 
% time 
in 25
th
-
75
th
 
range 
Retrospective 
52.8 46.4 48.8 33.0 46.6 
STAR-NICU 
55.0 51.6 53.3 35.8 51.8 
Retrospective 
and STAR-
NICU 
54.1 50.0 51.6 34.7 49.8 
STAR-
GRYPHON 68.4 64.4 64.4 53.5 61.6 
All cohorts 
55.7 51.2 53.0 36.7 51.1 
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In all cases, the STAR-GRYPHON derived stochastic model resulted in much narrower 
prediction ranges when used with other cohorts, resulting in much lower percent time in both 
the 25-75
th
 and 5
th
-95
th
 percentile ranges. On the other hand, when stochastic models derived 
from other data cohorts was used with the STAR-GRYPHON cohort, the percentage of 
predictions within the 25
th
-75
th
 and 5
th
-95
th
 percentile ranges was much higher than 50% and 
90% respectively. These results indicate that other stochastic models are overly conservative 
for this cohort, despite no statistically significant differences in Table 12.1 in GA, BW, or 
PNA. 
Figure 12.3 shows the cumulative distributions of SI for all data cohorts. All data cohorts 
significantly differ from each other in whole cohort SI distribution (p<0.001). STAR-
GRYPHON and STAR-NICU patients have lower (p<0.001) and less variable (p<0.001) SI 
than retrospective data, and the STAR-GRYPHON cohort is the least variable (p<0.001). 
 
Figure 12.3: SI distribution and variability for Retrospective, STAR-NICU, and STAR-
GRYPHON clinical data cohorts. The legend applies to both plots.  
0 0.5 1 1.5 2 2.5 3 3.5 4
x 10
-3
0
0.2
0.4
0.6
0.8
1
SI [L/mU/min]
F
(x
)
 
 
Retrospective clinical data
STAR-NICU clinical data
STAR-GRYPHON clinical data
-100 -80 -60 -40 -20 0 20 40 60 80 100
0
0.2
0.4
0.6
0.8
1
% change in SI
F
(x
)
 
 
Retro vs. STAR-NICU: p < 0.001
Retro vs. STAR-GRYPHON: p < 0.001
STAR-NICU vs. STAR-GRYPHON: p < 0.001
Retro vs. STAR-NICU: p < 0.001
Retro vs. STAR-GRYPHON: p < 0.001
STAR-NICU vs. STAR-GRYPHON: p < 0.001
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12.3.2 Per-patient Stochastic Model Performance 
Figure 12.4 shows the per-patient performance of a whole cohort (N=95) stochastic model 
used across the entire patient cohort (N=95). This model had a whole cohort percentage time 
in the 5
th
-95
th
 percentile band of 89.3%, indicating the stochastic model adequately reflected 
cohort behaviour as a whole. Of this cohort, 50 (53%) of patients had 90% or greater per-
patient percentage time in the 5
th
-95
th
 percentile band. In addition, 78 (82%) of patients had 
80% or greater per-patient percentage time in the 5
th
-95
th
 percentile band, while 1 patient had 
less than 50% of per-patient percentage time in the 5
th
-95
th
 percentile band. These results 
indicate that per-patient SI evolution is highly patient specific, and while stochastic models 
adequately capture whole cohort behaviour, a stochastic model is not itself necessarily 
reflective of any single patient‟s SI behaviour.  
 
 
Figure 12.4: Per-patient performance across the entire patient cohort (N=95) of 
stochastic models generated from the entire patient cohort (N=95). 
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Figure 12.5 is similar to Figure 12.4, but reflects SI behaviour within the retrospective cohort 
only. Again, 53% (13 of 25 patients) had 90% or more SI changes within the predicted 5
th
-
95
th
 percentile range. In addition, 21 (84%) of patients had 80% or more SI changes within 
the predicted 5
th
-95
th
 percentile range. This result reflects how even within more similar 
clinical sub cohorts there is significant inter-patient variability. Thus, the individuals create a 
stochastic model, but for this cohort, the model is not fully patient-specific. 
Figure 12.6 shows per-patient performance for the STAR-GRYPHON cohort when a 
stochastic model generated from STAR-NICU and retrospective data is used. This 
combination was one that showed a clearly over-conservative stochastic model, with 96% of 
whole cohort SI within the 5-95
th
 percentile prediction range. 62% (10 of 16) patients have 
95% or more of SI within the 5-95
th
 percentile prediction range, and 81% (13 of 16) have 
80% or more SI in the 5-95
th
 percentile prediction range. However, despite this high 
percentage of SI within the target range for most patients, 1 patient still was still under-
represented, with 60-65% of their SI within the 5
th
-95
th
 percentile prediction range.  
 
Figure 12.5: Per-patient performance across the retrospective patient cohort (N=25) of 
stochastic models generated from the retrospective patient cohort (N=25). 
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Figure 12.6: Per-patient performance across the STAR-GRYPHON patient cohort 
(N=16) of stochastic models generated from the STAR-NICU and retrospective patient 
cohorts (N=79) 
 
Patients with more than 5% of their SI above the 95
th
 percentile prediction, or more than 5% 
of their SI below the 5
th
 percentile prediction, were examined, and no trends in BW, weight, 
GA, or PNA were found. Thus, SI evolution is highly patient-specific, and dependent on 
more factors than examined in this analysis, and is not dependent on easily measured 
admission or patient demographics. 
12.3.3 Stochastic forecasting and SGA/AGA cohorts 
Of 79 total patients, 14 were SGA. Figure 12.7 shows cumulative distributions in SI and 
variation in SI by SGA and AGA cohorts. SGA infants have higher insulin and less variable 
SI (p<0.001). This outcome is surprising, as SGA infants are commonly regarded as sicker 
than their AGA counterparts, and thus one would expect greater stress response and greater 
dysfunction due to prematurity that would lead to greater variability.  
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Figure 12.7: Cumulative distributions of insulin sensitivity (SI) and variation in insulin 
sensitivity on the basis of weight for gestational age. The SGA cohort is small for 
gestational age, defined as BW below the 10
th
 percentile of weight for their gestational 
age. AGA is the appropriate for gestational age cohort, and consists of all infants of 
birth weight greater than the 10
th
 percentile for their gestational age. Birth weight 
percentiles were determined from (Beeby et al., 1996). 
 
12.3.4 Gestational Age and Weight Sub-Cohorts 
The entire data population was divided into sub-cohorts based on the population tertiles in 
weight and gestational age (767g and 920g, and 25.4 wk and 27.0 wk, respectively). Figure 
12.8 shows cumulative distributions in SI and SI variability for patient weight and GA. SI is 
lower with increasing prematurity and lower brith weight. Differences in variability between 
cohorts are more distinct when cohorts are divided by GA, but with no distinct trend in GA 
and variability. Table 12.3 shows that tertiles have relatively consistent distribution of patient 
numbers and SI hours between tertiles, eliminating bias due to low numbers. 
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Figure 12.8: Insulin sensitivity (SI) and insulin sensitivity variability with tertiles in a) 
gestational age (GA), and b) weight. 
 
Table 12.3: Patient numbers and SI hours for tertiles of gestational age (GA) and weight 
Weight Tertiles 
  Number hours data Number of patients 
Tertile 1 Weight < 767g 3454 79* 
Tertile 2 767g <=Weight < 920g 2766 64* 
Tertile 3 Weight >= 920g 2980 85* 
 Total 9200 95 
Gestational Age Tertiles 
Tertile 1 GA < 25.4wk 3838 31 
Tertile 2 25.4wk <=GA < 27.0wk 2871 31 
Tertile 3 Weight >= 27.0wk 2491 33 
 Total 9200 95 
* Most patients had more than 1 weight measurement 
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a) 
 
b) 
Figure 12.9: Insulin Sensitivity with a) patient weight and b) gestational age. 
 
SI is highly variable with weight, as shown in Figure 12.9. The data cohort was subdivided 
into two cohorts by a cut off weight that was made to vary between 600 and 1300g in 5g 
increments. It was found that almost all resulting SI cohorts across the weight range were 
statistically different in absolute SI (p≤0.01). Thus, weight cannot be used as a basis for 
creating different stochastic models for different cohorts within the dataset. However, SI 
variability is statistically different in infants of weight<650g and weight>805g. If SI 
variability was used instead of absolute SI in prediction, weight divisions could be used to 
define sub cohorts in SI behaviour. 
The same result of high variability was true for GA. The cohort was divided into two sub-
cohorts by GA, with the cut off weight made to vary between 24.0 and 30 weeks in steps of 
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statistically different in infants of GA<25.5weeks and GA>26.5 weeks. Thus, if SI variability 
was used instead of absolute SI in prediction, GA divisions can be used to define sub cohorts 
in SI behaviour.  
12.3.5 Insulin Sensitivity and Sex 
Figure 12.10 shows a difference in SI distributions between the sexes (p<0.001), with female 
infants showing lower model-based SI, and higher variability. This difference holds even if 
the non-sex differentiated model for insulin secretion of Equation 4.9 is used (p<0.001). The 
sexes are not different in GA, PNA, or BW (p≥0.55), as shown in Table 12.4. However, they 
are different in the quality of their control. The male infants had lower median BG (p<0.001), 
less hyperglycaemia (p=0.03), and higher time in band (p=0.06). Thus, the female infants 
were more insulin resistant and had poorer glycaemic control, likely reflecting greater 
sickness and injury than the male infants.  
 
 
Figure 12.10: Insulin sensitivity (SI) and glycaemic variability between male and female 
infants. To ensure differences were not directly model-induced, SI was also fit using the 
non-sex differentiated model of Equation 4.9.  
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Table 12.4: Characteristics and glycaemic control statistics for male and female cohorts 
 Female Male p 
N 51 44  
Gestational Age (GA) 
[weeks] 
24.4 [25 – 27.4] 25.8 [25.0 – 27.8] 0.97 
Post Natal Age (PNA) 
[days] 
4 [2 – 8] 4 [2 – 7] 0.55 
Birth Weight [g] 825 [635 – 933] 830 [635 – 940] 0.93 
Clinical glycaemic control stats: 
Median insulin rate [IQR] 
[U/kg/hr]: 
0.04 [0.02 - 
0.08] 
0.040 [0.02 - 
0.07] 
0.72 
Median glucose rate 
[IQR] (mg/kg/min): 
7.3 [4.6 - 8.9] 7.9 [6.3 - 9.2] 0.07 
Median BG [mmol/L] 7.3 [5.9 - 8.9] 6.7 [5.8 - 8.2] <0.001 
% BG within 4.0 - 8.0 
mmol/L 
59.8 69.7 0.06 
% BG>10 mmol/L 14.7 8.6 0.03 
% BG<4.0 mmol/L 2.9 2.6 0.21 
 
12.4 Discussion 
12.4.1 Clinical Cohorts in Stochastic Models 
Comparison of per-patient percentile band coverage for different cohort based stochastic 
matrices has shown that the cohorts are effectively captured by similar stochastic models, 
despite differences in SI distributions (p<0.001). The addition of 54 patient episodes (N=25 
to N=79) improved per-patient and whole cohort stochastic model coverage in the STAR-
NICU and retrospective cohorts slightly, but not to an extent that is likely to be clinically 
significant in use. This similarity in coverage with the use of different cohort stochastic 
forecasting verifies that the original data set was sufficiently representative of the STAR-
NICU population as previously thought, where initial work with stochastic matrices in adult 
ICU patients indicated N = 25 would be suitable (Lin et al., 2006).  
The high proportion of coverage above 90%, and in particular above 95% in the 5-95
th
 band 
when using the STAR-NICU and retrospective data derived stochastic models on the STAR-
GRYPHON cohort suggests that this cohort has different SI behaviour than the previous 
STAR-NICU cohort. This outcome was also seen when SI distributions were compared 
between cohorts, with the STAR-GRYPHON cohort displaying higher SI and lower SI 
variability than STAR-NICU and retrospective cohorts (p<0.001). This behaviour may result 
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from underlying differences in patient condition or patient demographics. Alternatively, it 
may be a result of greater consistency in measurement interval and fewer changes in nutrition 
reducing noise in the SI profile. Both causes are likely true.  
Previous discussion in Chapter 11 identified lower incidence of hyper-and hypo-glycaemic 
extremes, revealing slightly over-conservative stochastic models. Until the STAR-
GRYPHON cohort is larger, reaching approximately 25 patients (Lin et al., 2006), the STAR-
NICU and retrospective data based stochastic cohorts are adequate for glycaemic control. In 
addition, they seem to err on the side of safety through over-conservative SI predictions, 
resulting in more than 90% of SI within the 5
th
-95
th
 percentile prediction range. 
Per-patient percent time in the 5
th
-95
th
 percentile range showed that patient evolution of SI is 
highly patient specific. The high proportion of coverage above 90%, and in particular above 
95% in the 5-95
th
 band suggests that this band width is determined by the behaviour of a 
relative few patients. Ideally, for patient specificity, the majority of per-patient coverage 
would be close to the target 90%. The patient coverage of the 25-75
th
 percentiles is much 
wider, indicating significant inter-patient variability and lack of patient-specific coverage 
within these central tendency bounds. Overall it seems that inter-patient variation is more 
significant than intra-patient variation as a limiting factor in this stochastic forecasting model, 
and that a relative few more variable patients are quite different in behaviour. 
Population based stochastic models are clearly limited by their inability to adequately capture 
patient-specific SI behaviour. However, their use has proven safe in clinical usage, with 
additional constraints around insulin dosage rates limiting the impact of SI values outside the 
patient range. More patient-specific prediction methods, such as auto-regressive based 
methods, have been examined elsewhere (Le Compte, 2009), but suffer from the significant 
drawback that rapid changes in SI can render such data based models obsolete. In addition, 
much narrower prediction ranges than stochastic models provide, more readily results in 
more aggressive insulin dosing that can lead to hypoglycaemia when patient condition 
changes rapidly. Future work should examine other more patient specific forecasting methods 
that can ameliorate these risks. 
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12.4.2 Insulin Sensitivity and Patient Bedside Metrics 
Bedside metrics offer consistent, objective classification. SI was highly variable across all 
BW and GA ranges. Further, for patients not well represented by stochastic models in the 
per-patient percentage coverage statistics, there was no consistent trend with GA or BW to 
characterise these patients.  
However, SI was found to be higher and less variable in SGA infants, a result also seen in 
Chapter 7 with HINT patient data. This result is unusual in that SGA infants are generally 
considered to be more at risk, with more higher morbidity and worsened outcomes than their 
AGA counterparts (Girsen et al., 2015, Hei et al., 2014). This result may reflect the relatively 
small number of SGA infants (14 of 79), and warrants further investigation with a larger 
patient cohort. If indeed SGA infants have different SI behaviour than their AGA 
counterparts, then stochastic models can be created to capture this behaviour of an easily and 
objectively identified cohort.  
SI was found to differ between the sexes. Female infants were found to have lower SI and 
higher SI variability than their male counterparts, also reflected in the clinical glycaemic 
control statistics, with lower BG within the 4.0-8.0 mmol/L target range and higher incidence 
of hyperglycaemia (%BG<10.0 mmol/L.). This result is counter to expectation, as premature 
make infants are generally regarded as sicker than premature female infants, and with 
worsened outcomes such as higher mortality (Stevenson et al., 2000), and poorer neuro-
developmental outcome (Henderson-Smart et al., 2006). Further analysis is required to 
distinguish whether this is a consistent trend in this NICU population, or simply a result of 
unusually high numbers of sicker premature infants. 
12.5 Summary 
Analysis of model-based insulin sensitivity distributions for different clinical cohorts 
revealed that retrospective, STAR-NICU, and STAR-GRYPHON cohorts all differ in their SI 
behaviour (p<0.001). However, retrospective and STAR-NICU cohorts are both effectively 
captured by a stochastic model based on their combined SI behaviour. The STAR-
GRYPHON cohort to date has higher SI and lower variability than STAR-NICU and 
retrospective cohorts (p<0.001). This outcome may result from more consistent measurement 
intervals and lower variability in feed rates, or from differences in the underlying clinical 
characteristics of the patients not evident in the fundamental demographic data available. 
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Both reasons are likely true. However, more STAR-GRYPHON patients are needed to 
generate effective stochastic matrices for this population alone. In addition, though slightly 
over-conservative, the STAR-NICU and retrospective data based stochastic matrix currently 
in use is adequate and safe in control. 
Model-based SI was found to be higher in SGA and male infants. These results are 
surprising, given that these two cohorts usually are associated with greater sickness and 
injury, and worsened outcomes. Further analysis is required to determine whether they are 
typical of their NICU sub-cohort, or the result of unusually high numbers of healthier SGA or 
male infants. Model-based SI was found to be highly varied with birth weight and gestational 
age, resulting in no tangible benefit from stochastic models for weight or gestational age 
based clinical sub-cohorts. 
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Chapter 13: Conclusions 
 
13.1 Major Chapter Outcomes 
In neonatal intensive care hyperglycaemia is a common complication of prematurity, 
affecting up to 70% of very premature infants. Hyperglycaemia has been associated with 
mortality and worsened outcomes in neonatal intensive care. However, it is still debated 
whether hyperglycaemia is a reflection of worsened patient condition or a cause in itself, with 
both likely true.   
Studies examining glycaemic control outcomes in this cohort are relatively rare, and plagued 
by increased incidence of hypoglycaemia, which is also associated with worsened outcomes.  
The fragility of the cohort further limits data, studies, and the ability to learn from the results. 
Current clinical practice regarding glycaemic control differs between units, and insulin 
therapy and glucose restrictions are two approaches used to treat hyperglycaemia.  
Insulin therapy has been well established as an effective treatment for hyperglycaemia that 
also allows for increased glucose tolerance and higher weight gain. Clinical insulin therapy 
protocols are typically ad hoc and/or titrate insulin with blood glucose level. These 
approaches fail to adequately account for differences between patients and changing patient 
condition over time, resulting in poor control and increased risk of hypoglycaemia.  
Model-based control uses a time varying insulin sensitivity parameter to describe changing 
patient response to insulin over time, and between patients. Only one such model-based 
approach exists in premature neonatal cohorts. The object of this thesis was to improve on 
this approach by more comprehensive modelling of patient-specific aspects of glucose-insulin 
physiology, and to develop and optimise a STAR glycaemic control protocol for neonatal 
intensive care.  
The NICING (Neonatal Intensive Care Insulin-Nutrition-Glucose) model was developed 
from a similar fundamental model used in adult intensive care. In particular the modelling of 
insulin, glucose, and the breakdown and absorption of enteral glucose was revisited from the 
prior NICU model and adult models. Models were made specific to the very/extremely 
premature neonatal intensive care unit cohort using relatively rare clinical data and extensive 
analysis of relevant results in the literature. 
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Insulin secretion in this cohort was analysed using C-peptide measurements. This approach is 
extremely novel in this cohort, as previously only absolute insulin concentrations and insulin 
AUC estimates have been used to indirectly assess pancreatic function. Insulin secretion was 
found to be highly variable across the range of subjects and clinical variables. However, 
insulin secretion was found to be twice as high in female than male infants, and was also 
found to increase with increasing blood glucose concentration. Simple, but representative, 
first of their kind, linear models of insulin secretion as a function of blood glucose were 
created for male and female very premature infants.  
Insulin clearance is another unknown that increases apparent variability in response to 
treatment. Separate insulin clearance pathways were modelled using C-peptide and insulin 
concentrations in very premature infants. In particular, clearance by the liver and kidneys (   
and    respectively) was examined, as well as cellular degradation of insulin (  ), and 
diffusion of insulin between plasma and peripheral fluid compartments (  ). Renal clearance 
of insulin was modelled using the literature surrounding kidney function in this cohort. Based 
on age specific changes in kidney function, this renal clearance of insulin is also allowed to 
change with patient birth weight and post-natal age. Improved liver clearance, cellular 
degradation, and trans-capillary diffusion of insulin were then determined using the NICING 
model structure and C-peptide and insulin concentration measurements from a cohort of very 
premature infants.  
As part of the insulin clearance modelling, compartment fluid volumes were analysed. While 
blood plasma volume was found to remain relatively constant, the extracellular fluid 
compartment was found to contract significantly in the days following birth. Modelling this 
effect enables the wider insulin kinetic model to be modified to better reflect patient age. 
Within glucose modelling two key aspects of glucose modelling were examined: 1) 
endogenous glucose production (EGP); and 2) non-insulin mediated glucose uptake, 
predominantly by the central nervous system (CNS). EGP was examined using a meta-
analysis of data from the literature. EGP was found to be highly variable across a number of 
patient metrics. EGP was found to be suppressed with increasing glucose infusion, and in 
most cases be suppressed at higher blood glucose concentration. However, after further fitting 
and control performance based analysis, it was found that for the purposes of glycaemic 
control, EGP is best modelled as a population constant (EGP = 6.0 mg/kg/min). This result 
reflects the high variability in observed EGP rates in the literature. It also reflects the fact that 
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these rates were measured in non-hyperglycaemic, otherwise healthy, very premature infants, 
which may confound the issue.  
Non-insulin mediated CNS uptake was examined indirectly through the modelling of brain 
mass in very premature infants. Two models were compared. First brain mass was treated as 
a simple 14% of body weight, and second, brain mass was modelled as a function of head 
circumference. It was found that using head circumference to estimate brain mass generally 
resulted in larger brain mass estimations than when it was estimated as a proportion of body 
mass (median 121g vs.112g). This outcome was especially true in small for gestational age 
(SGA) infants. However, there was no control benefit to be gained from using head 
circumference over body mass to estimate brain mass, irrespective of whether the infant was 
SGA or not. As such, brain mass modelled as 14% of body mass is adequate for control, and, 
unlike head circumference based models, does not increase clinical workload or complexity. 
A two compartment model of glucose transfer through the stomach and absorption in the gut 
was implemented. Two key parameters are determined, the rate constant for gastric emptying 
from the stomach, d1, and the rate constant for glucose absorption from the gut to the 
bloodstream, d2. Gastric emptying half lives are reported for a range of different gestational 
ages in the literature, with slower gastric emptying in more premature infants. 
Using CGM data from preterm and term infants, the rate constant for glucose absorption from 
the gut to the blood stream was examined. In this analysis the rate constant d1 = 0.035 min
-1
, 
which corresponds to a gastric emptying half life of 20 minutes, was used. From glucose 
appearance in CGM data, the rate constant for glucose absorption was determined to be 
d2=0.014 min
-1
, corresponding to an absorption half life of 50 minutes. This absorption rate 
constant was not found to change with gestational age. Though determined from premature 
and term infants, this value is a better estimation of intestinal glucose absorption in 
very/extremely premature infants than adult values used previously. In very/extremely 
premature infants the gastric emptying rate constant can be set to the slower d1= 0.017 min
-1
 
(40 minutes half life) to better reflect their condition. 
Following model development virtual patients were created using the new NICING model 
fitted to clinical data. A virtual patient consists of a model based SI trace, and was used in 
virtual trials. Variations on a STAR (Stochastic Targeted) protocol were tested in virtual 
trials. These STAR protocol variations utilised stochastic forecasting models for insulin 
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sensitivity to generate percentiles of likely blood glucose outcomes. Insulin doses were 
chosen such that predicted blood glucose outcome percentiles met certain criteria. The chosen 
protocol placed the 5
th
 percentile of likely blood glucose outcomes within a 4.0-4.4 mmol/L 
target range. Adaptive limits in the limit on the increase in insulin infusion rate were applied 
with blood glucose concentration. The final protocol is known as the STAR-GRYPHON 
protocol, and clinically validated virtual trials showed a performance of 76.4% hourly re-
sampled blood glucose measurements within the clinically targeted 4.0-8.0 mmol/L range, 
and low incidence of hypoglycaemia (0.1% BG<2.6 mmol/l with 2 of 79 (2.5%) virtual 
patients with at least one re-sampled BG<2.6 mmol/L). .   
The STAR-GRYPHON protocol was implemented as a customised tablet computer-based 
application in Christchurch Women‟s Hospital NICU from January 2013 to January 2015. A 
total of 13 patients, totally 16 glycaemic episodes, were treated using STAR-GRYPHON 
during this time. Percentage time in band (re-sampled hourly) was 76.6%, with an average 
measurement interval of 4 hours. There were no instances of blood glucose measurements 
falling below 3.5 mmol/L, and no incidences of severe hypoglycaemia. Performance of 
STAR-GRYPHON improves on retrospective clinical percentage time in band by 26%, and is 
very near to pre-trial virtual trial results. Thus, STAR-GRYPHON is thus safer and more 
effective at providing glycaemic control than previous implementations and clinical practice. 
Using this clinically validated model, insulin sensitivity distributions were found to differ 
between the retrospective, STAR-NICU, and STAR-GRYPHON cohorts. Retrospective and 
STAR-NICU cohorts were found to be adequately represented by a stochastic model based 
on retrospective and STAR-NICU data. However, this stochastic model was found to be 
overly conservative for the STAR-GRYPHON cohort, with 96% of whole cohort insulin 
sensitivity within the 5
th
-95
th
 percentile prediction range. Further, 62% of patients had a per-
patient percentage of SI within this range greater than 95%. This result may reflect 
underlying differences in the STAR-GYRPHON cohort compared to previous cohorts, or be 
a result of more consistent measurement interval and lower variability in nutrition delivery. 
Both are likely true. Approximately 10 more patients are required to generate a STAR-
GRYPHON specific stochastic model for clinical use. In the meantime, the current 
retrospective and STAR-NICU data based stochastic model is safe and adequate for clinical 
use. 
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13.2 General Conclusions 
At the outset, this thesis aimed to take an existing model-based glycaemic control framework 
used in neonatal intensive care, and improve on its performance through more comprehensive 
modelling of glucose-insulin dynamics and better quantification of sources of variability. 
This goal was achieved using a novel clinical data set and detailed literature analysis. As a 
result, the NICING model has been developed, which, in particular, has more comprehensive 
and detailed modelling of insulin secretion and clearances. The NICING model tightens 
control, indicating that sources of insulin sensitivity variability have been better captured and 
accounted for in the model, providing a much better representation for accurate, safe, insulin 
dosing. 
A model-based protocol for glycaemic control in neonatal intensive care was developed, 
namely the STAR-GRYPHON protocol. Clinical results show significant improvement over 
retrospective data and previous protocol implementations, with no incidence of severe 
hypoglycaemia, a result unmatched in the literature to date.  
The majority of the literature surrounding glycaemic control in premature infants to date has 
focused on clinical outcomes. The weakness of this approach is that development and 
protocols for first achieving control have been overlooked. As a result, outcomes have been 
confounded by poor control and increased incidence of hypoglycaemia. The STAR 
framework as a glycaemic control tool has been previously shown to be safe and effective in 
adult and neonatal intensive care, and STAR-GRYPHON further improves on all glycaemic 
control in the literature to date. It can thus be used in a wider clinical and research context to 
assess the long and short term effects of glycaemic control on clinical outcomes such as 
morbidity, length of hospital stay, and length of mechanical ventilation. 
A major conclusion of this work is that the glucose-insulin system in preterm infants is very 
complex, with many immeasurable factors influencing it. This result is informally expressed 
in Figure 13.1 (Dickson et al., 2014), where the scatter in clinically measured data meant that 
more traditional models were often hard to fit. One of the temptations when faced with such 
complex systems is to increase model complexity to capture every potential influence. 
However, this thesis demonstrates that relatively simple models can be clinically applicable 
and accurate. The very simplicity of this model means that it can be used to significantly 
improve the standard of care without significantly increasing clinical workload, or demanding 
more measurements than are ethical or practically feasible.  
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Finally, this thesis lays out a model-based approach to dosing insulin in neonatal intensive 
care for the purposes of glycaemic control. In neonatal intensive care in general, drug therapy 
is often ad hoc, using dosage regimes extrapolated from paediatric or adult intensive care 
(Allegaert and van den Anker, 2014). This thesis demonstrates that using known 
physiological pathways to generate models can be an effective and relatively non-invasive 
way to safely and effectively improve drug therapy in this fragile cohort. 
 
 
 
Figure 13.1: Humans are horribly variable. Human physiology is complex and 
pathways rarely act in isolation. As such, clinical data is often highly variable in nature, 
with outcomes dependent on a number of different clinical and patient specific aspects, 
such as when comparing insulin secretion to a number of physiological markers. Figure 
source: Dickson et al. (2014) 
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Chapter 14: Current and Future Work 
 
A glycaemic control framework has been developed for neonatal intensive care, and 
implemented in Christchurch Women‟s Hospital. Initial results show improved care over 
retrospective data and results from the literature. Further avenues of exploration have been 
opened up by the work in this thesis.  
14.1 Use in Different NICU Centres 
STAR-GRYPHON is proving effective in the Christchurch Women‟s Hospital Neonatal 
Intensive Care Unit, and is currently used as a standard of care. However, for further proof of 
its efficacy, its use must be expanded into other NICU‟s, both in New Zealand, and overseas.  
Within New Zealand, STAR-GRYPHON is currently being used as the glycaemic control 
tool behind the tight glycaemic control arm of the HINT2 trial, a follow up trial to the 
published HINT trial.  This trial is taking place in Auckland NICU‟s, and will attempt to 
assess the effect of tight glycaemic control on outcomes in premature infants. Clinical 
enrolment in the trial began in July 2015. However, to date, only one infant has been 
randomised to the tight glycaemic control arm of the trial. Future work will require a long 
term follow up on the performance of STAR-GRYPHON within this different clinical 
context. 
Outside of New Zealand, STAR-GRYPHON is being trialled in Miskolc County Hospital 
NICU, Hungary. To date, staff incompliance has resulted in only two 12 hour periods of 
babies on insulin under the STAR-GRYPHON protocol. In both cases blood glucose was 
brought within the band with no incidence of hypoglycaemia, before a nursing shift change 
meant that STAR-GRYPHON was no longer used. Future work will require further nurse 
training and to improve compliance and assess performance in a clinical context that is 
potentially very different from that in New Zealand. 
Further potential avenues of expansion overseas include a NICU in Gyula, Hungary, and 
Belgium.  
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14.2 Quantification of the Effect of Glycaemic Control on Clinical 
Outcomes 
 To date, the literature surrounding glycaemic control in premature infants has focused on 
clinical outcomes rather than first achieving control, and results are thus confounded by poor 
control and increased incidence of hypoglycaemia. As a glycaemic control tool, STAR-
GRYPHON can be used to assess the long and short term effects of glycaemic control on 
clinical outcomes such as morbidity, length of hospital stay, and length of mechanical 
ventilation. 
Long-term follow up of STAR-GRYPHON clinical results and outcomes, and comparison to 
retrospective data and outcomes, may allow retrospective examination of the effect of tight 
glycaemic control on clinical outcomes. While incomplete in itself to prove or disprove the 
benefits of glycaemic control, this analysis would add to the growing literature surrounding 
glycaemic control in the premature infant cohort. 
STAR-GRYPHON is currently being used in the HINT2 randomised control trial to assess 
the affect of glycaemic control on outcomes. This, and other future trials, should enable more 
accurate and comprehensive analysis of the effect of glycaemic control on clinical outcomes. 
14.3 Expansion of Approach into Paediatric Intensive Care 
With model-based STAR glycaemic control protocols developed for neonatal and adult 
intensive care, the logical next step is to „close the gap‟ and develop a model-based approach 
for use in paediatric intensive care.  
Paediatric intensive care is another area where much time, effort, and resource has been spent 
in the last few years to determine and quantify the potential risks and benefits of glycaemic 
control. As in the neonatal intensive care setting, this work has been largely divorced from 
any real attempt to determine safe and effective protocols for dosing insulin, instead dealing 
with outcomes. There is thus scope for first the development of a glycaemic control tool, and 
then the use of it to more comprehensively and effectively determine the effect of glycaemic 
control on patient outcomes. 
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14.4 Quantification of External Contributions to Insulin Sensitivity 
Within a clinical context, demands on clinical time and resources mean that a number of 
external factors can influence system performance by contributing to noise in the insulin 
sensitivity trace. Such factors can include, but are not limited to, absorption of insulin by IV 
tubing, dead space within the pump and IV line, and timing or data entry errors around 
nutrition and insulin doses or changes. 
Insulin absorption by tubing has been reported in literature, with high rates of insulin 
absorption being reported even after pre-soaking of tubing in insulin. These studies tend to 
examine percentage absorption as a function of flow rate and/or insulin concentration. No 
study has comprehensively examined insulin absorption, accounting for surface area, 
concentration, and flow rate. Such a study can easily be carried out without risk or the need 
for clinical patients, and would allow more accurate modelling of insulin sensitivity during 
the first few hours of glycaemic control, thus improving control. 
The glucose-insulin model relies on knowledge of system inputs. A sensitivity analysis can 
be carried out to examine the impact of timing errors and dead space within the IV tubing on 
insulin sensitivity and glycaemic control performance. Such an analysis would have twofold 
benefits. First, it would allow for a more comprehensive knowledge of the limitations of the 
system and the nature of model based insulin sensitivity. Second, it allows clinical practice 
around glycaemic control to be more informed; highlighting areas where clinical staff need to 
ensure accuracy of the information entered. 
Many infusion pumps are now able to transmit information concerning rates and 
concentrations directly to electronic devices. At minimum, a one-way exchange of data with 
a model-based protocol on a tablet computer would allow the tablet computer to have more 
up to date and accurate information concerning system inputs, without increasing clinical 
workload. This would also reduce the effect of erroneous data entry on control, thereby 
improving the quality and effectiveness of glycaemic control. 
14.5 Quantification of Physiological Influences on Insulin Sensitivity 
Both the stress response and some types of medication are known to influence a patient‟s 
blood glucose and response to insulin. Observations on the correlations between patient 
condition and insulin sensitivity could potentially enable glycaemic control protocols to be 
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tailored to patient condition or medication regime. Further, it may also allow long term 
warning or diagnosis of changes in patient condition in cases such as pre-septic or septic 
infants. 
14.6 Investigation of SGA and Sex Based Cohorts 
Within this work both insulin secretion and insulin sensitivity were observed to differ 
between male and female infants. Analysis of insulin secretion over a larger and more 
frequently measured cohort would enable further investigation of sex based insulin secretion 
differences. In particular, quantitative analysis of insulin secretion in older infants and 
children would enable one aspect of the maturation of the glucose-insulin system to be 
examined, improving attempts at glycaemic control in these cohorts, and adding to current 
knowledge surrounding glycaemic development in children and young adults. 
One result of this thesis was that small for gestational age (SGA) and male infants had higher 
insulin sensitivity than appropriate for gestational age (AGA) and female infants. This result 
was surprising, as these are two cohorts generally considered to be more vulnerable and with 
worsened outcomes. Long term follow up of clinical data from a number of different 
glycaemic control cohorts is required to confirm or negate these observations, and determine 
clinical implications for glycaemic control in these infants. 
14.7 Validation of Gut Models 
In Chapter 8 a two compartment gut model was developed for term and premature infant 
cohorts. This model requires validation for glycaemic control in virtual trials and clinical 
patients. Virtual trials will test the effect of the new model on glycaemic control outcomes, 
and, if required, enable protocols to be developed to cope with large peaks in model 
predictions due to glucose appearance from enteral feeds. Once virtual trials have assessed 
the likely performance and safety of the new model, it can be used in clinical trials to assess 
clinical efficacy and safety. 
14.8 CGM use in Premature Infants 
The low blood volume, small size, and inherent fragility of the very premature infant cohort 
means that clinical measurements must be minimised. Continuous glucose monitors (CGMs) 
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may provide a way by which the amount of glycaemic information can be increased, and 
clinical blood glucose measurements decreased.  
Currently, CGMs are well known to suffer from noise and drift. While no CGM has been 
designed specifically for the term or premature infant cohort, several studies have used 
CGMs in these cohorts (Beardsall et al., 2005, Harris et al., 2013) to capture and quantify 
hypoglycaemic incidence.  
Analysis of CGM data from premature infants will allow CGM models to be built and 
potentially enable CGMs to be integrated with STAR-GRYPHON. This would increase the 
amount of data available to the model, improving model-based insulin sensitivity, and 
providing pre-emptive warnings of downward trends in blood glucose during insulin therapy. 
Thus, the efficacy and safety of model-based glycaemic control protocols could be improved 
through the use of CGMs. 
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